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Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many
diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal in-
jections are the method of choice to administer drugs to the retina, but this approach is applicable only in
selected cases (e.g. anti-VEGFantibodies and soluble receptors). There are twobasic approaches that can be
adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs
and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or
topical. Properties of the administration route, drug and delivery system determine the efficacy and safety
of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates
and doses that are needed for drug action. In addition, tolerability factors limit the use of manymaterials in
ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly
from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery
technologies, because they have already been reviewed several times recently. Instead,we aim to provide a
systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye
segment. This review is based on the literature and unpublished data from the authors' laboratory.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Drug delivery and pharmacokinetics play important roles in
current retinal therapeutics and the development of new medica-
tions. Retinal diseases lead to visual impairment and in many casesblindness. The number of patients suffering from retinal disease is
increasing due to the aging population; it has been predicted that
the number of patients suffering from age-related macular degen-
eration (AMD) will reach 288 million in 2040 (Wong et al., 2014).
Large patient populations with glaucoma and diabetic retinal
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lation. In addition, there are numerous inherited rare retinal de-
generations that lead to blindness at a young age.
As the mechanisms of retinal diseases are investigated and
revealed, new potential drug targets will emerge. The delivery of
drugs to retinal targets is challenging and various routes of drug
administration have been investigated (Fig. 1). Unfortunately, most
of them result in sub-therapeutic drug levels in the retina. Intra-
vitreal injection is currently the method of choice in retinal drug
delivery (Fig. 1). Intravitreal injections are used widely in the
clinics, especially in the delivery of anti-VEGF proteins (bev-
acizumab, ranibizumab, aflibercept) to patients suffering from the
wet form of AMD. These injections should be given every month or
two months, but in practice the compliance is poor and the in-
jections are given at longer intervals (Cohen et al., 2013; Holz et al.,
2015). This decreases the efficacy of the AMD treatments and there
is a need for longer acting intravitreal injections. It is important to
note that monthly and bimonthly injection intervals are feasible in
the case of anti-VEGF proteins, because these antibodies and sol-
uble receptors have long intravitreal half-lives (about one week),
they are highly potent compounds that show effects even at very
low concentrations, and they are tolerated at relatively high doses.Fig. 1. Routes of drug administration for retinal dIn fact, the vitreal drug concentrations show about 100-fold
changes during the AMD treatment. Small molecules have much
shorter half-lives (usually less than 10 h) than protein drugs in the
vitreous (Maurice and Mishima, 1984). Therefore, their dosing in-
tervals are too short to be clinically acceptable in chronic multiple
dose treatment. Also, many protein drugs (e.g. growth factors) have
much more narrow therapeutic indices than anti-VEGF antibodies
and would require frequent intravitreal dosing. For these reasons,
controlled release delivery systems are being investigated for
intravitreal drug delivery to the retina (see Fig. 1).
Retinal drug delivery could also be accomplished using other
methods, such as systemic, topical, periocular (sub-conjunctival,
sub-Tenon's, posterior juxtascleral, peribulbar and retrobulbar in-
jections), sub-retinal and suprachoroidal drug administration
(Fig. 1), but these approaches may not result in adequate drug
concentrations in the retina with currently available technologies.
These routes of drug delivery may become clinically feasible if new
improved drug delivery systems are developed.
This review aims to present systematic, critical and quantitative
treatise of the pharmacokinetic factors in retinal drug delivery of
small molecular weight drugs, biologics and controlled drug de-
livery systems. The delivery technologies and general ocularrug delivery, adapted from del Amo (2015).
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reviews that present these aspects in detail (Hamdi et al., 2015;
Herrero-Vanrell et al., 2014; Novack and Robin, 2016; Yasin et al.,
2014).2. Blood-ocular barriers
After intravitreal administration the drugs distribute in the
vitreous, and to the surrounding ocular tissues. Drug elimination
from the vitreous cavity takes place via blood-ocular barriers and
aqueous humor outflow to the systemic blood circulation. In the
case of systemic, suprachoroidal and periocular drug administra-
tion, the drug must cross the blood-ocular barrier before it can
reach the targets in the retina. Therefore, blood-ocular barriers play
an important role in defining drug permeation into the eye and
from the eye to the blood circulation.
The blood-ocular barriers consist of the anterior blood-aqueous
barrier (BAB) and posterior blood-retinal barrier (BRB) (Fig. 2)
(Raviola, 1977). The posterior iris, inner non-pigmented ciliary
epithelia and the tight endothelia around the iris and ciliary muscle
capillaries form the BAB. The BRB consists of the endothelia of the
retinal capillaries (inner BRB) and retinal pigment epithelium (RPE)
(outer BRB). Unfortunately, the permeability values for the vascular
components of the BAB are difficult to determine. Permeability of
the retinal pigment epithelium is easier to determine experimen-
tally and, therefore, its role in the blood-ocular barrier is easier to
quantitate. Qualitative data have been generated in experiments
using fluorescent tracers of various sizes. In other tight epithelial
membranes (intestine, conjunctiva, cornea), the diameters of par-
acellular holes have been determined to be in the range of 1e3 nm
(H€am€al€ainen et al., 1997; Linnankoski et al., 2010). We can assume
that the proteins of tight junctions will form a similar barrier in the
blood-ocular barriers. The experiments with fluorescent and radi-
olabeled tracers support this notion. Note that the cited size values
of the tracers were obtained from the original articles and theymay
differ from the values in some other sources.2.1. Inner blood retinal barrier: retinal capillaries
Tracer experiments have revealed that the retinal capillary walls
in various species (rat, monkey, pig) prevent permeation of i.v.
carbon nanoparticles (20 nm in diameter), 125I-albumin (7.2 nm),
horseradish peroxidase (4 nm), and microperoxidase (2 nm)
(Ashton and Cunha-Vaz, 1965; Smith and Rudt, 1975; T€ornquist
et al., 1990), but small molecules (molecular weights a few hundredFig. 2. Blood-ocular barriers. The thicker lines indicate tight endothelium/epDaltons) (e.g. mannitol, glycerol, fluorescein) were shown to be
permeable (Cunha-Vaz and Maurice, 1969, 1967; Tachikawa et al.,
2010; Thornit et al., 2010). These compounds are clearly smaller
than the size of typical paracellular spaces in the membranes with
tight junctions (about 2 nm) (H€am€al€ainen et al., 1997). In addition,
some compounds, like fluorescein, may permeate transcellularly by
passive diffusion and active transport (Cunha-Vaz and Maurice,
1969, 1967). The reported in vivo permeability values reflect the
permeation in the entire BRB, not only the retinal capillaries, and so
it is difficult to quantitate the permeability in the retinal capillaries.
Some investigators have reported permeabilities in cellular models,
but the relevance of these capillary cell models is not certain, as the
reported values are much higher than one would expect for the
membranes with tight junctions, i.e. in the range of 104 cm/s
(Haselton et al., 1998, 1996). Based on the existing data, we can
conclude that the retinal capillaries form a barrier that prevents
permeation of molecules with a diameter of 2 nm and higher, while
small molecules are able to permeate across the inner BRB to some
extent.2.2. Outer blood retinal barrier: retinal pigment epithelium
The retinal pigment epithelium is a tight cellular monolayer that
is located between the photoreceptors and choroid (Fig. 2). It has
important functions in the homeostasis of the neural retina and as
the outer part of the BRB. The roles of Bruch's membrane and
choroidal tissue as barriers to small molecules and neutral mac-
romolecules (up to 500 kDa) are negligible in comparison with the
RPE (Pitk€anen et al., 2005). The transepithelial resistance of the RPE
is typically in the range of 0.10e0.15 kOhm cm2 (Kimura et al., 1996;
Pitk€anen et al., 2005; Tsuboi and Pederson, 1986). Smith and Rudt
(1975) showed that microperoxidase (size 2 nm) does not
permeate through the RPE in vivo in monkeys.
Permeability of the RPE has been investigated in more detail
using Ussing chambers and ex vivo bovine RPE-choroid specimens
(Pitk€anen et al., 2005). Permeation of small molecules was
dependent on their lipophilicity; the permeability of small hydro-
philic compounds (e.g. nadolol) was in the range of 2  106 cm/s,
while lipophilic drugs (e.g. betaxolol) permeated much faster
(16  106 cm/s). The paracellular permeability of hydrophilic
solutes decreased with increasing molecular size, clearly high-
lighting the size dependent molecular exclusion by the RPE
(Table 1).
It is important to note that the inward permeability of FITC-
dextran 77,000 was only 0.027  106 cm/s; about 36 and 618ithelium while the dashed ones indicate leaky endothelium/epithelium.
Table 1
Permeability of hydrophilic and lipophilic solutes in the ex vivo bovine RPE-choroid membranes (Pitk€anen et al., 2005).
Compound Lipophilic/hydrophilic Molecular weight (Da) Molecular diameter (nm) Permeability (106 cm/s)
Betaxolol Lipophilic (LogD7.4) ¼ 1.59 307 0.9 10.3 ± 4.48 (outward)
16.7 ± 3.65 (inward)
Carboxyfluorescein Hydrophilic 376 1.0 2.33 ± 1.06 (outward)
0.96 ± 0.38 (inward)
FITC dextran Hydrophilic 4400 2.6 0.24 ± 0.16 (inward)
FITC dextran Hydrophilic 21,200 6.4 0.13 ± 0.18 (inward)
FITC dextran Hydrophilic 38,200 9.0 0.046 ± 0.029 (inward)
FITC dextran Hydrophilic 77,000 12.8 0.027 ± 0.032 (inward)
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olol respectively. This demonstrates the steep relationship between
the RPE permeability and molecular size. For comparison, the
choroidal tissue permeability is 1e2 orders of magnitude higher,
ranging from 100  106 cm/s (51Cr-EDTA) to 0.3  106 cm/s (al-
bumin) (T€ornquist et al., 1990). The permeability of the fenestrated
choroidal blood vessel walls is high, allowing rapid entry of drugs to
the extravascular choroid from the blood circulation (Bill et al.,
1980). After intravitreal administration the drug is cleared rapidly
to the blood circulation in the choroid after RPE passage. The
choroidal vessels have openings of 60e80 nm allowing permeation
of large molecules (e.g. albumin) (Bill et al., 1980).
Clear outward directionality of carboxyfluorescein and fluores-
cein permeation in the RPE indicates active transport (Tsuboi and
Pederson, 1986), but in later studies the directionality of carboxy-
fluorescein permeation was not as obvious (Kimura et al., 1996;
Pitk€anen et al., 2005, Table 1). Cunha-Vaz and Maurice (1967)
showed active transport of fluorescein in vivo, but the roles of
different tissues (RPE, retinal capillaries) in these findings are not
clear.2.3. Blood-aqueous barrier
The blood-aqueous barrier consists of endothelial (iris and
ciliary muscle vasculature) and epithelial barriers (posterior iris
epithelium and non-pigmented epithelium) (Fig. 2). It has been
shown that i.v. microperoxidase (2 nm), horseradish peroxidase
(4 nm) and carbon particles (20 nm) did not escape from the iris
vessels in rat, cat, rabbit and monkey healthy eyes (Ashton and
Cunha-Vaz, 1965; Bill, 1975; Raviola, 1974; Smith and Rudt, 1975;
Vegge, 1971). Butler et al. (1988) and Shakib and Cunha-Vaz (1966)
claimed species differences in the iris vessel permeability, but the
conclusions were contradictory (see also Ashton and Cunha-Vaz,
1965; Cole, 1974). Also, in ciliary muscle vessels, horseradish
peroxidase does not escape from the blood circulation to the
extravascular space (Raviola, 1977). However, the vessels of ciliary
processes are leaky in rabbits and monkeys allowing permeation of
proteins (myoglobin 4 nm; albumin 7 nm; gammaglobulin 11 nm)
across their walls (Bill, 1968; Bill et al., 1980; Smith and Rudt, 1975).
The epithelial components of BAB also have tight intercellular
junctions (Fig. 2). The iris posterior epithelium does not allow
permeation of horseradish peroxidase (4 nm) (Raviola, 1977;
Tonjum and Pedersen, 1977). Likewise, the non-pigmented
epithelium of monkey did not allow permeation of micro-
peroxidase or horseradish peroxidase (Raviola, 1974; Smith and
Rudt, 1975).
It is difficult to assess the permeability of the BAB and BRB
separately because an intravitreal drug is usually eliminated
through the BAB and BRB simultaneously (Fig. 2). Likewise, an
intravenously administered drug distributes to the eye through the
BAB and BRB (Fig. 2), therefore, it is difficult to assess the contri-
bution of each route separately. Some insight might be obtainedfrom intracameral elimination data. Intracameral drugs are elimi-
nated from the eye mainly via aqueous humor outflow and the
veins of the iris and ciliary body (Urtti, 2006). Aqueous humor
outflow is relatively constant and therefore the contribution of the
iris and ciliary body veins can easily be calculated when the
intracameral total clearance has been determined. Clearance via the
blood flow is essentially zero for large molecules (like inulin) and
approximately 10e20 ml/min for small lipophilic compounds (Urtti,
2006; Urtti et al., 1990). This means that the BAB, like the BRB, is a
tight barrier for proteins and other macromolecules (2 nm and
larger), but allows permeation of small molecules. The total blood
flow in the iris and ciliary body of rabbit is about 144 ml/min (del
Amo and Urtti, 2015; Nilsson and Alm, 2012). This indicates that
the small molecules have extraction ratios of approximately
0.07e0.14 in the rabbit iris and ciliary body.2.4. Active transport in blood-ocular barrier
The physical structure of the blood-ocular barrier defines the
level of passive drug permeation in the barrier. Obviously, the
permeability also depends on the chemical drug properties as
discussed above, however active transporters may affect perme-
ation of drugs that are substrates of transporter proteins. Trans-
porters have been reviewed thoroughly (Hosoya et al., 2011;
Mannermaa et al., 2006) and, therefore, we do not review this
aspect here in detail. It is important to note, however, that trans-
porter proteins have not been systematically quantitated in the eye
at the protein level. The expression levels of transporters vary be-
tween cell types (different in vitro models) and also contradictory
results have been published (e.g. P-gp expression in the ARPE19 cell
line) (for more information, see section 9.3). Little is known about
the localization of the transporter proteins (apical or basolateral
surface).
Physicochemical molecular descriptors (H-bonding and LogD7.4)
show good correlation with intravitreal half-life and clearance of
small molecular drugs without outliers (del Amo et al., 2015;
Kidron et al., 2012). This indicates that the active transport is not
an important factor in intravitreal clearance among those com-
pounds in the data sets (del Amo et al., 2015; Kidron et al., 2012). On
the other hand, in vivo fluorophotometry estimates of blood-ocular
barrier permeability suggest an important role of active transport.
The inward permeability of fluorescein is 107 - 106 cm/s, while
outward permeability is about 105 cm/s in monkeys and humans
(Blair and Rusin, 1986; Cunha-Vaz and Maurice, 1967; Oguro et al.,
1985) indicating directionality and active transport in the blood-
ocular barrier. Other examples, investigated in rats, include pra-
vastatin that was eliminated from the vitreous via active transport
(OATP1A4 and OAT3) after intravitreal injection (Fujii et al., 2015),
propranolol that was transported via influx transporters across
BRB, and inhibitors (pyrilamine, TEA, verapamil) that reduced the
retinal uptake of propranolol in the in vivo study (Kubo et al., 2013).
Active influx and efflux transport phenomena are complex and
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processes are active simultaneously. For example, SLC and ABC
transporters share many common substrates and, therefore, func-
tional consequences of the interactions are unclear (Chapy et al.,
2016).
Overall, the pharmacological significance of active transport in
the posterior eye segment is still unclear. More information about
the expression and localization of the transporters in the blood-
ocular barrier components is needed. Furthermore, it is important
to note that the importance of transporter activity is relative and
dependent on the rate of passive drug diffusion (Sugano et al.,
2010). For example, if the passive diffusion is much faster than
the maximal active transport (Vmax), it is obvious that the trans-
porters do not have a significant role. Extensive passive diffusion
tends to decrease the relative impact of active transport. Unlike
passive diffusion, active transport is saturable and its relative effi-
cacy and importance are pronounced at low drug concentrations,
but decreased at high drug concentrations. Drug concentrations at
the blood-ocular barriers after intravitreal administration are
clearly higher than after systemic or topical drug delivery.
2.5. Summary on barriers
Blood-ocular barriers do not allow permeation of proteins and
other large molecules, but they do allow permeation of small
molecules. For this reason, the intravitreal clearance of small mol-
ecules is much faster than the clearance of biologics and it is also
easier to deliver small drugs inwards into the eye. This aspect will
be discussed more quantitatively in the following chapters. It is
important to note that the role of barriers depends on the perme-
ating species (small molecule, biological, drug delivery system).
3. Intravitreal drug administration
There are numerous acquired and inherited posterior segment
diseases with existing and emerging drug targets. Some recent
reviews discuss the various drug targets in the retina and chroroid
(Campochiaro, 2015; Doonan et al., 2012; Grassmann et al., 2015;
Guadagni et al., 2015). Some of these targets are located in the
ganglion cells, photoreceptors, retinal pigment epithelial cells, and
chroroidal endothelial cells.
3.1. Drug distribution and interactions with the vitreous
After intravitreal injection, drugs distribute within the vitreal
cavity and they enter the extracellular and intracellular drug targets
in the posterior eye segment (Fig.1). The vitreous acts as a barrier in
drug delivery, but its role is strongly dependent on the drug mol-
ecules and formulations: the barrier function ranges from insig-
nificant to important.
3.1.1. Vitreous humor
The vitreous humor consists of hyaluronan, an anionic hydro-
philic polymer with a high molecular weight (MW 2e4 million Da),
and collagen fibres that provide strength and resistance to trac-
tional forces. Hyaluronan attracts counterions and water, but yet it
bears an overall net negative charge (Le Goff and Bishop, 2008).
Hyaluronan also provides swelling pressure that pushes apart the
fibrillar proteins. However, hyaluronan is not uniformly distributed
within the vitreous; the highest concentrations are in the posterior
vitreous cortex and the central vitreous is more liquid than the
cortical vitreous (Le Goff and Bishop, 2008) (Fig. 3). The kinematic
viscosity of the vitreous humor has been determined to be
300e2000 cSt (Yang et al., 2014) and hydraulic resistivity is
1.725 1013 M2 (Missel, 2012). It should be noted that, as a personages, the rheological properties of the vitreous change and tend
towards a more liquid form (Laude et al., 2010). Rabbit vitreous is
often considered to be more viscous than the vitreous in humans,
but this issue is not clear in the scientific literature. It is important
to note that, like in humans, the vitreous viscosity decreases with
age in rabbits (Los, 2008; Munger et al., 1989). It is known that the
hyaluronic acid concentration in rabbit and human vitreous are
20e40 and 100e400 mg/ml, respectively (Balazs, 1983; Boruchoff
and Woodin, 1956). Collagen concentrations in rabbit and human
do not show clear differences either. Proper rheological de-
terminations are needed to show the real vitreous viscosity pa-
rameters in the rabbit, man and other species.
Compared to the plasma, the average protein concentration in
the healthy human vitreous is low. The vitreous contains both
structural proteins (collagen II, IX and V/XI, fibrillin and cartilage
oligomeric matrix protein) (Bishop, 1996; Nguyen and Fife, 1986)
and non-structural proteins (albumin, immunoglobulin, comple-
ment proteins, globulins, transferrin) (Chen and Chen,1981; Laicine
and Haddad, 1994; Ulrich et al., 2008). In vitreoretinal disease,
protein concentrations may rise; it was reported in a recent study
that the vitreous protein concentration in a normal vitreous was
4.7 ± 1.2 mg/ml, while in proliferative diabetic retinopathy it was
5.1 ± 1.8 mg/ml (Loukovaara et al., 2015). From a pharmacokinetic
viewpoint this increase is insignificant.
The human vitreous has been analysed using proteomic
methods, such as 2D-PAGE, ESI-MS, MALDI-MS and LC-MS/MS.
These studies have compared the healthy and diseased eye (pro-
liferative diabetic retinopathy, proliferative vitreo-retinopathy,
diabetic retinopathy, diabetic macular oedema) (Gao et al., 2008;
Kim et al., 2007; Koyama et al., 2003; Nakanishi et al., 2002;
Ouchi et al., 2005; Robinson et al., 2006; Shitama et al., 2008;
Wang et al., 2012). The protein classes in the healthy eye include
proteases, protease inhibitors, complement and coagulation
cascade hormones, growth factors, cytokines, receptors, apoptosis
regulation, and proteins related to signalling activity and visual
perception (Murthy et al., 2014). Like other biological fluids, human
vitreous samples also showed heterogeneity between individual
test samples (Aretz et al., 2013). In the diseased eye (proliferative
diabetic retinopathy) some unique proteins (enolase, catalase)
were identified (Lee et al., 2004; Yamane, 2003). This suggest that
these proteins are specifically expressed in the diseased eye.
3.1.2. Diffusion in the vitreous
Diffusion of molecules and nanoparticles has been measured in
the vitreous using particle tracking methods and confocal micro-
scopy. The mesh size in the bovine vitreous was estimated to be in
the range of 500 nm (Peeters et al., 2005; Xu et al., 2013) and even
in a non-liquefied state the vitreous is not a tight barrier for
diffusion (Turunen, 2016). In comparison with the mesh size in the
tight epithelia and endothelia (about 2 nm), the vitreous is quite
open allowing relatively unrestricted molecular mobility. The
vitreal hindrance of diffusion can be estimated by comparing
diffusion in the vitreous to diffusion inwater. Upon liquefaction, the
viscosity of the vitreous is approaching that of water in some re-
gions, but detailed rheological data about these changes is still
missing. Despite this, we can assume that the diffusion coefficient
in water is the maximal diffusivity that could be achieved upon
complete liquefaction. Xu et al. (2013) measured diffusivity of flu-
orescently labelled nanoparticles in the bovine vitreous and
compared the diffusion coefficient values to the diffusivity in water
(calculated using Stokes-Einstein equation). The conclusion was
that the diffusion coefficient of neutral PEG-coated polystyrene
nanoparticles (up to the size of about 0.5 mm) is only about two
times smaller than in water, whereas the diffusivity of anionic
nanoparticles showed similar changes (about two times higher
Fig. 3. Zones of hyaluronic acid concentrations in the vitreous (Bos et al., 2001).
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2013). As the diffusion hindrance factor of the vitreous humor is
very small even for nanoparticles, it is obvious that the diffusion of
anionic and neutral molecules is not restricted in the vitreous. For
example, biologics are typically less than 10 nm in diameter (bev-
acizumab 6.5 nm; ranibizumab 4.1 nm) (Li et al., 2011), which is
very small compared to the mesh size in the bovine vitreous
(z500 nm). Thus, their movement is not restricted in the vitreous.
Peeters et al. (2005) also showed that the diffusivity of FITC-
dextrans is not significantly restricted in the vitreous humor.
Furthermore, it is unlikely that the vitreal liquefaction in elderly
patients would have any significant effects when the mesh size,
even before liquefaction, does not restrict diffusion.
In Fig. 4 we have collated diffusion coefficients from the litera-
ture (Xu et al., 2013) and from unpublished experiments with
similar method (Turunen, 2016) (see Figure legend). The experi-
mental diffusion coefficients in the vitreous were compared to the
calculated diffusion coefficients in water (Stokes-Einstein equa-
tion). Moreover, diffusion coefficients of small MW compounds
(Gisladottir et al., 2009; Tojo et al., 1999) and macromolecules (Dias
andMitra, 2000) were included. Their radii were obtained from the
literature (Ambati et al., 2000; Prausnitz and Noonan, 1998; Shatz
et al., 2016). Overall, the vitreous humor is a relatively loose
structure both in the normal and liquefied state (after hyaluroni-
dase treatment): the diffusivities were not significantly different
from water. Even though the vitreous has hardly any effect on the
diffusion of molecules or anionic nanoparticles, it may significantly
hinder the diffusion of particles with a size range above 500 nm (Xu
et al., 2013, Fig. 4). Importantly, the diffusion of positively charged
nanoparticles and polymers is dramatically restricted in the vitre-
ous (reduction of diffusion coefficient by factor of 103), both in the
liquefied and normal state (Fig. 4). This is understandable as the
vitreous is a negatively charged polymer network capable of
interacting with the cationic particles based on electrostatics. Un-
fortunately, the impact of cationic charge density of hydrophobic
regions on the mobility of macromolecules or particles in the vit-
reous is unclear. Surprisingly, the available data of experimental
diffusion in vitreous of the small molecule ganciclovir (Tojo et al.,
1999) and dexamethasone (Gisladottir et al., 2009) and the bigger
molecule FITC-dextran 4 kDa (Dias and Mitra, 2000) seemed to be
higher than their theoretical diffusivity in water (for more detailed
information see Supplementary Table 1). Overall, the conclusions
about the vitreal barrier are quite obvious: 1) for dissolved mole-
cules and small nanoparticles, the vitreous does not represent asignificant restriction to drug diffusion as compared to water; 2)
increased particle size decreases the mobility in the vitreous; 3)
liquefaction causes a modest increase in particle diffusion in the
vitreous; 4) multiple cationic charges in the particles cause major
restriction to particle movement in the vitreous.
Microspheres, suspension particles, and implants are much
bigger than nanoparticles and they do not diffuse through the
vitreous. PLGA microparticles are not expected to move in the vit-
reous as they have the tendency to aggregate after injection (Barcia
et al., 2009; Giordano et al., 1995; Herrero-Vanrell et al., 2014;
Herrero-Vanrell and Refojo, 2001). Microsphere movement may
change in some cases, for example in aphakic eyes and after
liquefaction of the vitreous. The influence of the lens on the
movement of microspheres has been described in rabbits (Algvere
and Bill, 1979). Intravitreously injected non-degradable plastic
microparticles (7e10 mm size) were retained in the vitreous cavity
in phakic eyes, while some particles moved to the anterior chamber
in aphakic eyes (Algvere and Bill, 1979). Intracameral injections of
non-degradable polystyrene microbeads (about 10 mm) to rats have
been used in purpose to elevate the intraocular pressure in animal
experiments (Smedowski et al., 2014). However, the impact of
particle size and surface characteristics on pharmaceutical particles
on the outflow facility is not known.
3.1.3. Convection in the vitreous
In addition to diffusion, also convection may play a role in
intravitreal drug distribution. The velocity of convective fluid flow
from the ciliary body across the retina has been estimated to be
about 2  105 cm/min in rabbit eyes (Araie and Maurice, 1991).
Velocity of posterior fluid movement is negligible compared to the
aqueous humor flow to the anterior chamber. Distribution contours
in the rabbit eyes after intravitreal injection of FITC-dextran
(66 kDa) indicated that convective flow towards the retina had
only a minor contribution in its ocular distribution (Araie and
Maurice, 1991). Later Missel (2012) investigated the role of
convective flow in the intravitreal molecular distribution using
finite element modeling. Based on current experimental evidence
the convective flow towards retina is not a major contributing
factor in the distribution of dissolved intravitreal drugs. The role of
convective flow in the distribution of drug formulations has not
been investigated.
3.1.4. Drug interactions with the vitreous
Compared to human plasma the number of proteins in the
Fig. 4. Diffusion coefficients of molecules and particles in the vitreous. The nanoparticle data have been extracted from Xu et al. (2013) and Turunen (2016). Xu et al. (2013) used
polystyrene and PLGA nanoparticles, whereas Turunen (2016) carried out the experiments using liposomes. In both studies diffusion coefficients were determined using particle
tracking with confocal microscope in intact posterior segment of the bovine and porcine eye, respectively. Liquefaction of the vitreous was done using hyaluronidase treatment
(Turunen, 2016). The red symbols correspond to cationic nanoparticles. For small compounds and macromolecules, the diffusion coefficients in water were calculated using the radii
obtained from literature for fluorescein, dexamethasone, ganciclovir, hyaluronic acid 500 kDa, pegaptanib, aflibercept, bevacizumab, albumin, ranibizumab, FITC-dextran 150 kDa,
FITC-dextran 80 kDa, FITC-dextran 40 kDa, FITC-dextran 20 kDa, FITC-dextran 10 kDa and FITC-dextran 4 kDa. The experimental diffusion coefficient in rabbit vitreous was obtained
for dexamethasone and FITC-dextran 4 kDa (Dias and Mitra, 2000; Tojo et al., 1999) and in porcine vitreous for ganciclovir (Gisladottir et al., 2009).
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plasma) and the protein concentration is less (<5 mg/ml, typically
0.5e1.5 mg/ml) than in the plasma (60e80 mg/ml) (Angi et al.,
2012). Only sparse data is available about the protein binding of
drugs in the vitreous, even though this factor might affect the
pharmacokinetics of small molecule drugs in the eye. Even though
the protein levels in vitreous are less than in the plasma, yet protein
binding is possible. Protein binding and other binding events in the
vitreous are expected to slow down drug elimination from the
vitreous, because the proteins have much slower elimination from
the vitreous than the small molecules (this may be analogous sit-
uation with the effect of plasma protein binding on renal clearance
of drugs). Two reports have studied protein binding of antibiotics
(fosfomycin, levofloxacin, vancomycin) in the human vitreous. The
binding was negligible unbound fraction being 90e99% (Petternel
et al., 2004; Schauersberger and Jager, 2002). The data about this
issue is so sparse that the outcome of that study should not be
generalized.
Protein stability involves physical phenomena and conforma-
tion changes that are not relevant for small molecules (Manning
et al., 2010). Intravitreal injection is challenging because the pro-
tein drug should remain stable during manufacturing, sterilization,
shelf-life and in vivo within the vitreous. In the case of controlled
release formulations, the protein drug must remain stable within
the formulation at vitreous temperature for weeks, even months.
After its release from the delivery system, the protein drug will be
exposed to the vitreous components without stabilizing excipients,
leaving the protein subject to possible destabilization. Aggregation
and conformational changes may decrease the efficacy of the pro-
tein drug and may also have immunological consequences. Patel
et al. (2015) investigated the stability of two antibodies and one
antibody fragment in three porcine vitreous models. It seems thatthe pH rise was the major factor that lead to the protein aggrega-
tion. Aggregation was avoided in a semi-dynamic model where pH
drift has been addressed. Proteins are also susceptible to proteolytic
enzymes. The levels of proteolytic enzymes (e.g. serine proteases)
are elevated in the aging human vitreous (Vaughan-Thomas et al.,
2000), but it is not yet clear if this has impact on protein drugs.3.1.5. Distribution to the surrounding ocular tissues
Intravitreal drugs distribute to the surrounding tissues
depending on their membrane permeability and binding affinity to
lipids, proteins, melanin and other cell components. Particularly,
drug binding to melanin may increase drug concentration in the
cells substantially (Potts, 1964). The cellular drug delivery issues are
discussed more in chapter 9.
The volume of distribution is a pharmacokinetic parameter that
describes the extent of drug distribution and binding after its
administration. After intravitreal injection, the eye behaves like an
isolated tissue, because the blood circulation acts like a sink where
the drug is diluted so much that the drug concentrations in the
plasma do not have influence on ocular drug concentration profiles.
Therefore, a separate volume of distribution can be determined for
the eye. Del Amo et al. (2015) collected all available intravitreal
injection data from rabbit and human experiments and determined
the intravitreal volumes of drug distribution. Interestingly, the
intravitreal volumes of drug distributionwere nearly constant (80%
in the range 1.2e2.2 ml in the rabbits) and the volumes were not
dependent on drug properties (e.g. molecular weight and lip-
ophilicity) (see Section 3.2.3). The volume of drug distribution in
rabbit eyes is close to the anatomical volume of the vitreous humor,
indicating that the surrounding tissues (retina, lens, ciliary body,
iris) have only a minor impact on the volume of distribution. This is
due to two factors: 1) the anatomical size of the surrounding tissues
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for volume distribution is as follows: Vss ¼ Vv þ Kp1 V1 þ Kp2 V2 …,
where Vv is the volume of vitreous, Kp1, Kp2 and so on are the
partition coefficients between the tissue and vitreous, and V1, V2
etc. describe the anatomical volumes of the surrounding tissues. In
the eye Vv [ V1, V2 …; 2) Most surrounding tissues (except the
lens) are not only drug distribution sites, but they also act as routes
for drug elimination towards the systemic blood circulation.
Therefore, back diffusion from these sites to the vitreous is limited
and it does not affect volume of distribution significantly.
3.2. Drug elimination from the vitreous
In principle, drug elimination from the vitreous could take place
via biotransformation or physical elimination to the blood circu-
lation. Mostly, drugs are eliminated using the second mechanism
and from the blood circulation, are then eliminated from the body
by metabolic clearance (mostly in the liver) and renal excretion to
the urine.
3.2.1. Metabolic drug elimination
Drug metabolism in the vitreous has not been explored in a
systematic manner. There is, however, some evidence for the
presence of minor amounts of metabolic enzymes in the vitreous
humor. For example, esterase and peptidase activity exists in the
vitreous humor (Dias et al., 2002). This has been used in the case of
ester pro-drugs of acyclovir and ganciclovir (Duvvuri et al., 2004),
even though the esterase activity in many other ocular tissues (e.g.
iris, ciliary body) and plasma is much higher (J€arvinen et al., 1995).
Dipeptide prodrugs of ganciclovir are also converted to the parent
compound in the vitreous humor (Majumdar et al., 2006). However,
there are no reports showing the presence of any phase I or phase II
metabolic enzymes in the vitreous humor. This may explain the low
importance of metabolic drug clearance in the vitreous.
There are other enzymes in the vitreous that are relevant for the
action of some drug delivery systems: matrix metalloproteinases
(MMP's), Trypsin 1 and Trypsin-2 are present in the vitreous
humor and are capable of digesting collagen II (van Deemter et al.,
2013). Alcohol dehydrogenase and various other enzymes are
involved in the production of hyaluronic acid and lipid metabolismFig. 5. Elimination routes of drugs from the vitreal cavity. Anterior clearance route means
humor via outflow channels in the trabecular meshwork (A), while posterior clearance take
(B).in the vitreous (Berman, 1991). In the ageing human vitreous the
levels of certain matrix metalloproteinases (MMP's), cysteine pro-
teases and serine proteases were found to be elevated (Vaughan-
Thomas et al., 2000).3.2.2. Drug elimination through blood-ocular barriers
After intravitreal injection, drugs are eliminated from the eye
either via the anterior route or posterior route (Fig. 5) (Maurice and
Mishima, 1984). The anterior route is available for all drugs and it is
based on drug diffusion through the vitreous humor towards the
posterior chamber where it enters the aqueous humor. Thereafter,
the drug will be subject to elimination in the outflow of aqueous
humor (arrow 1 in Fig. 5). The posterior route is available only for
the compounds that are capable of crossing the endothelia and
epithelia of blood-ocular barriers (see section 2). These barriers are
selective, allowing passage of small molecules, while restricting the
permeation of large molecules (appr. 2 nm and bigger). Posterior
routes involve drug elimination through the blood-aqueous barrier
(vascular endothelia and epithelia in the ciliary body and iris) (ar-
rows 2 and 3 in Fig. 5B), and blood-retinal barrier (retinal capillaries
and retinal pigment epithelium) (arrow 4 in Fig. 5B). Therefore,
small molecules with lipophilic properties are cleared from the
vitreous faster than large molecules. The half-lives of small mole-
cules are typically in the range of 1e10 h, while the half-lives of
proteins and other large molecules are several days (del Amo et al.,
2015; Kidron et al., 2012; Maurice and Mishima, 1984).
Recently thorough analysis of the drug elimination from the
vitreous in rabbits and humans were carried out (del Amo et al.,
2015; del Amo and Urtti, 2015). The published intravitreal injec-
tion data were subjected to curve fitting analyses to determine the
clearance and volume of distribution. Herein, three new com-
pounds were added to the previous data set of 52 intravitreal drugs
in rabbit eye (del Amo et al., 2015): melphalan (MW ¼ 305.2 Da,
Vss,ivt ¼ 1.62 ml, CLivt ¼ 1.033 ml/h, t1/2, ivt ¼ 1.1 h); daptomycin
(MW ¼ 1620.67 Da, Vss, ivt ¼ 1.47 ml, CLivt ¼ 0.041 ml/h, t1/2,
ivt ¼ 24.6 h) and ziv-aflibercept (MW ¼ 97,000 Da, Vss,ivt ¼ 4.04 ml,
CLivt ¼ 0.028 ml/h, t1/2,ivt ¼ 100 h) (pharmacokinetic data was
extracted from Buitrago et al. (2016), Ozcimen et al. (2015) and Park
et al. (2015) respectively). The results are shown in Fig. 6 (more
detailed data are found in the Supplementary Material Table 2). It isdiffusion in the vitreous to the posterior chamber and, thereafter, flow in the aqueous
s place when the drug is eliminated through blood-retinal and blood-aqueous barriers
Fig. 6. Pharmacokinetics of intravitreal drugs in the rabbit eyes. The data presents all published literature till 2016 that fulfilled the quality criteria (del Amo et al., 2015) with a final
set of 55 compounds. A) Clearance from the vitreous for small lipophilic (LogD7.4 > 0) (red symbols), small hydrophilic (LogD7.4 < 0) (blue symbols), and macromolecules (green
symbols). For the full data, see Supplementary Material Table 2 and del Amo et al. (2015). Flow rates in the choroid and aqueous humor are presented for comparison. Also, ciliary
body (1), iridial (2) and retinal (3) blood flows are presented. B) Volume of distribution of drugs in the rabbit vitreous. Symbols are the same as in 6A. The dotted line is average
anatomical volume of the rabbit vitreous. C) RPE contribution to the vitreal clearance was calculated for betaxolol and carboxyfluorescein (orange symbols) based in their
permeability in the RPE (Pitk€anen et al., 2005) and surface area of the rabbit RPE. The RPE mediated clearance is in the same range with the expected total in vivo clearance from the
vitreous indicating a major role of the RPE in the elimination of these compounds. D) RPE contribution to the vitreal clearance was calculated in the same way for FITC-dextrans
(orange symbols). The RPE mediated protein clearance is much smaller than the expected total in vivo clearance from the vitreous (green symbols). This indicates that the RPE is a
major barrier for macromolecule elimination from the vitreous, and only 3e20% of the injected dose is eliminated through the RPE.
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smaller than the clearance of small molecules or the rate of aqueous
humor outflow (Fig. 6A).
For small molecular weight compounds, the clearance values are
higher than for proteins and the clearance values of small mole-
cules show about 50-fold range (Fig. 6A). The highest clearance
values are much higher than the aqueous humor outflow, while the
smallest values are far below the rate of aqueous humor turnover
(Fig. 6A). This indicates that the compounds with high clearance
values are eliminated through blood-ocular barriers and the
permeability in these barriers is the most important determinant ofthe clearance. Clearance values of small molecules were correlated
with molecular descriptors using the quantitative structure prop-
erty relationship (QSPR) approach. The model demonstrated that
intravitreal clearance (CLivt) can be predicted with a simple equa-
tion based on hydrogen bonding (HD) and LogD7.4 values: Log
CLivt ¼ 0.252690.53747 (Log HD) þ 0.05189 (Log D7.4) (del Amo
et al., 2015). These molecular descriptors (LogD7.4, HD) are relevant
for permeability in the lipid membranes, such as blood-ocular
barriers, supporting the notion that the clearance depends on the
membrane permeability. Small molecular diffusion is expected to
be nearly constant in the vitreous, but the clearance values show
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an important parameter for the clearance of small molecular drugs.
Rather, the permeability in the blood-ocular barriers is the rate-
limiting step.
3.2.3. Elimination via anterior route
For anterior elimination, the drug must diffuse in the vitreous
and gain access to the aqueous humor in the posterior chamber.
Accordingly, the differences in the diffusivity of biologicals in the
vitreous determine the anterior clearance that is relatively constant
(maximally about 3-fold range over MW range of
7100e177,000 Da) (Fig. 6A, green triangles). This is in line with the
relatively unrestricted diffusion in the vitreous and modest differ-
ences that are expected from Stokes-Einstein equation for molec-
ular diffusion. Niwa et al. (2015) studied the elimination and
efficacy of the anti-VEGF proteins ranibizumab and aflibercept in
normal and vitrectomized monkey eyes. The area under the con-
centrationetime curve (AUC) values of intravitreal ranibizumab
and aflibercept changed slightly after vitrectomy: ranibizumab
(normal: 171,000 ± 65,200 day x ng/ml, vitrectomized:
154,000 ± 42,400 day x ng/ml) and aflibercept (normal;
174,000 ± 35,200 day x ng/ml, vitrectomized 124,000 ± 64,300 day
x ng/ml). These results are in line with the modest effects of vitreal
liquefaction on the diffusivity (Fig. 4) and narrow (3-fold) range of
clearance values for anteriorly eliminated biologics (Fig. 6A).
Recently, it was shown that intravitreal clearance of antibodies
correlates well with the hydrodynamic molecular radii (Shatz et al.,
2016). This was explained based on the relationship between the
diffusion coefficient in the vitreous and hydrodynamic radii of the
compounds. These conclusions also indicate that investigations on
the macromolecule diffusion in the vitreous may be useful in pre-
dicting the clearance of large molecules from the vitreous. It seems
that the vitreous has an impact on protein drug elimination, but the
range of clearance values is narrow.
Intravitreal clearance should be equal with the rate of aqueous
humor outflow if the vitreous and aqueous humors act as a single
mixed tank, but they do not. The iris, ciliary body, lens and vitreous
humor are limiting the access of the drug to the aqueous humor
(Fig. 5). It is unlikely that the drugs would diffuse through these
tissues, but they do diffuse through the vitreous humor to the
aqueous humor. Interestingly, the clearance values of macromole-
cules are about 5e50 times higher than the expected clearance
through the RPE (calculated as permeability x surface area ; based
on RPE permeability values of FITC dextrans with similar MW range
than the macromolecules) (Fig. 6D; del Amo and Urtti, 2015;
Pitk€anen et al., 2005). This indicates that the posterior elimina-
tion of proteins via BRB is negligible and they are eliminated via the
anterior pathway (Fig. 5A). Some investigations have claimed that
proteins, like bevacizumab, permeate through the BRB and are
eliminated mostly via this route to the blood circulation (Gal-Or
et al., 2016; Stewart, 2014). These claims are not on solid ground
quantitatively, because bevacizumab permeation to retinal layers
and the choroid has been shown only qualitatively with immuno-
histochemistry (Heiduschka et al., 2007). Bevacizumab entrance to
the blood stream has been quantitated, but this drug also enters the
blood stream via the anterior route, and this does not prove pos-
terior clearance either. A study by Nomoto et al. (2009) has also
been used as an argument for posterior elimination of bev-
acizumab, but this study is an outlier; three other rabbit and human
studies indicate an anterior elimination (Bakri et al., 2007; Krohne
et al., 2008; Meyer et al., 2011) (for detailed data analyses, see del
Amo and Urtti (2015)). The anterior route of elimination has been
observed for ranibizumab in human eyes (Krohne et al., 2012) and
for 125I-albumin and fluoresceinated-dextran (MW of 66 kDa) in
rabbit eyes (Araie and Maurice, 1991; Johnson and Maurice, 1984;Maurice, 1976, 1959; Maurice and Mishima, 1984).
Pharmacological activity of anti-VEGF proteins (ranibizumab,
bevacizumab, aflibercept) leads to reduced choroidal vessel leaki-
ness and oedema. This does not mean that these proteins would
permeate to a great extent through blood retina barrier. Firstly, the
exact sites of action for VEGF binding activity of the drugs are not
known. They may bind VEGF in the retina leading to sequestration
of VEGF and reduced VEGF-receptor occupancy. Secondly, these
compounds are active at low concentrations so that only a small
fraction of the dose is needed for pharmacological activity in the
choroidal vessels. Thirdly, blood retina barrier may be compro-
mised in the disease and facilitating drug access to the choroid. This
is discussed in more detail in the chapter 10.1.
3.2.4. Roles of blood-ocular barrier components in vitreal drug
elimination
The flux of a drug across a biomembrane (J; mg/h) is defined by
the equation J ¼ C x CL ¼ C x P x S, where C is the concentration
gradient (e.g. vitreous vs. blood) (mg/ml), CL is the drug clearance
from the donor compartment through the membrane (ml/h), P is
the drug permeability in the membrane (cm/h) and S is the surface
area of the membrane (cm2). Importantly, the permeability de-
pends on the partition coefficient of the drug between the vitreous
and the blood-ocular barrier membrane, membrane thickness and
the diffusion coefficient of the drug in the membrane. Therefore,
the drugs with high partitioning and permeation in the blood-
ocular barriers will have high intravitreal clearance. Using indi-
vidual clearances for different parts of blood ocular barrier, it
should be possible to dissect the roles of each barrier, but unfor-
tunately the experimental data and methods do not provide
adequate support for this approach.
In the blood-retinal barrier, the RPE is amajor barrier and its role
can be dissected because RPE permeability can be studied reliably
ex vivo (Pitk€anen et al., 2005). Based on the equation above, the
clearance values of small molecules through the RPE are estimated
to be 0.02e0.36 ml/h depending on the RPE permeability of the
compounds (S¼ 5.2 cm2; P¼ 1e19 106 cm/s) (Mannermaa et al.,
2010; Pitk€anen et al., 2005). Blood circulation in the choroid is high
(62 ml/h in rabbits, 96 ml/h in pigs), the blood vessels have high
surface area (400e600 mm2 in rabbits) (Bill et al., 1980), and leaky
structure with openings of 70e80 nm. The openings are much
bigger than the size of drug molecules, and choroidal tissue is an
order of magnitude leakier than the RPE (T€ornquist et al., 1990).
Therefore, the choroid acts as a sink that efficiently removes drugs
to the blood circulation. Drug concentrations in the extravascular
choroidal tissue are expected to equilibrate rapidly with the
plasma. Two conclusions can be obtained from the RPE mediated
clearances (0.02e0.36 ml/h): 1) The process is membrane
controlled, because the clearance values are low compared to the
blood flow in the choroid (62 ml/min); 2) Comparison of total
clearance values from the vitreous and the RPE mediated clearance
values (Fig. 6A) indicates that the RPE permeation constitutes a
major fraction of the vitreal clearance for the high clearance com-
pounds (Fig. 6C), but the RPE is insignificant player in the vitreal
clearance of macromolecules (Fig. 6D).
Permeability of retinal capillaries is difficult to measure and
there are no reliable estimates. It is obvious from the anatomy that
the surface area of the capillaries (20e25 mm2) (Maurice and
Street, 1957) is much smaller than that of the RPE (520 mm2) in
rabbits (Reichenbach et al., 1994) and also in humans. Retinal
capillary endothelia have tight junctions, and therefore it is likely
that the contribution of retinal capillaries to the vitreal drug
clearance is much smaller than that of the RPE.
In the blood-aqueous barrier, the surface area of the non-
pigmented ciliary epithelium in human eye is relatively large
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and retinal elimination in overall posterior route clearance are not
known, but based on the large surface area of the non-pigmented
epithelium (in the same range with human RPE,
1204 ± 184 mm2) (Panda-Jonas et al., 1994), modest blood flow of
ciliary body (4.91 ml/h in rabbit, 5.34 ml/h in monkey) and iris
(3.72 ml/h in rabbit, 1.02 ml/h in monkey) (Alm and Bill, 1973;
Nilsson and Alm, 2012) and large surface area of leaky blood ves-
sels in the ciliary processes (670 mm2 in rabbits) (Bill et al., 1980),
this route may play a significant role in the vitreal drug clearance.
However, more research is needed to quantitate the contribution of
blood-aqueous barrier in vitreal drug clearance.
Leakiness of the blood-ocular barriers may be altered in the
pathological conditions. This aspect depends on the disease state
and drug properties. Often times the disease effects are considered
to be prominent by definition. However, based on our literature
analyses of the real pharmacokinetic data indicate that these effects
are surprisingly small (for more information, see chapter 10.1.).
There are two aspects to be considered herein. Firstly, in the case of
highly permeable drugs, the clearance is already quite high and
membrane leakiness may increase the clearance only modestly.
Secondly, clearance of large molecules (like anti-VEGF compounds)
takes place predominantly via anterior route (Fig. 6D). Therefore,
even 10-fold increase in the RPE permeability is expected to in-
crease protein clearance only modestly (about 1.5 fold; calculation
based on the clearance data in del Amo and Urtti (2015)). Excellent
correlation and only 40% difference was seen between the intra-
vitreal clearance values of healthy rabbits and human patients (del
Amo and Urtti, 2015). This difference can be explained based on the
eye size.
3.2.5. Other mechanisms
Target mediated elimination kinetics imply that the drug binds
to its extracellular target at such an extent that it has influence on
the overall drug clearance. This has been shownwith some proteins
in the systemic circulation, including bevacizumab (Panoilia et al.,
2015) and aflibercept (Stewart, 2012). For example, Stewart,
(2012) points out that free aflibercept in the circulation has a
half-life of 1e3 days, but the half-life is extended to 18 days when
the drug is bound to its VEGF-target. Thus, binding to VEGF plays a
role in aflibercept clearance also noted by Dixon et al. (2009).
Because molecular weight affects drug clearance from the vitreous
(Fig. 6A), it is possible that VEGF binding could reduce the clearance
of aflibercept if a large fraction of the dose would be VEGF bound,
but this has not been proven yet. Currently, there is no evidence for
target-mediated elimination from the vitreous.
The neonatal Fc receptor (FcRn) protects immunoglobulin G
(IgG) from catabolism, controls its transport between cell layers
and extends its serum half-life by preventing lysosomal degrada-
tion. The Fc portion of IgG binds with high affinity to FcRn at an
acidic pH (<6.5) but not at a physiological pH (7.4). In systemic
pharmacokinetics FcRn is involved in recycling of monoclonal an-
tibodies so that the half-life of the drug is prolonged in the systemic
circulation. In principle, this kind of recycling might contribute to
intraocular pharmacokinetics as FcRn is expressed in the blood-
ocular barrier of several species (rat, mouse, pig, human) (Kim
et al., 2009a; Powner et al., 2014; van Bilsen et al., 2011). Kim
et al. (2009a) showed that FcRn is expressed in the blood-ocular
barrier and that it plays a role in the elimination of intravitreally
administered IgGs across the BRB. A recent study on porcine eyes
suggests that the FcRn recycling function in the RPE could play a
role in the pharmacokinetics of the posterior eye segment by
maintaining the bevacizumab concentration in the retina (Dithmer
et al., 2016). Also, Deissler et al. (2016) showed that there is an
active FcRn mediated transcytosis of bevacizumab in the retinalendothelial cells. Even though it seems that FcRn is present and
active, it does not seem to have a true quantitative pharmacokinetic
impact in the vitreous like it has in plasma (Gadkar et al., 2015).
Moreover, for aflibercept FcRn related mechanisms of transport
have been shown (Kuo and Aveson, 2011; Zehetner et al., 2015), but
their impact on intravitreal pharmacokinetics has not been proven.
3.3. Drug delivery to the retinal layers from the vitreous
The retina is a crucial tissue as it contains the light sensing cells
and supporting cells that are needed for the vision. The light in-
formation is transferred from the retina to the brain via the optic
nerve. The cellular structure of the retina is complex and drug
distribution and delivery in the retina is not well understood
(Fig. 7). The roles of the retinal pigment epithelium and retinal
endothelia as barriers to drug delivery have been discussed earlier
in this review. The inner limiting membrane, outer limiting mem-
brane and Müller cells represent additional barriers for drug de-
livery from the vitreous to the retina.
3.3.1. The inner limiting membrane (ILM)
The inner limiting membrane (ILM) is located at the vitreal
border of the retina, between the end feet of retinal Müller cells and
the vitreous. The ILM also acts as the basement membrane for
Müller cells. The main components of the ILM are collagen and
glycosaminoglycans and it is a mechanical and electrostatic barrier
with a net negative charge. The pore size of human ILM is suggested
to be approximately 10 nm (Jackson et al., 2003).
It is clear that the hydrophilic ILM structure based on glycos-
aminoglycans and collagen cannot block the diffusion of small
molecules (Jackson et al., 2003). The small molecular drugs diffuse
relatively freely in the vitreous and enter the extracellular space in
the retina easily. The RPE and retinal endothelia constitute barriers,
especially for the hydrophilic compounds. Intracellular delivery of
small molecules into the retinal cell types depends on the usual
factors (passive diffusion and active transport). Unfortunately, there
are only sparse data about the expression of membrane trans-
porters in different cell types in the retina.
In the case of biologics, the ILM does not seem to limit retinal
drug delivery when the molecular weights of the compounds are
below 100 kDa (Jackson et al., 2003). These investigators deter-
mined the maximum molecular sizes that freely penetrate to the
retina in pig, cattle, and rabbit to be 60 ± 11.5, 78.5 ± 20.5 and
86 ± 30 kDa, respectively. Other studies also indicate that there is a
molecular size cut-off, but many biologics have relatively unre-
stricted access to the retina from the vitreous. For example, tissue
plasminogen activator (70 kDa) and rhodamine labelled dextran
(20 kDa) permeated from the vitreous into the sub-retinal space
(Kamei et al., 1999). Likewise, heat shock protein (70 kDa) and
tenecteplase (70 kDa) penetrated to various layers of the retina in
rats and pigs (Yu et al., 2001). These conclusions are supported by
the findings of Pitk€anen et al. (2004), who used ex vivo bovine eyes
in their studies. In these experiments, access of fluorescently
labelled materials to the RPE was determined with flow cytometry
in the presence and absence of the neural retina. The data indicated
that the ILM posed an insignificant barrier for the diffusion of FITC-
dextrans of 20 kDa and 500 kDa. However, the neural retina almost
completely blocked the permeation of highly cationic poly-L-lysine
(20 kDa) to the RPE, suggesting the important role of an electro-
static barrier. There are still important open questions related to the
retinal penetration of biologicals: 1) What is the real actual cut-off
size in terms of molecular radius? FITC-dextran is a polydisperse
material, and therefore, it is difficult to make firm conclusions
about the size cut-off; 2) Poly-L-lysine has a high cationic charge
density, but what is the effect of cationic charges at a smaller charge
Fig. 7. Retinal layers: the outer limiting barrier (OLM), the outer nuclear layer (ONL), outer plexiform layer (OPL), the inner nuclear layer (INL), inner plexiform Layer (IPL), the
ganglion cell Layer (GCL), nerve fibre layer (NFL) and the inner limiting membrane (ILM). Among them the layers that may restrict movement of some molecules and particles are
the inner limiting membrane (ILM), Müller glial cells, outer limiting barrier (OLM), besides the already discussed RPE and the endothelial walls of the retinal capillaries between the
retinal tissue and blood circulation (not shown in the figure). Figure is from Goldman (2014); with permission from Nature Publishing Company.
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histology. Integrity of the tissue becomes an issue. Moreover, these
data are qualitative, not quantitative. What is the quantitative
impact of different retinal layers on the distribution of biologicals?
Quantitation and more accurate cell specific data on the retinal
delivery are needed, because many drugs have intracellular targets
and they must be delivered to the target cells in the retina. The
cellular delivery aspect is more critical for the drugs, especially
biologicals that have intracellular target sites. The ILM and Müller
cell barriers could be significant for nanocarriers (liposomes,
nanoparticles) that are typically larger than the ILM pore size and
many studies suggest that the ILM limits the access of nanoparticles
to the retina (Gan et al., 2013; Kim et al., 2009b; Koo et al., 2012;
Merodio et al., 2002). However, confocal images of Bourges et al.
(2003) showed some permeation of poly(lactide) nanoparticles
(sizes 140 and 300 nm) to the retina. The authors discussed that the
permeation may have been facilitated by ILM rupture, inflamma-
tion or microglial cell activation.
Currently used anti-VEGF drugs (ranibizumab, bevacizumab,
aflibercept, pegaptanib) have extracellular targets, i.e. they bind
extracellular VEGF. Furthermore, it is not clear how deep these
drugs must permeate to the retinal tissue in order to be active. It is
also possible that they sequester VEGF from a distance. Based onthe ILM pore size these drugs should be able to permeate to the
retinal layers, but it is unlikely that they would permeate through
the RPE. Julien et al. (2014) showed that ranibizumab penetrated to
the monkey retina via inter-cellular clefts, whereas aflibercept was
distributed to the neuronal and RPE cells. Heiduschka et al. (2007)
showed that bevacizumab crossed the retina despite a transitory
accumulation in ILM. A possible involvement of retinal glial cell
activation in the permeation is speculated. However, these drugs
are primarily eliminated from the eye via the anterior route (see
section 3.2.3).
There are also variations in the condition of inner limiting
membrane. Thickness of the inner limiting membrane varies being
thicker at the macular region than elsewhere (Heegaard, 1997;
Heegaard et al., 1986). Furthermore, its thickness is increased in
diabetics (To et al., 2013). The impact of the regional and disease
related changes on drug permeation have not been investigated.
Peeling of the inner limiting membrane might increase material
permeation from the vitreous to the retina, but there are no pub-
lished experiments to prove this issue.3.3.2. Müller cells
Müller cells aremajor glial cells in the retina and they contribute
to the normal retinal structure and homeostasis. These cells span all
Table 2
Permeation of various molecules across the outer limiting membrane in the rabbit
retina (Bunt-Milam et al., 1985).
Compound Source Molecular weight (Da) Traverses OLM
Myoglobin Horse muscle 18,000 Yes
Peroxidase Horseradish 44,000 Yes
Albumin Bovine serum 67,000 No
Gamma globulin Rabbit serum 160,000 No
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outer nuclear layer (Fig. 7). They also contribute to the formation of
ILM and outer limiting membrane (OLM). Importantly, like the RPE
cells, the Müller cells are phagocytosing cells and represent part of
the defence mechanism of the eye.
The active receptor mediated endocytosis processes of Müller
cells may play an important role in the retinal pharmacokinetics of
nanoparticles. Dalkara et al. (2009) studied the retinal distribution
of fluorescently labelled AAV-viruses of different serotypes after
intravitreal injection in rats. They showed that only serotypes
having binding sites on ILM and/or Müller cell end feet had access
to retinal layers. Also, studies with hyaluronan- and albumin coated
nanoparticles suggest that active uptake by Müller cells would
provide particles a pathway through the retina (H. Kim et al.,
2009b; Koo et al., 2012). Similarly Kim et al. (2015) postulated
that retinal delivery of albumin nanoparticles with neurotrophic
brimonidine may be mediated via TGF beta receptor mediated
uptake into the Müller cells and retinal ganglion cells. The data is
based on qualitative assays and no truly quantitative data exists in
the literature.
3.3.3. Outer limiting membrane (OLM)
Outer limiting membrane (OLM) is formed by adherent and
tight junctions between the apical processes of Müller cells and
inner segments of the photoreceptor cells. The work by Omri et al.
(2010) suggests that tight junctions may exist in OLM and it should
be considered as part of a retinal barrier that can be disrupted in
pathological conditions. The pore radius of OLM has been estimated
to be 3.0e3.6 nm in rabbit retina. This means that, for example,
albumin and gamma-globulin are too large to diffuse through an
intact OLM (Bunt-Milam et al., 1985). FITC-dextrans were injected
in sub-retinal space of rabbits and their diffusion to the vitreous
was followed by fluorophotometry (Marmor et al., 1985). Carbox-
yfluorescein and FITC-dextran 10-S diffused quickly into the vitre-
ous and disappeared in 8 and 30 h, respectively. However, diffusion
of FITC-dextran 70-S and 150-S (both larger than albumin) was
slow, and about 80% of the 150-S was still in the sub-retinal space
after 3 days (Marmor et al., 1985). Table 2 shows information about
the permeation of various macromolecules across the OLM in the
rabbits suggesting that the molecular weight cut-off is about the
size of an albumin molecule (Bunt-Milam et al., 1985).
However, the size limit and barrier role of OLM is not quite clear.
There are other reports that do not support the barrier role of OLM.
Several studies are showing permeation of macromolecules and
even nanoparticles from the vitreous through OLM (Bourges et al.,
2003; Julien et al., 2014) suggesting that it is much leakier structure
than suggested by Bunt-Milam et al. (1985).
3.3.4. Summary
Several barriers in the neural retina may affect permeation of
large molecules and particles to the retina. The roles of these bar-
riers have not been quantitated and their roles are still not fully
clear. These barriers are difficult to study in quantitative ways,
because they cannot be isolated and placed to diffusion chambers
and the permeants cannot be quantitated in the intact neural
retinal layers.
3.4. Intravitreal drug delivery systems
3.4.1. Macroscopic drug delivery systems
Currently, intravitreal drug delivery is carried out using in-
jections (solutions, suspensions) and implants (del Amo and Urtti,
2008). There are some controlled release intravitreal drug de-
livery systems in clinical use, for example non-degradable (poly-
vinyl/silicone laminate, Retisert) and degradable (polylactic acid -glycolic acid matrix; Ozurdex) implants. They provide long dosing
intervals of 6 months for dexamethasone (Ozurdex) and 3 years for
fluocinolone acetonide (Retisert, Iluvien). Intravitreal drug delivery
systems are widely studied, because there is a need to prolong the
dosing intervals in retinal drug treatment using implants, refillable
injection ports and gels. There are several excellent reviews about
these technologies for interested readers (Hamdi et al., 2015;
Herrero-Vanrell et al., 2014; Yasin et al., 2014). Pharmacokinetics
of the injected solutions was discussed earlier in this review (sec-
tion 3.2). In the case of implants, the relevant kinetic issues are
discussed in section 3.5 (i.e. design of the required release rate,
biodegradation and sink condition aspects).
3.4.2. Particulate drug delivery systems
Particulate systems, such as microspheres and nanoparticles,
have been used for intravitreal drug delivery, because they can be
injected with a small needle. The particles have more complex
intravitreal kinetics than the implants making their design more
difficult. In contrast to the implants, the particles may move in the
vitreous cavity. Therefore, particles may be useful for drug targeting
in the posterior eye segment, but on the other hand, particle
movement may be unpredictable and lead to toxicity. Particle
movement depends on the material, and in some cases particles
may be immobile in the vitreous.
Diffusion in the vitreous is a key parameter that affects the
particle distribution in the vitreal cavity. As shown earlier, poly-
styrene and PLGA nanoparticles with negative or neutral charge
and a size below 500 nm diffuse in the bovine vitreous with little
hindrance (Xu et al., 2013), and the enzymatic cleavage of hyal-
uronic acid slightly changes their diffusivity in porcine vitreous
(Turunen, 2016) (Fig. 4). Cationic liposomes (116e139 nm) showed
about 103 times slower diffusion in the porcine vitreous than
anionic liposomes (138e170 nm), and their diffusion is only slightly
affected by the liquefaction of the vitreous (Fig. 4) (Turunen, 2016).
Microspheres and suspension particles are not capable of diffusing
through the normal vitreous and, therefore, liquefaction should
make a major difference. The changes in the aging vitreous and its
heterogeneous nature (Fig. 3) may change microparticle and sus-
pension distribution potentially leading to interspecies differences
and inter-subject variability (Awwad et al., 2015; Laude et al., 2010).
Quantitative experimental data is, however, needed to prove this
commonly presented clinical viewpoint.
Macromolecules are primarily eliminated from the vitreous via
aqueous humor outflow, because they have insignificant perme-
ation across blood-ocular barriers that limit the permeation to the
entities smaller than 2e4 nm (section 2). Therefore, it is expected
that the anterior, rather than the posterior route, would be relevant
in the elimination of nanoparticles (typically 50e500 nm) and
microparticles (typical diameter in the range of 1e50 mm) from the
vitreous. However, biodegradable polymers may be degraded to
soluble polymer fragments (e.g. polylactide-co-glycolide polymers)
that may be eliminated also across the blood-ocular barriers. As
illustrated in Fig. 8, particle diffusion, material degradation, and
diffusion of degradation products are significant factors in the
elimination process. In addition, there are some active cellular
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vitreous (Fig. 8). The mechanisms are not well understood, because
no mechanistic and quantitative studies have been done to explore
the routes of particle elimination. Most published studies are
qualitative, but a quantitative understanding of the elimination
pathways would be important for the development of particulate
drug delivery systems.
Many nanoparticle and microparticle formulations have been
investigated as intravitreal injectables. Nanoparticles have been
shown to retain in the vitreous or retina for days or weeks (Gan
et al., 2013; Koo et al., 2012; Merodio et al., 2002), whereas the
retention times of microspheres (e.g. PLGA, porous silicon) are 1e6
months depending on the formulation (Giordano et al., 1995;
Moritera et al., 1991; Nieto et al., 2015; Shelke et al., 2011). For
example, bovine serum albumin based nanoparticles with ganci-
clovir (size: 290e303 nm; zeta-potential 27.8 to 25.1 mV)
retained in the rat retina for two weeks (Merodio et al., 2002). Gan
et al. (2013) showed that 75% hyaluronan modified core-shell lip-
onanoparticles (size: 420 nm; zeta-potential25mV)were present
in the posterior eye segment of rats seven days post-injection. Long
retention of polylactide microparticles (mean size 7.6 mm) was
shown in the study Shelke et al. (2011): after three months 17% of
injected particles were still found in the vitreous of rabbits. The
longer retention times of microspheres can be explained in various
ways: 1) Diffusion in the vitreous could be the explanation, since
microspheres have much lower mobility in the vitreous than
nanoparticles (Fig. 4). Therefore, nanoparticles would reach the
aqueous humor more rapidly and become eliminated via the
anterior route; 2) Drug release kinetics may explain the results,
because nanoparticles have higher surface area per weight unit.
They have also a shorter diffusion pathlength for contents release
and the carrier material is more available for hydrolytic and enzy-
matic degradation processes; 3) Nanoparticle studies have been
done in rats (Gan et al., 2013; Koo et al., 2012; Merodio et al., 2002),
whereas microspheres have been tested in rabbits (Moritera et al.,
1991; Nieto et al., 2015; Shelke et al., 2011). Because diffusion time
increases as a function of the distance squared (l2), shorter distance
from injection site in the rat might lead to faster elimination than in
the rabbits; 4) Cellular uptake of the nanoparticles is more effective
than the cellular removal of microspheres (Fig. 8). There are indeedFig. 8. Possible routes of elimination of particulaseveral reasons that might explain the experimental results.
Certainly, it is possible to tune the particle processes in the vitreous
with particle design (Fig. 8).
Microspheres retain longer in the vitreous than nanoparticles,
but the overall picture of particle behaviour in the vitreal cavity is
still far from complete. Only one study has attempted to analyse
retention of both drug and particle material. Shelke et al. (2011)
analysed the retention of particle mass and remaining drug (TG-
0054) in the vitreous of New Zealand White albino rabbits.
Biodegradable poly(L-lactide) microparticles (mean diameter
7.6 mm) were used. In this case, the drug elimination was slightly
faster (17% remaining at 3 months) than the elimination of the
particles (27% remaining at 3 months). In many cases, the analyses
are based only on drug concentrations, but drug release can be
much faster than particle elimination from the vitreous, thereby
leading to erroneous conclusions. Many studies are based on visual
fundus examination and observation of the particles (Giordano
et al., 1995; Moritera et al., 1991; Nieto et al., 2015) or histological
analyses (Gan et al., 2013; Koo et al., 2012; Merodio et al., 2002)
without true quantitation of intact particles or degradation
products.
The vitreal elimination processes compete with each other
(Fig. 8). Particle degradation in the vitreous is not dependent on
particle diffusion, and thus degradation could be the major elimi-
nation mechanism of biomaterial if the degradation takes place
more rapidly than the physical elimination of the particles.
Biodegradation can take place via chemical hydrolysis in the bulk
polymer (PLGA) or at its surface (polyesteramides; Andres-
Guerrero et al., 2015). Enzymatic degradation of the delivery sys-
temmight be subject to inter-subject and inter-species variations of
enzyme expression (section 3.2). As discussed later, the rate of
degradation and the size of the resulting fragments have impact on
the polymer borne material that is present in the vitreous during
the treatment (see section 3.5.).
Without biodegradation the material elimination is expected to
take place mostly via the anterior route. In this case, the choice of
animal species and vitreous viscosity can play a role. It has been
observed that the particles may enter the anterior chamber in the
monkey eyes after intravitreal injection, but not in the rabbit eyes
(Daugherty, conference presentation, Controlled Release Societyte drug delivery systems from the vitreous.
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movement to the anterior chamber in primates, but in rabbits this
movement may be restricted by the more viscous vitreous humor,
but there may be other explanations (e.g. different obstruction by
the lens and iris). Theoretically, obstruction of the outflow channels
is a potential risk related to particle entrance to the anterior
chamber. The critical size and surface characteristics that cause
outflow blockade are not completely known, but intracameral in-
jection of polystyrene particles with diameter of 6e10 mm has been
used to block outflow and generate animal models for elevated
intraocular pressure (Smedowski et al., 2014), but it is not known
whether smaller particles may cause obstruction during long-term
exposure.
Lymphatic drainage is another putative route for particle elim-
ination from the anterior chamber. De Kozak et al. (2004) injected
tamoxifen intravitreally as free drug in solution and in polyethylene
glycol coated polymeric nanoparticles of about 100 nm in diameter
to the rats with experimental autoimmune uveoretinitis. Drug
loaded nanoparticles inhibited ocular inflammation more effi-
ciently than the free tamoxifen and some nanoparticles were
detected inmacrophages in the cervical lymph nodes, but not in the
inguinal lymph nodes. Yücel et al. (2009) showed recently that
nanoparticles (carboxylate modified FluoSpheres, 20 nm) are
localized after intracameral injection to the lymphatic vessel like
structures in the ciliary body in sheep. Lymphatic uveoscleral
clearance from the aqueous humor was also shown with radio-
labeled albumin that was localized to the lymph nodes (Yücel et al.,
2009). However, the concentration of radioactivity in the lymph
nodes (per gram) was one order of magnitude smaller than in
plasma, suggesting that even though such a clearance mechanism
exists, its role is much smaller than the clearance via trabecular
meshwork that leads to systemic circulation. There also seems to be
species differences, since lymphatic clearance was not seen in cats.
Overall, the nanoparticles andmacromolecules are cleared from the
vitreous and aqueous humor using several mechanisms, but cur-
rent evidence supports the major role of aqueous humor outflow
mediated elimination.
Cellular elimination is the main route of nanoparticle elimina-
tion from plasma (Gregoriadis and Ryman, 1972; Poste et al., 1982).
Phagocytosing macrophages of mononuclear phagocyte system
remove the particles effectively in the liver and spleen after their
recognition. Cellular recognition is enhanced by binding of opsonin
proteins (e.g. antibodies, complement components) on the particle
surface in plasma (Owens and Peppas, 2006). This defence mech-
anism has been partly overcome with coated particles that have
reduced protein adherence and slowed removal from the blood
circulation (Illum and Davis, 1984; Owens and Peppas, 2006;
Vonarbourg et al., 2006). In the eye, the phagocytosing defence
cells include Müller cells, astrocytes, and RPE cells. Obviously, the
cellular elimination may be activated in inflamed eye with mac-
rophages (Zeng et al., 2008). These cells phagocytose particles
(even micron size scale) and the Müller cells have similar func-
tionality. Particle recognition and immunological aspects play a
role, but these factors are discussed in section 10 of this review.
Quantitatively, it is not clear how large fraction of the injected
particles can be ingested by the cells and subsequently degraded.
Overall, quantitation of the particle elimination processes is
needed, but this is methodologically challenging.
3.5. PK and PK/PD models for intravitreal drugs
3.5.1. Models for drugs
Pharmacokinetic (PK) and pharmacodynamic (PD) models are
useful scientific tools in drug development. The models integrate
the PK and PK/PD processes in mathematical models that arenecessary in 1) the determination of kinetic parameters; 2) sorting
out the influence of patient related factors in drug kinetics and
responses; 3) preclinical to clinical translation in drug discovery
and development; 4) drug delivery system development; 5) design
of dosing regimens and route of drug administration. Pharmaco-
kinetic models can be divided into top-down and bottom-up
models. Top-down models are used with the existing in vivo data
to solve kinetic parameters. Bottom-upmodels are based on in silico
and in vitro data that are used as components in integratingmodels.
In general pharmacology, the use of PK/PD models is increasing,
because they may speed up drug discovery and development. In
addition, reliable PK/PD models may reduce, replace and refine
animal experiments. Furthermore, the FDA encourages the phar-
maceutical industry to use pharmacokinetic modeling in the
documentation of new drug applications. In ophthalmology, PK/PD
modeling has similar advantages as it has in general pharmacology.
In the following paragraphs we present an update and viewpoints
concerning ocular PK/PD modeling of intravitreal drugs.
The top-down approach has been used to solve intravitreal
ocular PK parameters, such as clearance, volume of distribution and
half-life (for complete analyses of the rabbit data in the literature,
see supplementary materials of del Amo et al. (2015) and
Supplementary Table 2). During the analysis of the intravitreal PK
data, several problems were noticed in the design of the published
studies. For that reason, 58% of the studies could not be included in
the estimation of clearance and volume of distribution values.
Typical problems were related to the sampling times, such as
missing initial, intermediate or terminal phase samples, too short
duration of the study or too sparse sampling (del Amo and Urtti,
2015). These problems undermine the reliability of the PK param-
eter estimates. Intravitreal drug studies involve invasive sampling
procedures and typically the animals are killed at each time point.
Therefore, it is important to design the studies so that maximal
information can be gained with minimal number of laboratory
animals. Pharmacokinetic parameters are important because they
can be used to simulate different situations, such as dosing sce-
narios, thereby being information rich and generalizable. Therefore,
proper design of intravitreal PK studies is important for progress in
the field (for more advice, see del Amo and Urtti (2015)).
Despite some progress in non-invasive sampling (microdialysis
of drugs from the vitreous) and analysis (e.g. magnetic resonance
imaging, in vivo fluorophotometry) intravitreal pharmacokinetic
studies are still invasive. Microdialysis can be used only for a rela-
tively short time (a few hours) and the non-invasive analytical
methods are not applicable for most drugs (see section 10). On the
other hand, the pharmacodynamic responses can be determined
non-invasively using optical coherence tomography, electroreti-
nogram or fluorescence angiography. Furthermore, these methods
are also feasible in clinical studies. Thus, pharmacodynamics (PD)
data is easier to obtain than the pharmacokinetics (PK) data.
Population PK/PD analyses are widely used in systemic phar-
macology, but still only a few examples are found in the ocular
literature. Yet, population PK/PD would be a suitable approach for
ocular studies, because this method is capable of maximally uti-
lizing data from sparse samples from large number of patients.
Audren et al. (2004) carried out population PK/PD modeling of
intravitreal triamcinolone acetonide for diabetic macular oedema.
PK and PD data was obtained from phase II studies. Central macular
thickness was used as the drug response PD parameter that was
measured by optical coherence tomography (OCT). This study did
not include analyses of intraocular concentrations of triamcinolone.
Instead, a previous human study of intravitreal triamcinolone
acetonide was used. Central macular thickness changes with time
were described with an indirect PD model and triamcinolone
inhibited the increase of thickness in a concentration-dependent
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The authors were able to simultaneously model all data with
nonlinear mixed-effect modeling and extract the typical parame-
ters and interindividual and residual variability. This approach
allowed them to estimate the duration of activity, maximal drug
response, and phases of drug response in the patients.
Other population PK/PD analyses include the VEGF-A suppres-
sion effect in the aqueous humor after intravitreal ranibizumab
administration. In this case, ranibizumab concentrations were
analysed and the VEGF-A levels were used as the indicator for drug
response. This analysis helped to estimate the dosing interval of
ranibizumab (Saunders et al., 2015). A PK/PD model of another
antibody, lambalizumab against complement factor D, was devel-
oped based on cynomolgus monkey data (Le et al., 2015). This
model helped to evaluate target-mediated drug disposition, target
turnover, drug distribution across ocular tissues and systemic
circulation.
Interestingly, Hutton-Smith et al. (2016) developed a mecha-
nistic hybridmodel for ranibizumab that includes several aspects of
PK/PD including pharmacokinetics (based on clinical data of
Saunders et al. (2015)), in vivo drug and VEGF dissociation constants
and duration of VEGF suppression. This model uses partly top-
down data (from Saunders et al. (2015)) and partly bottom-up
parameters. This kind of model is useful in the design of dosing
regimens or drug release. Importantly, modeling revealed that the
effective affinity of ranibizumab to VEGF in vivowas different from
the in vitro affinity.
The current trend is to build bottom-up models that include
anatomical and physiological factors, pharmacokinetic parameters,
and take into account physico-chemical features of drugs. Such
models are called physiologically based pharmacokinetic models
(PBPK) that can be extended to pharmacodynamics (PBPKPD). PBPK
models require knowledge of the physiological processes and rich
prior data that is used in the model parameterisation. A typical
approach in PBPK modeling is to use in silico and in vitro data for
model building. Then, the model performance is tested in in vivo
animal experiments. PBPK models can be conveniently scaled up to
humans, because the physiological processes are the same, but the
sizes and rates are different. This approach has not been used for
intravitreal drug administration even though it could provide
certain advantages. Firstly, PBPK models are useful in inter-species
scaling. Secondly, the disease state effects on PK can be taken into
account in these models. Thirdly, growing in silico and in vitro data
can be incorporated to the models to improve their predictability
continuously. Fourthly, QSPR models and other generalized ap-
proaches can be used to define parameters in PBPK models. This
will provide breadth to the applicability domain of the models,
particularly helping the use of the models to predict ocular PK of
new compounds.
Finite element modeling is a modeling type that is related to the
PBPK. This is also a bottom-up approach where a 3D ‘virtual eye’ is
built using CAD systems and then drug movement in different
tissues can be defined accurately, because the eye is composed of
thousands of voxels (elements of volume) (Missel, 2012; Missel
et al., 2010). Since so many voxels are included in the model, the
concentration gradients can be simulated within the small ocular
tissues. Finite element modeling allows simulation of accurate in-
jection sites within the vitreous. The drawback of this modeling
type is that it requires plenty of computing power. It also includes
plenty of details and therefore its reliability depends on the avail-
ability of the supporting data. For some issues the data is available,
for example diffusion in the vitreous, but in some cases the data is
lacking (e.g. permeation across the non-pigmented epithelium).
Elegant finite element models have been built for rabbit, monkey
and human eyes (Missel, 2012; Missel et al., 2010), but theperformance of these models in broad sense is uncertain, since no
wide comparisons to the experimental data has been performed.
In summary, intravitreal PK/PD modeling has progressed well
due to technical advances in the modeling tools (Missel, 2012) and
integrating approaches to predict compound clearance from the
vitreous (del Amo et al., 2015). The challenge is to integrate the
broader chemoinformatic aspects to the PBPK modeling. Other
major aspects include integration of drug responses and disease
progression (Hutton-Smith et al., 2016), and the retinal tissue, for
example inner and outer limiting membranes, to the models.
3.5.2. PK modeling in controlled release system design
Controlled drug release is an important goal in intravitreal drug
delivery, because long dosing intervals are desirable to reduce the
burden of injections to the patients and health care (del Amo and
Urtti, 2008). Drug release rate from the delivery system (Jivt) and
clearance (CLivt) of free drug determine the steady-state concen-
tration in the vitreous:
Css ¼ Jivt=CLivt
Clearance can be determined in vivo after intravitreal injection
or it can be predicted for small molecules using the QSPR model
(see section 3.2.) (del Amo et al., 2015), where the required pa-
rameters HD and LogD7.4 can be calculated in silico when the
chemical structure is known. Del Amo et al. (2015) demonstrated
recently how clearance values could be used to determine the
required release rate to achieve certain target concentration in the
vitreous.We assumed that the injected doses are 0.1,1,10,100,1000
and 10,000 mg. Note that the highest dose of 10 mg would mean
that the drug constitutes about 10% of the total weight of the in-
jection (maximal volume of 100 ml). First order drug release rate
constants for the drug delivery systems were varied and drug
concentrations in the vitreous just before the next dose (i.e. 3
months after previous injection) was simulated as a function of the
release rate constant and initial drug dose in the device (Fig. 9).
Three example drug profiles are shown: tobramycin (CLivt 0.04 ml/
h, Vss,ivt 1.22 ml), fluconazole (CLivt 0.753 ml/h, Vss,ivt 1.93 ml) and
bevacizumab (CLivt 0.019 ml/h, Vss,ivt 2.02 ml). It is obvious from
these graphs that high clearance drug (fluconazole) requires high
drug doses (1e10mg) in the device and a slow release rate constant
to maintain the concentration above 1 mg/ml. In the case of tobra-
mycin much higher concentrations can be reached and many dose
and rate constant combinations yield concentrations above 1 mg/
ml. For example, drug loading of 10 mg is adequate at many rate
constants. The influence of clearance is even clearer in the case of
bevacizumab that shows about 40 fold higher concentrations in the
vitreous than fluconazole. Formulation of drugs to small devices is
challenging and a low required dose is an advantage. In the case of
high clearance compounds, a long duration of action may be ach-
ieved only with potent compounds that are active at very low drug
concentrations, whereas requirements are more relaxed in the case
of low clearance compounds. Note that in these simulations we
assume that the delivery system remains in the vitreous (e.g.
implant). Pharmacokinetic simulations can be exploited in the
design of drug delivery systems for intravitreal administration.
Knowing or predicting the clearance it is possible to simulate the
release rate and drug loading in the delivery system that are
required to achieve certain drug concentration profiles.
3.5.3. Degradation rate of polymers
Drug delivery systems can be non-degradable (e.g. Iluvien) or
degradable (e.g. Ozurdex). In the latter case, the polymer is
degrading to smaller fragments that dissolve within the vitreous
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This is due to the analytical challenges, since the methods in
polymer degradation studies (e.g. size exclusion chromatography,
free flow fractionation) are not sensitive enough to analyse the
concentrations of polymer fragments in vivo. There are some re-
ports that are based on visual inspection or imaging of delivery
system retention in the vitreous or analysis of the remaining mass
(de Almeida et al., 2015), but these data do not provide an exact
view on the polymer degradation or dissolution in the vitreous. The
investigated materials include poly(lactide eco-glycolides (de
Almeida et al., 2015; Jansen et al., 2011), poly(orthoesters)
(Einmahl et al., 2003, 2000), poly(trimethylene carbonate) (Jansen
et al., 2011), polyesteramides (Andres-Guerrero et al., 2015), and
poly-e-caprolactone (Silva-Cunha et al., 2009). In some cases, the
polymer degradation is much slower than drug release, resulting in
retention of an empty ’ghost’ device in the eye after drug release
(Andres-Guerrero et al., 2015; de Almeida et al., 2015; Jansen et al.,
2011).
Tolerability of the material in the eye is one of the major hurdles
in the development of drug delivery systems. The degradation
products from the delivery system impose a potential risk of
toxicity. Toxicity is dependent on the intrinsic toxicity of the
compound and exposure to the material (i.e. concentration and
duration). Degradation of the drug delivery system can take place
by different mechanisms, for example chemical hydrolysis to
smaller fragments or erosion that leads to polymer dissolution
without changes in the molecular weight (Kohn et al., 2004).
Herein degradation refers to all mechanisms that lead to the
elimination of a polymer or its fragments from the eye.
It is known that molecular size has an impact on the clearance
from the vitreous (Fig. 6A) and thus it is expected that the degra-
dation rate of the polymer should have an influence on the rate of
material elimination and concentration of the polymer fragments
in the vitreous. We simulated the impact of these processes using
hypothetical rates for polymer degradation and molecular weight
dependent rates of vitreal clearance. Two models were constructed
with STELLA software (ISEE Systems 10.0). The models are not
based on a specific polymer carrier, but instead they illustrate the
inter-dependencies of the processes (dissolution, hydrolysis and
clearance). In the first model, a polymer carrier needs to be dis-
solved before undergoing hydrolysis and elimination (Fig. 10). In
the second model, dissolution and hydrolysis take place simulta-
neously within the polymeric device (Fig. 11).
In both models the polymer carrier dose was set as 5 mg. The
dissolution rate was defined as P x K x (CsC)/Cs, where P ¼ intact
polymer remaining (mg), K ¼ dissolution rate constant (1/h),
Cs ¼ polymer solubility (high value of 1000mg/ml was used; i.e. we
simulate a process that is not solubility limited) and Cvitreous ¼ free
polymer concentration in the vitreous (mg/ml). In the simulations
both dissolution and hydrolysis rates were varied to investigate
different scenarios. The range of dissolution rates was 0e0.07 h1
(i.e. polymer dissolution in 2, 20 or 200 days). Hydrolysis rates in
the simulations were 0e7 h 1 (hydrolysis times: no hydrolysis,
30min, 5 h, 2 days, 20 days). In themodels we took into account the
route of elimination of the degraded fragments, either through the
anterior route or both the anterior and posterior route. Anterior
clearance for polymeric species (0.01e0.04 ml/h) was estimated
based on the known values for the vitreal clearance of hydrophilic
compoundswith different molecular weights (vancomycin 0.04ml/
h; proteins 0.01e0.03 ml/h) (del Amo et al., 2015). The values
representing both anterior and posterior clearance were 0.01, 0.04,
0.055 ml/h (value of netilmicin) and 0.501 ml/h (value of hesper-
etin) (del Amo et al., 2015). The volume of distribution for all
degradation products was set to 1.18 ml.
Fig. 12 shows that the polymer exposure in the vitreous depends
Fig. 11. Scheme for polymer biodegradation simulation # 2. It is assumed that the
intact polymer is dissolved and eliminated as such. In addition, the polymer is
degraded in the delivery system to smaller fragments that are released from the device
and eliminated from the vitreous. Different rates of dissolution and hydrolytic
degradation were simulated. Polymer solubility is not limiting the dissolution in the
model. In the simulations, the clearances of each three degradation products are
dependent on the molecular size of the degradation products.
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scenario (Fig. 10). Obviously, slow dissolution leads to prolonged
exposure at smaller concentrations than fast dissolution. Compared
to the casewithout polymer hydrolysis (blue lines) the hydrolysis of
polymer decreases the levels of polymer borne species in the vit-
reous significantly (10e100 fold), especially when the posterior
clearance is present. This is understandable because the clearance
of smaller fragments is faster than the clearance of intact polymer
or larger fragments. The impact of the hydrolysis rate is pronounced
at the highest rate of dissolution, because in that case the hydrolysis
becomes the rate-controlling factor in elimination. Rapid hydrolysis
to small fragments is expected to facilitate removal of materials
from the vitreous. Exposure to the polymer fragments is at the
lowest levels when polymer dissolution is slow (20 or 200 d), but
the dissolved polymer is hydrolysed fast (5 h or 2 d).
The simulation results from the second scenario are shown in
Fig. 13. In this case, dissolution and hydrolysis take place at the
same time (Fig. 11). Again, fast hydrolysis causes accelerated ma-
terial elimination from the vitreous. In this case, faster hydrolysis
leads also to a higher peak concentration of degradation products
independently from the polymer dissolution rate. Without hydro-
lysis the elimination of the polymer takes longer, but the peak
concentration is lower than for polymer carriers that undergo hy-
drolysis. From toxicity point of view, a fast hydrolysis is beneficial
regarding the total exposure. Intravitreal AUC is dramatically
decreased with fast hydrolysis of the polymer to small fragments
with increased clearance (Fig. 13).
The kinetic simulationmodels for polymer degradation could be
used in the design of drug delivery systems. Firstly, in vitro esti-
mates for polymer dissolution and hydrolysis rates in the vitreal
conditions are needed. Thereafter, total concentration profiles of
polymer and degradation products can be simulated. This con-
centration range can be compared to the in vitro cellular toxicity
data, particularly the concentration ranges for toxic responses. This
gives early prediction for the risk of toxicity in the eye andmay help
in the design of the polymers and material quantities to be used in
the eye. Secondly, drug release and polymer degradation needs toFig. 10. Scheme for polymer biodegradation simulation #1. It is assumed that the
intact polymer is dissolved and thereafter degraded in the vitreous. Different rates of
dissolution and hydrolytic degradation were simulated. Polymer solubility is not
limiting the dissolution in the model. In the simulations, the clearances of each three
degradation products are dependent on the molecular size of the degradation
products.be synchronized. Often a drug is released from the device much
faster than the polymer degradation. In chronic drug treatment,
this leads to the situation when a new drug dose is injected before
the previous polymeric implant has degraded. Simulations are
useful in estimating the disappearance of the ‘ghost’ devices from
the eye and exposure to the free polymer and fragments.3.5.4. Relationship between drug solubility and release rate
Normally drug release from the formulations is tested in sink
conditions. This means that solubility in the dissolution medium
should not limit drug release from the delivery system. Typically,
this is arranged so that the dissolved drug concentration in the
medium is less than 10% of drug solubility. Sink conditions prevail
in some cases in vivo, but not always. For example, drug release
from the transdermal patches is much lower on the skin as
compared to the release rate in sink conditions (Sutinen et al.,
2000). This is due to the low permeability of the skin causing
drug accumulation on the skin surface and loss of the drug con-
centration gradient between the patch and skin subsequently
leading to decreased rate of drug release. This could happen in the
vitreous, if the drug clearance is not fast enough to maintain the
free drug concentration in the vitreous below the limit (<10% of
drug solubility or drug concentration in the device). If these con-
ditions are not met, the concentration of free drug in the vitreous
increases and leads to a decreased rate of drug release from the
device. Then, drug release gradually shifts from device-controlled
situation to solubility-limited release. In the case of poorly water-
soluble corticosteroids, low solubility has been used to achieve
prolonged drug action. Due to the low solubility of triamcinolone
acetonide, it dissolves slowly during several weeks after the
intravitreal injection of suspension.
Drug release testing should preferably be carried out using a
system that mimics the release conditions in the vitreous
(including vitreal enzymes, pH, viscosity, clearance). Recently, a
release methodology with anterior clearance component was
introduced for intravitreal drug release studies (Awwad et al.,
2015). Optimal release system should mimic the intravitreal clear-
ance conditions (CL ¼ P x S; where P ¼ membrane permeability;
Fig. 12. Simulations of free concentrations of polymer borne species in the vitreous over time after intravitreal injections (unpublished simulations). The initial polymer content in
the biodegradable device was 5 mg. Three durations of polymer dissolution (2, 20 and 200 days) were simulated. The times of polymer hydrolysis (i.e. 5 half-lives) were 20 d (red
lines), 2 d (green lines), and 5 h (purple lines). Blue line shows the simulation without hydrolysis. The simulations were done using the model from Fig. 10. The clearance values of
the degradation products were 0.01, 0.02, 0.03 and 0.04 ml/h for anterior elimination and 0.01, 0.04, 0.055 and 0.501 ml/h for anterior and posterior elimination.
E.M. del Amo et al. / Progress in Retinal and Eye Research 57 (2017) 134e185 153S ¼ surface area), but these conditions are not necessarily sink
conditions. Simulations can also be used to extrapolate from in vitro
testing to in vivo conditions. We carried out simulations on the
effects of drug solubility and in vitro release rate (sink conditions)
on the expected steady-state concentration of released drug in the
rabbit vitreous. In the simulations we assume that the zero-order
release rate in vivo decreases proportionally if the concentration
of released drug increases in the vitreous (in vivo release
rate¼ in vitro release rate(drug solubility e drug concentration in
the vitreous)/drug solubility). Two clearance values were used in
the simulations: 0.03 ml/h (low clearance) and 1 ml/h (high
clearance).
The simulations demonstrate that sink conditions prevail in the
vitreous at all release rates (up to 5 mg/h) only when the drug
solubilities are at least 0.1 mg/ml or 1 mg/ml at clearance levels of
1 ml/h and 0.03 ml/h, respectively (Fig. 14). At lower solubility
values the expected rates of drug release in vivo are much less than
in vitro at sink conditions (Fig. 14). It is evident that the clearance
values are affecting the conditions for drug release. At higher
clearance levels sink conditions are easier to maintain than at lower
values of clearance (Fig. 14A and B).
It is important to develop predictive in vitro release methods
and simulation tools to provide relevant and predictive data before
in vivo testing. Important considerations in the method develop-
ment include: 1) In vitro clearance should mimic in vivo drug
clearance so that the concentration gradient between the device
and free drug is relevant; 2) Dissolution medium should mimic the
vitreous in terms of pH, enzymatic activity and viscosity. The
relevance of the enzymes depends on the susceptibility of the de-
livery system to the enzymes. The role of viscosity is not known, butin principle higher viscosity could lead to a thicker hydrodynamic
diffusion layer that may reduce the release rate, especially in the
case of lipophilic and large molecules. Obviously, the sink condi-
tions are lost easier when the drug has low solubility and/or low
intravitreal clearance.
4. Systemic drug delivery to the retina
Systemic drug administration as tablets is the most common
way of drug delivery in the clinical practice, but not so common in
ophthalmology. Drugs that do not absorb adequately to the blood
circulation from the intestine are given as parenteral s.c., i.m. and
i.v. injections. In ophthalmic treatment the systemic route has been
used to deliver antibiotics to treat endophthalmitis, carbonic
anhydrase inhibitors to treat elevated intraocular pressure, and
methotrexate and parenteral antibodies to treat uveitis (Bartlett
and Cullen, 1989; Schwartz and Budenz, 2004; Yanoff and Duker,
2014). Systemic drugs that are intended for other indications may
also enter the eye, and in this case, they may cause adverse effects
(Blomquist and Palmer, 2011; Miguel et al., 2014; Potts, 1974). For
example, chloroquine, sildenafil, chlorpromazine, alendronate and
tamoxifen may cause retinal side effects. Understanding drug dis-
tribution across blood-ocular barriers from systemic circulation to
the eye is a key factor in effective ocular treatment with systemic
medications, and on the other hand, it determines the ocular
exposure to the systemic drugs.
4.1. Drug distribution from blood circulation to the retina
Properties of blood-ocular barriers have been described in detail
Fig. 13. Simulations of free concentrations of polymer borne species in the vitreous over time after intravitreal injections (unpublished simulations). The initial polymer content in
the biodegradable device was 5 mg. Three durations of polymer dissolution (2, 20 and 200 days) were simulated. The polymer hydrolysis times (5 half-lives) were 2 d (red lines), 5 h
(green lines), and 30 min (purple lines). Blue line shows the simulation without hydrolysis. The simulations were done using the model from Fig. 11. The clearance values of the
degradation products were 0.01, 0.02, 0.03 and 0.04 ml/h for anterior elimination and 0.01, 0.04, 0.055 and 0.501 ml/h for anterior and posterior elimination.
Fig. 14. Simulated steady state concentrations in the vitreous humor for compounds having different vitreous solubilities (0.1, 1.0, 10, 100, and 1000 mg/ml), release rates in the sink
conditions (0.1, 0.5, 1, 2 and 5 mg/h) and vitreal clearances (A: 1 ml/h; B: 0.03 ml/h).
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blood circulation and the eye in both directions. Ocular distribution
of systemic drugs has been studied in rabbits (for references, see
Vellonen et al. (2016)). The studies that report drug concentrations
both in plasma and in vitreous humor are particularly useful for
understanding the drug distribution from plasma to the posterior
eye segment.
Drug distribution from rabbit plasma to the vitreous was
recently analysed in a systematic manner (Vellonen et al., 2016). A
simulation model was built to describe pharmacokinetics in the
systemic circulation and drug distribution to the vitreous (Fig. 15).
The model was based on two key factors: 1) Free drugconcentration in plasma (Cu ¼ fu C, where fu is the free fraction of
the drug in plasma); 2) Distribution clearance between plasma and
vitreous was assumed to be the same as drug clearance from the
vitreous. Previously, clearance from the vitreous was modeled us-
ing the QSPR approach (del Amo et al., 2015). This model provides
clearance estimates computationally from the chemical structure.
The predicted clearance values were used as estimates of the dis-
tribution clearance of drugs in the ocular drug distribution model
(Fig. 15) (Vellonen et al., 2016). The assumption of similar clearance
across blood-ocular barriers in both directions is valid if there is no
active transport that would lead to significant directionality in the
barrier.
Fig. 16. Correlation of measured and simulated AUC0elast in rabbit vitreous after
intravenous administration. Drug distribution clearance between systemic circulation
and the eye (CLivt) was defined computationally (QSPR; solid circles) and Vss,ivt of
1.48 mL was used. Also, experimental values of CLivt and Vss,ivt (Exp.; open circles) were
used for comparison. Solid line represents the slope of 1 and dotted lines are 2-fold
deviation from 1:1 relationship. Reprinted (adapted) with permission from Vellonen
et al. (2016), Copyright (2016) American Chemical Society.
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the vitreal drug exposure obtained (area under the drug concen-
tration vs. time curve in the vitreous; AUC) correlated well with the
real experimental values (Fig. 16). Among ten drugs the deviation
was less than 2.0-fold in 80% of cases and the maximal deviation
from the experimental values was 3.8 fold in rabbit eyes (Fig. 16).
The AUC values in plasma and the vitreous were spanning over
three orders of magnitude, but the model provided an accurate
matchwith the real data. It seems that the computational estimates
of ocular distribution clearance values are useful in this context.
The clearance values are conveniently calculated for small mole-
cules based on the chemical structure (del Amo et al., 2015). This
approach is not applicable to protein drugs, and the QSPR model
was originally built using small molecules with low or medium
lipophilicity (LogD7.4 range from 10.59 to 2.19). Therefore, its
reliability for more lipophilic compounds is uncertain. Plasma
protein binding and distribution clearance were needed for the
prediction; lipophilicity or protein binding alone lead to poor
predictions of ocular drug distribution from plasma (Vellonen et al.,
2016).
In the case of passive diffusion, the distribution clearance does
not depend on the direction of drug transfer, but transporter-
mediated permeation could lead to preferred direction of drug
transport in the blood-ocular barrier (either inwards or outwards).
CLivt was predicted with two physicochemical factors, LogD7.4 and
hydrogen bonding capacity (HD), without outliers suggesting that
the transporters do not have a major influence on drug clearance
from the vitreous (del Amo et al., 2015). In accordance with this, no
substantial deviations are seen in the plasma-to-vitreous simula-
tions (Fig. 16). However, many compounds in the data set are
substrates of transporters and in some cases transporter effects
may be present. For example, ciprofloxacin, fleroxacin, and oflox-
acin are transporter substrates. This is in line with the simulated
AUC values that are greater than the experimental values (Fig. 16).
Mercaptopurine also shows higher simulated AUC values than
experimental values in the vitreous, and this could be due to the
actions of influx transporter OAT3 (ocular side) and efflux trans-
porter MRP4 (blood side) (Hosoya et al., 2011; Tagami et al., 2009).
Thus, it seems that the transporter activity may modulate the
ocular distribution of systemic drugs.
Protein binding in plasma was taken into account in the model
assuming that the protein bound drug does not permeate across the
blood-ocular barrier. This is reasonable assumption in the light of
the properties of the blood-ocular barrier (section 2). This rationale
is also supported by the data from post-mortem human plasma and
vitreous (Holmgren et al., 2004). In that study, a correlation be-
tween the degree of protein binding of the drugs and vitreous/
femoral blood concentration ratio was found. The model of
Vellonen et al. (2016) does not take into account the proteinFig. 15. Drug distribution from plasma to vitreous humor. A simulation model was used to pr
plasma. The model was based on free drug concentration in plasma and computational di
Reprinted (adapted) with permission from Vellonen et al. (2016), Copyright (2016) Americabinding or other binding events in the vitreous, because no quan-
titative data exists about these factors. It is known that the protein
quantity in the vitreous is less than in plasma (section 3). It is likely
that the protein binding in the vitreous is less important than it is in
plasma, since model predictions were successful even without the
vitreal binding factor. Certainly, the model can be improved if the
vitreal protein binding data will become available.
Overall, small molecular drugs do permeate across blood-ocular
barriers to the eye and it is in principle possible to treat the retina
with systemic drugs. However, systemic aldose reductase inhibitors
failed in the clinical studies due to their minimal efficacy in the
treatment of diabetic retinopathy (Ramana, 2011). Sometimes
systemic toxicity may become limiting factor for systemic drugs. It
is also known that systemic use of carbonic anhydrase inhibitors
(like acetazolamide) is associatedwith serious adverse effects (such
as tiredness, anorexia and dysesthesia in the fingers and around the
mouth) (Inoue, 2014).
Drug distribution from plasma to the eye is also often seen in
preclinical animal studies when a drug is dosed only to one eye and
the other eye serves as a control. Systemic drug absorption is rapid
and nearly complete after topical eye drop instillation and sub-
conjunctival injections (Amrite et al., 2008; Lee and Robinson,
2004; Urtti and Salminen, 1993). In rabbit experiments, the dose
is usually the same as in humans, but the systemic drug clearanceedict vitreal drug concentrations that result from known drug concentration profiles in
stribution clearance between systemic circulation and the eye (del Amo et al., 2015).
n Chemical Society.
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overestimation of systemic drug distribution to the contralateral
eye. After chronic dosing of timolol (six days, twice daily) drug
levels in the contralateral eye in the rabbits (four hours after the last
dose) reached high levels in vascularized ocular tissues (10e60% of
the values in the treated eye), but low levels (2% of the concen-
tration in the treated eye) in the avascular cornea (Salminen and
Urtti, 1984).
4.2. Retinal targeting from the blood stream
Distribution of free drug from the blood stream to the vitreous is
driven by the concentration gradient and ability to cross the blood-
ocular barriers (i.e. distribution clearance) (Vellonen et al., 2016).
Free drug may accumulate more than expected to the retina and
choroid if the drug is binding to cellular components (especially
melanin) or it is a substrate for a significant active transport process
(for more, see section 9.3.). Another option is formulating the drug
into a targeting system.
Targeted drug delivery from systemic circulation to the tumours,
central nervous system and other tissues is widely studied topic in
pharmaceutical literature. Targeted drug delivery from systemic
blood circulation to the tissues is often accomplished using nano-
particles and liposomes (Goyal et al., 2014), antibody-drug and
polymer-drug conjugates (Sassoon and Blanc, 2013), and small
molecular prodrugs (Huttunen and Rautio, 2011). Active drug tar-
geting relies on homing compounds that have a high affinity to the
target cells or tissues (Steichen et al., 2013), while passive targeting
is based on accumulation of the nanoparticles or polymers to the
tumour tissue due to its leaky vasculature and inefficient lymphatic
removal from the tumours (i.e. enhanced permeation and retention
(EPR) effect (Maeda, 2001)). Carrier mediated drug delivery may
have safety related advantages, because the encapsulated drug
does not cause side effects (e.g. liposomal encapsulation of doxo-
rubicin protects from the cardiac toxicity of the drug). Similar
principles should also be applicable for retinal drug targeting (Liu
et al., 1989). It should be noted, however, that intravenously
administered nanoparticles are mostly distributed from blood cir-
culation to the cells of the reticuloendothelial system of the liver
and spleen (Lehtinen et al., 2012b).
Targeted retinal drug delivery from the systemic circulation has
been investigated in preclinical animal models, but not in humans.
Most studies are qualitative investigations where microscopy,
immunohistochemistry, and fluorescein angiography have been
used as end-points. Investigated materials include gold nano-
particles (J. H. Kim et al., 2009), liposomes with conjugated tar-
geting antibodies (Zhu et al., 2002), liposomes with conjugated
peptides (Salehi-Had et al., 2011), PLGA nanoparticles with target-
ing moieties (Singh et al., 2009), antibody-drug conjugate
(Kamizuru et al., 2001), and externally triggered liposomes (Gross
et al., 2013). Unfortunately, no general conclusions can be drawn
from these studies regarding the impact of particle or conjugate
size, charge, or affinity of targeting ligand to the retinal targets.
Some results show effective drug targeting to the retina. For
example, liposomal delivery systems (mean size 45 nm; zeta
potential þ 35 mV) with targeting to choroidal neovascularization
lead to transgene expression in the choroidal vessels (Salehi-Had
et al., 2011) and anti-angiogenic efficacy of paclitaxel (Gross et al.,
2013). Also, systemically given antibody conjugates of mitomycin
C were shown to reduce choroidal neovascularization (Kamizuru
et al., 2001). Likewise, targeted PLGA nanoparticles (size
270e430 nm; decorated with RGD peptide and transferrin) allevi-
ated choroidal neovascularization in rats (Singh et al., 2009). Li-
posomes with transferrin were shown to transfect the RPE and
ciliary body after systemic delivery in mice and monkeys (Zhanget al., 2003; Zhu et al., 2002). Despite many positive results
(Zhang et al., 2003; Zhu et al., 2002) no follow up or confirming
studies have been performed. Therefore, it is difficult to assess the
true potential of this approach at this point. The results suggest that
poly(lactide-co-glycolide) nanoparticles (270e420 nm in diameter;
negatively charged) are targeting to the neovessels (Singh et al.,
2009). This was explained by the increased leakiness of the
blood-retinal barrier, but this could also reflect changes in the
endothelial cells (over-expression of target receptors, changes in
the endocytic capacity). Small liposomes (85 nm) were needed to
reach the RPE cells in healthy eyes, which is in line with the limits
set by the choroidal vessel pores (Zhang et al., 2003; Zhu et al.,
2002). Quantitative information about the retinal bioavailability
or mechanistic data about targeting at different layers in the retina
still does not exist.
Targeted drug delivery requires homing of the delivery system
to the desired tissue. On top of that, the drug should be released
from the carrier, but this is often a difficult task and only rarely drug
release is at the cellular level quantitated (Soininen et al., 2016).
Drug release can be triggered using endogenous (e.g. reduced pH in
the cellular endosomes) or exogenous factors (e.g. light) (Lajunen
et al., 2016a). The eye is particularly well suited for exogenous
triggering of drug release, because it is transparent and ophthal-
mologists routinely investigate the retina with an ophthalmoscope
and use lasers for diagnostics and treatment. Early works of
Khoobehi et al. (1988) demonstrated that it is possible to induce
contents release from i.v. liposomes in the posterior eye segment
with microwaves. Furthermore, the light activated systems are
interesting in ophthalmology, because the light can be accurately
projected to the site of interest with excellent spatial resolution. It
is important to ‘sensitize’ the delivery system to the light signal so
that effective release can be achieved using safe levels of light in-
tensity. Light triggering agents can be divided to metallic nano-
particles, light induced chromophores, degradable lipids,
photopolymerizable liposomes, and indocyanine green (Lajunen
et al., 2016b). All these agents are capable of inducing light trig-
gered release from the liposomes or other particles, but many
systems are based on toxic compounds that cannot be used in
clinical drug delivery. Gold nanoparticles absorb light and release
the absorbed energy as heat to the lipid bilayer that becomes per-
meabilised, inducing the contents release from the liposomes
(Paasonen et al., 2010, 2007). The appropriate wavelength depends
on the size and shape of the gold nanoparticles. Visible and near-
infrared light can induce relatively large gold particles (diameters
20e50 nm) therebymaking formulation of small liposomes smaller
than the pore size of choriocapillaries (70e80 nm) impossible.
Recently, we reported the use of indocyanine green (ICG) as a light
induction agent in liposomes with similar actions as gold nano-
particles (Lajunen et al., 2016a). As a clinically used imaging agent
ICG should be safe. In addition, it can be formulated to small lipo-
somes for effective induction of drug release with near-infrared
light (Lajunen et al., 2016b). The idea of light triggered release in
retinal drug targeting is an interesting possibility, but the retinal
safety of the light (wavelength, intensity, pulse duration) must be
ascertained before these systems can be used in the clinics. Light
activation has already been used in the clinics in the case of Ver-
teporfin, a photodynamic therapy treatment of age-relatedmacular
degeneration (Lai et al., 2015).
Some background facts support the rarely studied approach of
targeted retinal drug delivery. Firstly, choroidal blood flow relative
to the tissue size is extremely high and the choriocapillaries are
leaky, having pores of 70e80 nm, thereby allowing extravasation of
polymers or nanoparticles. Secondly, the target cells (e.g. RPE and
neural retina cells) are in close proximity of the extravascular
choroid. Thirdly, RPE is active in internalization of materials
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segment is easy to reach with various methods of external release
triggering signals (e.g. light, ultrasound, magnetic fields). Huge
activity has been undertaken to target drugs to tumours, whereas
retinal drug targeting has been only rarely investigated. There may
be possibilities for breakthroughs in this field, since many relevant
nanotechnologies have been developed in other fields of drug
delivery.
5. Periocular drug administration
Periocular administration means drug injection to a region
surrounding the eye, for example sub-conjunctival, sub-Tenon's,
peribulbar, retrobulbar or posterior juxtascleral injections (see
upper insert in Fig. 1). These injections differ on the location/di-
rection of the injection in the proximity of the sclera. The scleral
thickness diminishes near the equator region (from 0.53 ± 0.14 mm
into 0.39 ± 0.17 mm) (Olsen et al., 1998) potentially leading to
increased drug penetration (e.g. posterior juxtascleral injection).
On the other hand, sub-conjunctival injections have been used for a
long time in the clinics to deliver drugs to the anterior part of the
eye. In this chapter, sub-conjunctival injection will be discussed.
Higher concentrations in the anterior chamber tissues are reached
with such injections as compared to the topical eye drop admin-
istration and this mode of delivery has been investigated as an
option for posterior segment drug delivery.
Sub-conjunctival injections result in drug distribution to the
anterior chamber at higher levels than after topical instillation of
eye drops. The drug bioavailability to the aqueous humor is about
10% after sub-conjunctival injection, because the corneal barrier is
circumvented and the retention at the injection site is longer than
after eye drop administration. Systemic absorption from the sub-
conjunctival space is often rapid and it limits the bioavailability
(Maurice and Mishima, 1984).
Drug delivery from the sub-conjunctival space to the retina is
more challenging than the delivery to the anterior chamber. Sub-
conjunctival administration has been investigated as an alterna-
tive to intravitreal injections for retinal drug delivery (for ref. see,
Ranta and Urtti (2006)). The overall conclusion is that the retinal
bioavailability is in the range of 0.1% after sub-conjunctival in-
jections (Kim et al., 2004). This is better than after topical admin-
istration (Weijtens et al., 1999), but less than the retinal
bioavailability after intravitreal injections. Sub-conjunctival injec-
tion volumes can be high (even 0.5 ml) which makes loading of an
adequate drug dose easier.
Retinal bioavailability after sub-conjunctival injections is low,
because there are several barriers between the injection site and
retina (Maurice and Mishima, 1984, Fig. 17). The sub-conjunctival
drug delivery to the retina has been simulated, to explore the
roles of various barriers in defining the low retinal bioavailability
(Ranta et al., 2010). The simulation model was based on experi-
mental results: 1) drug elimination rates in vivo from the sub-
conjunctival depot; 2) scleral permeability in Ussing chambers; 3)
known diffusion coefficients in similar tissues to the extravascular
choroid; 4) in vivo elimination rate from the choroid; 5) drug
permeability in the ex vivo RPE; 6) in vivo clearance from the vitreal
compartment. The simulation model integrates these factors in the
rabbit eye for three model drugs; a small lipophilic compound, a
small hydrophilic drug and a macromolecule. All aforementioned
pieces of data were not available for any single compound, but the
values for the compound classes were distinct from each other.
Thus, simulations were carried out as ’typical profiles' for each
class.
As shown in the schematic model structure (Fig. 17) the barriers
can be divided to two groups: 1) flow barriers (elimination to bloodflow and lymphatic flow from the sub-conjunctival space and
choroid); 2) penetration barriers (sclera, extravascular choroid,
RPE). After sub-conjunctival injection about 80e95% of the small
molecular drug absorbs rapidly to the systemic circulation, and only
a minority permeates across the sclera, but the systemic absorption
of proteins (e.g. Gd-albumin) can be even 70 times slower than the
absorption of small drugs (Amrite et al., 2008; Kim et al., 2008;
Ranta et al., 2010). In sclera, the permeability of small molecules
is relatively constant and independent on lipophilicity, whereas the
macromolecules permeate about ten times slower than the small
molecules (Olsen et al., 1995; Prausnitz and Noonan, 1998). In the
extravascular choroid diffusivity is relatively fast and the distance is
short; therefore, the drugs reach the choroidal vessels rapidly, and
depending on drug properties they do reach to the systemic cir-
culation (Ranta et al., 2010). Blood flow in the choroid is extremely
high for such a small tissue (62 ml/h in rabbit) (Nilsson and Alm,
2012) and the leakiness of the vessels leads to rapid transfer to
the blood stream, especially in the case of small molecules (Bill,
1968; Bill et al., 1980; T€ornquist, 1979). Recent experimental
study shows that the choroidal blood flow decreases the retinal
bioavailability of periocularly administered triamcinolone aceto-
nide (Li et al., 2016). In the RPE, the permeability of small lipophilic
compounds is about 8 and 500 times faster than the permeability of
small hydrophilic and large molecules, respectively (Mannermaa
et al., 2010; Pitk€anen et al., 2005). Overall, there is a clear trend:
the small molecules, especially lipophilic ones, permeate faster
than macromolecules through the penetration barriers (Pitk€anen
et al., 2005; Prausnitz and Noonan, 1998), but they are eliminated
faster to the blood stream than the macromolecules. Apparently,
the flow factors have a bigger impact and eventually the small
molecular weight does not facilitate retinal bioavailability, but
rather decreases drug distribution to the vitreal cavity (Ranta et al.,
2010).
In addition to the blood flow, lymphatic flow also plays a role in
drug clearance from the sub-conjunctival and choroidal spaces
(Kim et al., 2004; Robinson et al., 2006). The role of lymphatic flow
may be particularly important in clearing the particles and mac-
romolecules from the interstitial fluid and shuttling them to the
lymphatic nodes (Muthuchamy and Zawieja, 2008). The role and
existence of lymphatic vessels in the inner eye is still somewhat
controversial (Schroedl et al., 2014), but the presence of lymphatics
in the conjunctiva is well established. A rich network of lymphatic
vessels is found in the conjunctiva, representing approximately 50%
of its surface area (Guo et al., 2012). Activity of the lymphatic sys-
tem in removing the sub-conjunctival compounds has also been
demonstrated (Kim et al., 2004), but the role of this system in the
removal of nanoparticles has not been studied.
Because drugs in solution are rapidly eliminated from the in-
jection site, the duration of action of the sub-conjunctival injections
is short, unless slow drug dissolution or release is involved. Thus, it
is necessary to prolong drug retention and release in the sub-
conjunctival space before this approach can be used in chronic
multiple dosing drug treatment. It is not feasible in clinics to have
frequent sub-conjunctival injections. Several technologies have
been developed to prolong and improve retinal drug delivery from
the sub-conjunctival injections, but we are not reviewing the sub-
conjunctival delivery systems here, because they are well covered
in the literature (Imai et al., 2015; Kim et al., 2007, 2014; Kompella
et al., 2003; Misra et al., 2009; Sabzevari et al., 2013). Instead, we
have simulated pharmacokinetics of sub-conjunctival depots to
estimate required drug doses and release rates for retinal drug
action. The simulations were carried out using the previous model
(Ranta et al., 2010). A first order release rate from the drug delivery
device was added as input, with a dose range of 0.1 mge10 mg.
Fig. 18 illustrates the impact of release rate constant on the
Fig. 17. Schematic presentation of the kinetic phases of sub-conjunctival and suprachoroidal injections for retinal drug delivery.
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administration. Equal dose (1 mg) results in clearly higher con-
centrations of macromolecule than in the case of small hydrophilic
and lipophilic compounds. Lipophilicity has relatively small influ-
ence, because the increased lipophilicity improves the permeation
across the RPE, whereas it increases also drug loss from the sub-
conjunctival and choroidal space to the blood stream. For macro-
molecule prolonged action of 2e4 months can be obtained if the
limit of drug activity is about 1e10 ng/ml, but for small molecules
the limit for target site concentration is around 0.01e1 ng/ml. Sub-
conjunctival drug dose can be increased at least by one order of
magnitude. At the dose of 10 mg the simulations suggest that the
required concentrations would be in the range of 1010e108 M;
meaning that this approach is suitable only for very potent com-
pounds. This is due to the low retinal bioavailability (0.1%) after
sub-conjunctival drug delivery. In the case of choroid, the
bioavailability is much better (5e20%) (Ranta et al., 2010). For
choroidal targets concentrations of 108e106 M may be reached
over prolonged periods. Sub-conjunctival injection is given on one
side of the eye and drug bioavailability to the other side of the
eyeball is lower than the values above. For example, in the case of
topical application of controlled release devices the drug concen-
trations in the superior and inferior halves of the eyeball differ
substantially (even 60 fold) (Urtti et al., 1988).
The loss of drug to the systemic circulation from the injection
site is rapid, especially for small lipophilic molecules (elimination
half-life from injection site is about 5 min) and hydrophilic small
molecules (half-life z 25 min) (Amrite et al., 2008; Kim et al.,
2008). It is possible to prolong the retention and release times in
the sub-conjunctival space with formulations, such as particles and
implants (for ref. see Kim et al. (2014)) In principle, polymeric
conjugates should also result in increased retention, since it is
known that large molecules (e.g. albumin) retain much longer in
the sub-conjunctival injection site (elimination half-life z 6 h).
Controlled release is a feasible strategy to prolong the concentra-
tion profiles, but it does not change the bioavailability in the ocular
tissues. The relative rates of transfer towards the inner eye and
systemic circulation are expected to remain the same (Fig.17; Ranta
et al., 2010).
Increased retinal bioavailability after sub-conjunctival injection
is achieved only if the drug transfer to the eye is increased relative
to the rate of systemic drug loss (Fig. 17). Permeability of the sclera
is the key point in this case. Permeability of macromolecules (FITCdextrans up to the size of 6.5 nm) in the sclera is relatively high
(106e105 cm/s) both in rabbits and humans (Ambati et al., 2000;
Olsen et al., 1995). Thus, it is also likely that synthetic polymers
permeate well in the sclera. Nanoparticles have been used to
enhance drug delivery from posterior periocular space to the retina
and choroid (Amrite et al., 2008). Small bodipy labelled carboxyl-
ated polystyrene nanoparticles (20 nm) permeated across the
sclera slowly (less than 0.5% in 24 h), whereas 200 nm particles did
not permeate across the sclera. On the other hand, the 20 nm
nanoparticles were eliminated rapidly (half-life 5.5 h) to the sys-
temic circulation, but 200 nm nanoparticles retained at the injec-
tion site for months. Thus, periocular small nanoparticles are not
feasible for retinal drug delivery due to the particle loss to the
systemic and lymphatic flow (Amrite et al., 2008). There are,
however, problems associated with this approach. If the particles
enter choroid from one side it is not clear whether they can
distribute in the choroid and reach the diseased areas on the other
side of the eye. Furthermore, if the target site is located in the
neural retina, the particles should permeate across the RPE that is
about 100 times tighter barrier than sclera to macromolecules
(Pitk€anen et al., 2005). Indeed, polystyrene nanoparticles (20 nm)
were not able to permeate at all across sclera-choroid-RPE speci-
mens (Amrite et al., 2008). At cellular level the particles might get
internalized to the choroidal endothelial cells and the RPE cells
with endocytic processes, but the spatial distribution within the
tissues may be limited.
Sub-conjunctival injection is less invasive than intravitreal in-
jection, avoiding the risks of endophthalmitis and cataract, but
currently retinal bioavailability is still too low (about 0.1%) and it is
more suitable for anterior segment drug delivery (bioavailability
about 10%). In this case, the most evident advantage of drug de-
livery systems is the prolonged action and controlled release at the
injection or implantation site. The potential in drug targeting and
enhanced bioavailability to the retina is still poorly defined. The
potency of the drug needs to be considered: for retinal treatment
the drug should be active at nM levels. Then, dosing of 10 mg
subconjunctuvally might lead to adequate drug response.6. Suprachoroidal drug delivery
Suprachoroidal drug delivery is a relatively new mode of drug
administration that was introduced recently (Einmahl et al., 2002),











































































































E.M. del Amo et al. / Progress in Retinal and Eye Research 57 (2017) 134e185 159suprachoroidal space, just beneath the inner surface of sclera. The
injection volume is small, about 50 ml and typically these injections
are given with microneedles (Olsen et al., 2011; Patel et al., 2012,
2011), but also cannulation is possible (Olsen et al., 2006). After
the injection, the fluid distributes around in the suprachoroidal
space that is limited anteriorly by the scleral spur and posteriorly by
the optic nerve. The spreading is probably due to the pressure that
the injection exerts on the small suprachoroidal space (Patel et al.,
2011). With suprachoroidal injection it is possible to a reach wider
area around the eyeball than in the case of sub-conjunctival in-
jection. However, the spreading is not complete and it seems that
the ciliary arteries of the choroid limit the spreading (Chiang et al.,
2016). The suprachoroidal route avoids direct entry into the inner
eye and decreases the risks for endophthalmitis, retinal detach-
ment, and cataract formation. Compared to the sub-conjunctival
delivery the injection site is closer to the retina and choroid and
higher bioavailability is expected. Pharmacokinetics of supra-
choroidal drugs in solution has been studied in animal models. For
example, suprachoroidal bevacizumab reached mainly the choroid,
RPE and photoreceptor outer segments, whereas intravitreal drug
distributed more to the inner retina (Olsen et al., 2011). Supra-
choroidal microneedle injections were also used recently in
humans (Morales-Canton et al., 2013). Suprachoroidal drug de-
livery has been recently reviewed in more detail (Rai et al., 2015).
Bioavailability of suprachoroidal drug to the retina and vitreal
cavity depends on the rate of drug elimination to the chorioca-
pillaries and permeability of the drug across the RPE (Fig. 17). The
drug must pass through the RPE to reach the neural retina, but a
major part of the drug dose will be lost to the choroidal blood flow
(Ranta et al., 2010). Clearance to the blood flow is significant based
on the high blood flow in the choroid (62 ml/h in rabbit, 43 ml/h in
man) and leakiness of these vessels (70e80 nm holes) (del Amo and
Urtti, 2015). In vivo studies demonstrated that the choroidal com-
pounds disappeared to the blood circulation rapidly in minutes or
hours (Abarca et al., 2013; Bill, 1968; Bill et al., 1980; Kim et al.,
2014; T€ornquist, 1979). Delivery to the vitreous, sclera and retina
increased by an order of magnitude in non-perfused eyes, further
demonstrating the importance of blood flow as mechanism of drug
loss (Abarca et al., 2013). Obviously, choroidal bioavailability at least
at the injection site is 100%, but the retinal bioavailability depends
on the competing processes of the RPE permeation and choroidal
drugs loss. Based on the kinetic model of Ranta et al. (2010) the
retinal bioavailability can be estimated to be in the range of 0.2e4%.
Even though retinal bioavailability of suprachoroidally injected
drug in solution would be adequate, the duration of drug action is
too short after injection of the drug solution. Half-lives of com-
pounds in the suprachoroidal space vary between 1.2 and 7.9 h for
sodium fluorescein, dextrans and bevacizumab (Patel et al., 2012).
This means that the solution-based injections should be given
frequently and this is not acceptable in the clinical practice. Pro-
longation of action is necessary to make suprachoroidal drug
administration attractive in a clinical setting. Controlled drug
release formulations have been tested for suprachoroidal admin-
istration. Compared to the solution, non-biodegradable fluorescent
polystyrene particles (20 nm-10 mm in size) stayed in the supra-
choroidal space much longer (at least 1e2 months) (Patel et al.,
2012). Clinically, non-degradable particles are not feasible for
suprachoroidal administration, because they would accumulate to
the tissue and their rescue from the tissue is difficult. The study of
Patel et al. (2012) demonstrated that the polystyrene particles are
not effectively cleared from the suprachoroidal space and pro-
longed drug release would be a possible approach for biodegrad-
able formulations. Triamcinolone acetonide suspension has been
given as suprachoroidal injection and the drug produced high












































































































































E.M. del Amo et al. / Progress in Retinal and Eye Research 57 (2017) 134e185160case, triamcinolone acetonide was continuously delivered to the
retina over a prolonged time and this treatment was found effective
in the porcine model of posterior uveitis (Gilger et al., 2013).
We used the model from Ranta et al. (2010) to evaluate the re-
lationships between dose, drug release rate and expected drug
concentrations in the neural retina-vitreous compartment (Fig. 17).
We simulated the pharmacokinetics after suprachoroidal injections
of 10 ml. Drug bioavailability to the vitreal compartment was
simulated for a small lipophilic drug, a small hydrophilic drug and a
macromolecule. Compared to the sub-conjunctival injection the
bioavailability increased 6e23 fold: 1.5%, 0.19% and 4.2%, for lipo-
philic, hydrophilic and macromolecule compound, respectively.
These findings suggest that lipophilic drugs and bio-
macromolecules benefit more than small hydrophilic drugs from
the suprachoroidal route when the scleral barrier is avoided. The
simulated concentrations in the retina/vitreous for the small mol-
ecules and macromolecule are shown in Fig. 19. The simulated dose
was 1 mg. We can conclude that a long duration of action (2e4
months) can be reached for macromolecules that require at least
concentration of 0.01e0.1 mg/ml for activity. For small molecules, it
is difficult to obtain long duration: only the slow release (0.001 h1)
and potent drug (active at 1 ng/ml) are expected to yield long
duration of drug action (2e4 months). If we assume that the mo-
lecular weights are 500 and 50,000 for small drugs and macro-
molecule, respectively, the potency limits for the macromolecules
would be 108-107 M and 109 M for small molecules at the dose
of 1 mg. In the case of choroidal targets the situation is easier,
because the bioavailability is practically 100%. However, the rapid
choroidal clearance decreases these concentrations. We can esti-
mate that the potency limit for long action in the choroidal extra-
cellular targets is in the range of 2 x 107 - 106 nM.
Retinal and choroidal bioavailability of drugs after supra-
choroidal injection is higher than the bioavailability after trans-
cleral drug delivery. The overall conclusion is that suprachoroidal
drug administration shows approximately one order of magnitude
higher retinal and choroidal bioavailability than sub-conjunctival
drug delivery. Suprachoroidal drug delivery is suitable for potent
drugs that are active at low concentrations, especially in the case of
retinal targets. Prolonged retention of the formulation and
controlled release over months is preferable. Otherwise, this mode
of administration is not clinically attractive. Other pending issues
are reproducibility of injections to the small tissue and the
requirement for biodegradable formulations, because the delivery
system cannot be rescued from this tissue in the case of problems.
7. Sub-retinal drug delivery
Sub-retinal injections are used in some specialized experi-
mental purposes when delivery of therapeutics is aimed to reach
the RPE or photoreceptors. The injection is applied between the
RPE and neural retina. This leads to formation of a bleb that dis-
appears later when the aqueous solution is resorbed to the body.
This is technically demanding delivery method that is used only in
quite specialized clinical applications and in early phase ocular
pharmacological experiments with mice and rats.
Sub-retinal injection of tissue plasminogen factor is used to
assist the removal of sub-retinal haemorrhage (Sandhu et al., 2010).
Sub-retinal implant (i.e. artificial retina) product has been recently
accepted for clinical use (Stingl et al., 2015), but this is not drug
containing system. Furthermore, stem cell derived retinal cells and
viral vectors for gene therapy have been applied sub-retinally.
Namely, some adeno associated virus 2 based systems are in clin-
ical trials with promising results in the treatment of retinal de-
generations (Bainbridge et al., 2015; Maguire et al., 2008; Weleber
et al., 2016). However, it is important to note that these are special
Fig. 20. Potential routes of drug penetration from conjunctival surface to the inner eye
tissues are shown. Drug transfer through conjunctiva and sclera leads to different
tissue distribution than typical transcorneal absorption from the eye drops (from
Shikamura et al. (2016) with permission from Taylor & Francis Group).
E.M. del Amo et al. / Progress in Retinal and Eye Research 57 (2017) 134e185 161applications. In chronic treatments sub-retinal injections should
have long duration of action (preferably years per injection).
8. Topical drug delivery
8.1. Drug absorption, distribution and efficacy
Topical ocular drug delivery with eye drops is commonly used in
the treatment of anterior segment disorders, such as elevated
intraocular pressure, infections and inflammations. The eye drops
are instilled daily or several times per day to deliver small molec-
ular weight drugs to the anterior segment tissues. Most clinical
drugs have adequate corneal permeability for transcorneal drug
absorption into the anterior chamber. Ocular bioavailability,
determined from aqueous humor, is typically in the range of 1e4%,
but much less for small hydrophilic drugs and practically zero for
proteins (Maurice and Mishima, 1984; Urtti et al., 1990). Low
bioavailability is due to the rapid drainage of eye drops from the
ocular surface and systemic absorption through conjunctiva
(Maurice and Mishima, 1984; Urtti et al., 1985). From aqueous hu-
mor the drugs distribute easily to the iris, ciliary body and lens, and
they are eliminated via aqueous humor outflow and venous blood
flow of the anterior uvea (Maurice and Mishima, 1984; Urtti, 2006).
Corneal permeation of the drug depends on its lipophilicity (Huang
and Schoenwald, 1983; Kidron et al., 2010), and results in typical
drug distribution pattern with concentrations in the tissues
following the order lacrimal fluid [ cornea > aqueous
humor z iris z ciliary body > anterior
sclera > lens [ retina z choroid z vitreous humor (Chien et al.,
1990; Urtti et al., 1990). Aqueous humor flow, blood flow in the
iris and ciliary body and the lens barrier prevent effective drug
distribution to the posterior segment (Maurice andMishima,1984).
Typically, drug concentrations in the vitreous are 10 and 100 times
less than in the aqueous humor and cornea, respectively, but the
concentrations are detectable with sensitive analytical methods
(Urtti et al., 1990). It is unlikely that improvements in drug corneal
permeation would lead to any significant improvements in retinal
drug delivery.
The non-corneal route of drug absorption through the con-
junctiva and sclera was demonstrated in the studies in which the
corneal and conjunctival drug absorption processes were isolated
from each other with a cylinder around the cornea thereby allowing
drug instillation only on the corneal or conjunctival surface (Ahmed
and Patton, 1987, 1985; Chien et al., 1990; Doane et al., 1978). Drug
exposure on only the cornea lead to the typical drug distribution
pattern that is seenwithout the cylinder, lipophilic small molecules
(brimonidine, timolol) being delivered transcorneally to the
aqueous humor, whereas the conjunctival exposure results in low
aqueous humor drug levels, but improved delivery to the posterior
segment, and this was seen also in the case of bigger molecules like
inulin (Ahmed and Patton, 1985; Chien et al., 1990). The routes of
ofloxacin absorption were also explored in a recent study in which
hydrogel lenses (corneal and cornea-conjunctival lenses) and rings
that are in contact with the conjunctiva were used (Shikamura
et al., 2016). All hydrogels showed improved ofloxacin absorption
as compared to the eye drops, likely due to the longer contact with
the ocular surface. The hydrogel rings resulted in about 10 and 40
times higher ofloxacin levels in the retina-choroid than the corneal
hydrogel lens and eye drops, respectively, and to much higher
levels in the conjunctiva and sclera. Shikamura et al. (2016) also
showed gradually declining levels in the ocular segments from the
anterior to the posterior part of the eye, the anterior retina had
about 10 times higher levels than the posterior retina. Poly(-
hydroxyethyl methacrylate) hydrogel ring released about 1 mg of
ofloxacin in 9 h and resulted in the posterior retina concentrationsof 0.1 mg/ml (about 107 M) during the drug release period, but this
approachwould require daily administration of new hydrogel rings.
Note that the dosing rate here is 10e100 times higher than the
initial maximal release rate in the sub-conjunctival simulations
(Fig. 18). For example, release of 1 mg of the drug during 1e4
months should result the concentrations of about 1010 - 109 M in
the retina, limiting this approach to the retinal delivery for highly
potent compounds.
Based on the tissue distributions it is likely that the permeation
routes for non-corneal absorption are as shown in Fig. 20. The non-
corneal route through the conjunctiva, sclera and choroid might be
a useful strategy for the delivery of drugs from the ocular surface to
the retina. A major advantage of this approach is that it is non-
invasive and allows self-administration of the drugs.
In order to reach higher drug levels in the retina, long acting
topical drug delivery systems should be able to localize on the
conjunctival surface, incorporate high drug dose, andmaintain high
dosing rate over prolonged times. With eye drops, bioavailability is
lower than with the drug delivery systems, but on the other hand,
eye drops can be instilled frequently to maintain high dosing rate.
Patient compliance is an important issue in topical self-
administered medications. For example, compliance is only 56%
in chronic treatment of glaucoma with eye drops (Reardon et al.,
2011).
In clinical practice eye drops are not used for drug delivery to the
posterior eye segment, because they are not effective treatment.
Nevertheless, drug delivery from eye drops to the vitreous and/or
retina has been shown in numerous studies (Acheampong, 2002;
Hu and Koevary, 2016; Inoue et al., 2004; Kiuchi et al., 2008;
Koevary et al., 2002; Takahashi et al., 2003). Many studies have
been done in small animals (mice, rats) and these results are
probably not translatable to humans. In mice and rats, the barriers
are thinner, distances are smaller and drug distribution from blood
circulation to the eyes is also more significant than in humans
(because the systemic drug clearance and volume aremuch smaller
than in humans). Many studies are based on qualitative methods,
such as imaging or histology (Kiuchi et al., 2008; Takahashi et al.,
2003). In those cases, it is difficult to assess the quantitative sig-
nificance of the results. However, also many rabbit, monkey and
human studies claim successful drug transfer to the retina and/or
choroid from eye drops (Acheampong, 2002; Chastain et al., 2016;
Genead and Fishman, 2010; Hughes et al., 2005; Kent et al., 2001;
Tajika et al., 2011; Takahashi et al., 2003). We shall discuss these
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Clear non-corneal local distribution to the posterior segment
was shown for topical brimonidine. About 20 times higher vitreal
brimonidine concentrations were seen in the treated cynomolgus
monkey eyes as compared to the untreated contralateral eye
(Acheampong, 2002). In this case, the pattern of drug concentra-
tions in the ocular tissues resembles the distribution after pure
conjunctival exposure (i.e. drug concentrations 10e60 times higher
in the anterior sclera than in the aqueous humor) supporting the
drug distribution routes shown in Fig. 20. In fact, brimonidine
concentration in the vitreous of humans after 1e2 weeks of mul-
tiple eye drop dosing was clearly higher (185 nM) than the EC50 for
a2-receptors (2 nM) (Kent et al., 2001). It is noteworthy that bri-
monidine binds strongly to the pigmented tissues around the vit-
reous. Peak levels and AUC values of 14C-brimonidine borne
radioactivity in the pigmented iris, ciliary body and retina/choroid
were 400e9000 and 1400e11,000 times higher than in the vitre-
ous, respectively (Acheampong, 2002). It is very difficult to avoid
any cross-contamination in this kind of studies, especially when the
neighbouring tissues have 102e104 times higher drug levels than
the vitreous. Therefore, it is difficult to judge whether the radio-
activities in the vitreous represent free brimonidine concentrations
in the retina. The rationale of this study was to provide neuro-
protective effects in the retina with topical brimonidine. Neuro-
protective efficacy of topical brimonidine was shown in rodent
models (Kim et al., 2015), but yet the clinical development of bri-
monidine is based on the intravitreal implant technology (Holz
et al., 2014; Querques et al., 2015).
Even though the efficacy of eye drops in the clinical treatment of
retinal conditions is considered to be inadequate, there are reports
showing pharmacological effects of eye drops in retinal patients.
Patients with either retinitis pigmentosa or Usher syndrome
received treatment of cystoid macular oedema with topical dor-
zolamide eye drops (Fishman and Apushkin, 2007; Genead and
Fishman, 2010; Grover et al., 2006). Optical coherence tomogra-
phy showed a decrease in the central foveal zone thickness in most
cases and visual acuity improved in almost one-third of the pa-
tients. On the other hand, topical treatment of cystoid macular
oedema (after cataract surgery) with non-steroidal anti-inflam-
matory eye drops (e.g. phenoprofen, ketorolac, indomethacin) was
shown to have insufficient efficacy in a compiled analysis of the
clinical studies (Sivaprasad et al., 2005). Interestingly, Bayer was
developing a topically applied small molecule drug (regorafenib) to
treat neovascular age-related macular degeneration. This drug had
200 and 7 times higher drug concentrations in the posterior eye
segment than in plasma in rats and monkeys, respectively (Joussen
et al., 2016). However, this drug failed due to inadequate efficacy in
clinical phase 2b studies.Table 3
Permeability coefficients of drugs in the conjunctiva, RPE and sclera. Typical values for s













8.4e16.7 (timolol, betaxolol) 1.0e5.6 (carbo
atenolol, pindo8.2. Strategies for posterior segment drug delivery
Fig. 20 illustrates the likely route for posterior segment drug
distribution after topical administration. The relevant physical
barriers are the conjunctiva, sclera and RPE, and the flow barriers
include blood and lymphatic flows in the conjunctiva and choroid.
Five main factors are affecting the potential success of topical drug
delivery to the posterior segment: 1) retention time on the ocular
surface; 2) permeability and transport in the barrier membranes
(conjunctiva, sclera, RPE); 3) role of the flow factors (drug loss or
distribution to the tissues); 4) preferential homing of drug to the
retina (e.g. melanin binding); 5) potency of the drug and target (e.g.
neural retina, RPE or choroid); 6) drug dose and dosing rate on the
ocular surface.
Rapid elimination of eye drops from the ocular surface limits
drug absorption, but the bioavailability can be increased with
prolonged drug retention on the ocular surface (Maurice and
Mishima, 1984). However, the maximal attainable bioavailability
is limited to about 10% by the conjunctival systemic drug absorp-
tion and tear turnover processes that cannot be stopped (Kyyr€onen
and Urtti, 1990; Urtti et al., 1990). Retention time on the ocular
surface can be increased with various technologies that have been
reviewed previously (Cholkar et al., 2013; Kim et al., 2014). The
effect of prolonged conjunctival retention on the posterior segment
drug delivery was demonstrated recently (Shikamura et al., 2016).
In the case of ofloxacin, drug concentrations in the posterior
segment were increased 40 fold with the hydrogel ring as
compared to the eye drops. The level of improvement depends on
the drug, but the retention factor is always important for the
improvement of posterior segment drug delivery.
Drugs must be able to permeate in the barrier membranes in
order to reach the retina. Two barriers are lipoidal epithelia with
tight junctions (conjunctival epithelium and RPE), whereas the
sclera is a porous membrane with a mesh size that allows perme-
ation of macromolecules (Prausnitz and Noonan, 1998). Lip-
ophilicity has an impact on drug permeability in the conjunctiva
(Ahmed and Patton, 1987) and the RPE (Pitk€anen et al., 2005). The
extravascular choroid and Bruch's membrane are much more leaky
than the RPE and conjunctiva; therefore, they are not considered to
be permeation rate limiting barriers (Miller and Edelman, 1990;
Pitk€anen et al., 2005). Permeability of the conjunctiva, sclera and
RPE are compared in Table 3. It is obvious that the sclera is the most
permeable membrane, particular in the case of hydrophilic and
large compounds. Therefore, permeation enhancement strategies
should rather focus on the rate limiting barriers, i.e. conjunctiva
and RPE. It is easier to modify the conjunctival transport than the
RPE, because the conjunctival epithelium is on the ocular surface
and themanipulations can be controlled more accurately. Targeting
the drug transporters is one potential approach, but the knowledge
of transporters in the conjunctiva and RPE is too limited for this
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be improved with nanoparticles that are internalized and trans-
cytosed. Davis et al. (2014) used a topical liposomal drug carrier
with anionic phospholipid binding protein annexin A5 to deliver
bevacizumab to the rabbit vitreous and retina. These liposomes
were able to undergo transcytosis process in the corneal epithe-
lium, and they possibly transcytose in the conjunctiva. Bev-
acizumab from eye drop solutions had negligible permeation to the
rabbit retina and vitreous, but after the liposomal eye drops, a
bevacizumab concentration of 18 ng/ml was reached in the retina.
This is higher than the anti-VEGF EC50 of bevacizumab in vitro, but
less than the required concentration of bevacizumab in vivo
(Hutton-Smith et al., 2016). Nevertheless, the study of Davis et al.
(2014) shows a rational strategy to overcome the ocular epithelial
barriers for posterior segment drug delivery.
Blood flow and lymphatic flow are effective in the conjunctiva
and choroid (Robinson et al., 2006; Schroedl et al., 2014). It has
been demonstrated that inulin (MW about 5000 Da) permeated at
higher amounts to the posterior eye segment than small lipophilic
timolol (Ahmed and Patton, 1987, 1985). This result was explained
by the slower removal of inulin to the blood flow in the conjunctiva.
Rabbit experiments have also shown that small lipophilic pred-
nisolone is cleared from the sub-conjunctival space 64 times more
rapidly than Gd-albumin, and most of the sub-conjunctival drug is
cleared to the systemic circulation (Kim et al., 2008; Lee and
Robinson, 2004; Ranta et al., 2010). Thus, it might be possible to
minimize drug loss to the blood circulation using vasoconstrictors,
such as phenylephrine. This approach has been used in the context
of timolol administration. Even though phenylephrine coadminis-
tration reduced the peak concentrations of timolol in plasma by
80% (Kyyr€onen and Urtti, 1990) ocular timolol concentrations were
not affected, possibly because timolol is primarily absorbing to the
eye via the cornea (Ahmed and Patton, 1985). Effects of blood flow
may be complex because blood is flowing in many directions. Some
surprising results may be due to unexpected blood flow effects. For
example, small (70 nm) transferrin targeted liposomes (HSPC/
cholesterol/DSPE-PEG-Transferrin/ATTO-DOPE; molar ratios of 2:
1: 0.02: 0.005) were found in the RPE already 5min after the topical
instillation (Lajunen et al., 2014). Normal permeation across the
barriers cannot take place so fast. Therefore, some blood flow factor
might explain these findings.
Some drugs may also have preferential targeting to the retina or
choroid. The most common mechanism is melanin binding in
pigmented animals, which leads to increased concentrations in
these tissues (Acheampong, 2002; Salminen and Urtti, 1984).
Melanin bindingmay lead to 1e2 ordersmagnitude increases in the
drug concentrations (e.g. pigmented retina and choroid compared
to the non-pigmented vitreous). This does not necessarily translate
to the increased drug effects, because most of the drug in the pig-
mented cells is bound to melanin and not free for receptor binding
(Rimpel€a et al., 2016). Melanin binding will be discussed in more
detail later in this review (section 9.2.).
Drug potency and dose are the final strategic points. It is evident
that the retinal bioavailability is low after topical administration (≪
0.1%), but the concentrations that are needed for pharmacological
activity are compound dependent. Topical administration may be
suitable only for highly potent compounds that are active at low
concentrations, preferably in the nanomolar or picomolar range.
Topical drug administration to treat retinal diseases is a major
challenge and no solid success has been shown, even though many
encouraging results have been published. The route of drug ab-
sorption and distribution to the retina is complex and includes
many barriers. A combination of beneficial features in the delivery
system design may lead to improvements that enable topical non-
invasive drug delivery to the back of the eye. Successful deliverysystem should retain on the ocular surface and release drug at
adequate rate.
9. Retinal pharmacokinetics and drug delivery at cellular
level
9.1. Challenge of intracellular targets in the retina
Retinal diseases are a large group of different disorders that are
affecting different cell types, such as the RPE (dry age-related
macular degeneration, proliferative vitreoretinopathy), photore-
ceptors (rare inherited retinal degenerations), ganglion cells
(glaucoma), and endothelial cells (neovascular disorders). New
potential cellular and extracellular drug targets and compounds
with new mechanisms of action are being developed (Zhang et al.,
2012). The emerging compounds are small molecular compounds,
proteins, and RNA- and DNA-based therapeutics. The diseases,
targets and new compound classes have been presented in more
detail elsewhere in the literature. It is also worth noting that the
current anti-VEGF therapies have also been put under scrutiny as it
is becoming increasingly evident that some VEGF isoforms possess
antiangiogenic and neuroprotective properties, thus rendering
their inhibition undesirable and emphasizing a need for more se-
lective blocking of pro-angiogenic VEGF isoforms (Amadio et al.,
2016).
Drug delivery challenges include prolongation of drug action,
drug targeting to the retina and the issues of administration routes,
as discussed earlier. However, there are also cellular level factors
that are important. The retinal cells are protected by the plasma
membrane and they contain complex systems for intracellular or-
ganelles. These membranes form cellular level barriers that limit
the delivery of drugs to the intracellular targets, especially in the
case of hydrophilic drugs and biologicals. The intracellular targets
include, for example, intracellular protein aggregation cascades in
geographic atrophy, inflammasomes, and genetic defects of the
photoreceptors (Arango-Gonzalez et al., 2014; Hanus et al., 2013;
Kauppinen et al., 2016). Some of the emerging therapeutic strate-
gies impose major challenges to the cellular drug delivery: CRISPR/
Cas9 gene editing approach is a potentially attractive system for the
treatment of genetic retinal degenerations (Nash et al., 2015), but
the delivery of this system (including both RNA and protein) is
difficult. Likewise, siRNA, miRNA and mRNA are not effectively
delivered to their target sites in the cytosol and nucleus without
carrier systems (Xue et al., 2015). Gene therapy relies on carrier
systems that are mostly based on modified viruses, such as AAV-2
(Sch€on et al., 2015). Also, many proteins have intracellular sites of
action, but limited intracellular permeation (e.g. HSP-70, tran-
scription factors) (Subrizi et al., 2015).
Properties of different retinal cell types from a drug targeting
point of view have not been investigated systemically. Therefore,
this review presents general principles of intracellular and non-
viral drug and gene delivery. These principles are applicable with
specificmodifications to the retinal cells. Intracellular targeted drug
delivery requires that the carrier systems reach the surface of the
target cells, but several barriers limit their access to the target cells
(e.g. the inner limiting membrane, outer limiting membrane, RPE)
(section 3.3). In general, drug carrier systems rely on endocytosis or
phagocytosis processes for cellular uptake (Friend et al., 1996;
Wrobel and Collins, 1995) (Fig. 21). Thus, cellular uptake depends
on the inherent activity of the endocytic machinery of the cells.
Macrophages, Müller cells and RPE cells are phagocytic and able to
ingest even micron sized particles (Tuovinen et al., 2004), but the
internalization to the photoreceptors and many other cells is much
more difficult (Reinisalo et al., 2003). Even if the nanoparticles can
diffuse and reach the cell surface, the cellular uptakemay be at least
Fig. 21. Illustration of the intracellular routes of nanoparticle delivery, adapted from Soininen (2016).
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(e.g. from the vitreous) have bound to the nanoparticle surface
(Ruponen et al., 1999; Xu and Szoka, 1996). These mechanisms can
be effectively studied with cells in culture.
After internalization of the nanoparticles there are still many
intracellular hurdles before the impermeable drug can be delivered
to the cytosol or nucleus (Fig. 21). A detailed discussion of endocytic
pathways is beyond the scope of this review. Certain pathways and
cell types may be targeted with ligands that recognize receptors
(Conner and Schmid, 2003). Such ligands can be linked to the
surface of the nanoparticles or to the conjugates. Generally, endo-
cytic and phagocytic routes are trafficking the cargo to the lyso-
somes (Gruenberg and van der Goot, 2006) (Fig. 21). Sometimes
lysosomes can be relevant target organelles (e.g. lysosomal storage
diseases, dry age related macular degeneration), but lysosomal
delivery of sensitive drug cargoes should be avoided. For example,
RNA, DNA and many proteins are degraded and inactivated due to
the enzymatic activity in the lysosomes (Fonseca et al., 2009). There
are several technologies that have been used to facilitate drug
release from the endosomes to the cytosol to avoid lysosomal
localization: 1) pH sensitive materials that will fuse to the endo-
somal wall (Chu et al., 1990). These systems rely on the acidification
of the endosomes during their maturation (pH decrease in about
30 min from 7.4 to 5.0e5.5); 2) Endosomolytic peptides (Fattal
et al., 1994; Wagner et al., 1992); 3) Light triggered release from
gold nanoparticle containing liposomes (Lajunen et al., 2015); 4)
Osmotic effects due to the proton sponge effect (Boussif et al.,
1995). Another challenge is the release of the drug from the car-
rier system, because only the free drug is able to exert the phar-
macological actions. The release can take place using pH sensitive
structures (e.g. pH sensitive liposomes), enzymatic or hydrolytic
mechanisms, external signal based induction (e.g. light activation,
magnetic field) or electrostatic exchange of the carrier with
endogenous compounds (e.g. oligonucleotide release from the
cationic liposomes based on the fusion to the endosomal wall)
(J€a€askel€ainen et al., 1994; Karimi et al., 2016; Zelphati and Szoka,
1996). In the case of nuclear targets, the drug must be able to get
across the nuclear envelope (Fig. 21). The nuclear membrane has
pores that allow diffusion of molecules that are smaller than100 kDa; therefore, oligonucleotides can cross this barrier, but
plasmid DNA does not (Dowty et al., 1995; Ludtke et al., 1999;Wang
and Brattain, 2007). Larger molecules can enter the nucleus if the
cells are dividing (Brunner et al., 2000; M€annist€o et al., 2007), but
this is rarely the case in retinal disease.
There are a few retinal examples of intracellular targeted drug
delivery. For example, when peptide for ocular delivery (POD), a
peptide capable of delivering e.g. siRNA and DNA to murine retinal
and ocular tissues in vivo (Johnson et al., 2008), was fused together
with green fluorescent protein (GFP), this endogenously expressed
POD-GFP fusion proteinwas also observed to localize in the nucleus
in human embryonic retinoblast cells in vitro (Johnson et al., 2010).
Additionally, another study demonstrated how both nucleolin
binding peptide-conjugated DNA and GFP were uptaken and
guided into the nucleus of retinal and corneal cells in vivo (Binder
et al., 2011), further attesting the functionality of certain cell
penetrating peptides also as nuclear localization signals.
Overall, the cellular level barriers for biologicals are formidable,
and currently there are no clinically used biologicals in ophthal-
mology that have intracellular sites of action. The eye is an attrac-
tive target organ, because local drug administration can be used to
avoid many complex issues in the systemic circulation.9.2. Pigment binding
9.2.1. Melanin and melanosomes
Many drugs bind to melanin and this may modify ocular drug
distribution significantly (Potts, 1964). Melanin binding can in-
crease total drug concentrations in the pigmented tissues and it can
prolong the duration of drug action (Salazar et al. (1976); Salazar
and Patil (1976); Salminen and Urtti (1984); Urtti et al. (1984)).
Several ocular tissues contain melanin, including the retinal
pigment epithelium and choroid.
Melanins are a diverse group of polymers. The most common
forms of melanin in the human body are eumelanin and pheome-
lanin (D'Ischia et al., 2015). In melanin biosynthesis, melanogenesis,
L-dihydroxyphenylalanine (L-DOPA) and other intermediates of
melanin such as L-dopaquinone, L-cysteinyldopa, 5,6-
dihydroxyindole (DHI) and 5,6-dihydroxyindole-2-carboxylic acid
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(Simon et al., 2008). These intermediates polymerize to black or
brownish eumelanin and yellow/reddish pheomelanin. The ma-
jority of melanin in the RPE is eumelanin whereas melanin in
choroidal melanocytes consists of a mixture of eumelanin and
pheomelanin (Hu et al., 2008; Wakamatsu et al., 2008).
Melanin is synthesized and packed within melanosomes, cell
organelles displaying similarities with lysosomes (Fig. 22) (Raposo
and Marks, 2007; Wasmeier et al., 2008). The melanosomes have
four developmental stages from depigmented to mature stage IV
melanosomes. Synthesized melanin is deposited onto melanoso-
mal PMEL17 protein fibrils that form the protein component in
natural melanin. Melanogenesis takes place at neutral melanoso-
mal pH that is optimal for tyrosinase activity. Tyrosinase enzyme
displays low or no activity at luminal pH below pH 5. The mela-
nosomal pH in adult RPE cells is unknown, but due to halted
melanin synthesis one can assume that the luminal pH is acidic. In
contrast to choroidal melanocytes with continuous melanin syn-
thesis through the lifespan, in the RPE, the bulk of melanin/mela-
nosomes is synthesized during fetal development. In the RPE,
melanin is stored in melanosomes until senescence, with no
turnover (Boulton, 2014; Lopes et al., 2007). Melanosomes protect
the retina against solar radiation (Sanyal and Zeilmaker, 1988;
Sarna et al., 2003) and maintain the cellular homeostasis of metal
ions and oxidative stress (Hong and Simon, 2007; Hu et al., 2008).
Peripheral regions of the RPE have the highest melanin concen-
trations and the macular region has the lowest (Schmidt and
Peisch, 1986). Levels of RPE melanin decrease during age-related
macular degeneration (Sarna et al., 2003; Thompson et al., 2007).
Aging decreases the melanin levels in the RPE, but increases the
concentration in the choroid (Boulton and Dayhaw-Barker, 2001;
Schmidt and Peisch, 1986; Wakamatsu et al., 2008).9.2.2. Binding of drugs to melanin
Melanin binding of drugs has been observed already decades
ago, but the binding still remains poorly known (Leblanc et al.,
1998; Potts, 1964). Melanin is a negatively charged polymer with
carboxylic groups (Ito, 1986) and melanin granules are about one
micron sized particles (Pitk€anen et al., 2007). The substances that
bind to melanin are a heterogeneous group of drugs (e.g. antibi-
otics, beta blockers, antipsychotics, antimalarial drugs), dyes, her-
bicides, alkaloids and metals (Dayhaw-Barker, 2002; Hollo et al.,
2006; Larsson, 1993; Leblanc et al., 1998). Both eumelanin and
pheomelanin are capable of binding drugs (Mårs and Larsson,
1999). Leblanc et al. (1998) conclude in their review that lipo-
philic and basic (positive LogP, pKa over 7) bind preferably to
melanin. However, the structural features that drive melanin
binding of drugs have not been explored systematically.
Themechanisms of drug binding tomelanin are notwell known,Fig. 22. Organization of mebut it is believed that ionic interactions, van der Waals forces, hy-
drophobic interactions, and charge-transfer interactions may be
involved in binding (Larsson, 1993). Many investigators have used
one- and two-site Langmuir bindingmodels to describe the binding
equilibria of drugs with melanin. Recently, a more realistic Sips
binding model was used to take into account the nature of drug
binding with melanin, i.e. charged surface without specific binding
pockets and drug molecules moving around on the surface
(Manzanares et al., 2016). Melanin binding of drugs has typically
low affinity (millimolar or micromolar) and high capacity (large
quantity of drug can bind to melanin) (Manzanares et al., 2016). In
addition to the affinity, also the rate constants for association and
dissociation of the drugs are important in defining the effects of
binding on pharmacokinetics in the eye.
The effect of melanin binding on drug distribution in the back of
the eye has been shown in in vivo (Robbie et al., 2013; Salminen and
Urtti, 1984; Tanaka et al., 2004) as well as in in vitro studies
(Pitk€anen et al., 2007; Rimpel€a et al., 2016). Melanin binding of
drugs leads to significantly elevated drug concentrations (differ-
ences of 1e3 ordersmagnitude) in the pigmented tissues compared
to the non-pigmented tissues or the tissues of albino animal. In
some cases, the retention (chloroquine, 14C-pazopanib, 14C-
GW771806, brimonidine) (Acheampong, 2002; Larsson and Tj€alve,
1979; Robbie et al., 2013; Tanaka et al., 2004) and duration of drug
action (atropine) (Salazar et al., 1976) can change dramatically in
pigmented tissues (even to weeks or months). For example, the
half-life of brimonidine elimination from pigmented iris of cyn-
omolgus monkeys was 33 days, and the AUC values of brimonidine
in iris, ciliary body and retina/choroid were 11,103, 1396 and 1561
times higher than in the vitreous humor after multiple topical drug
dosing (Acheampong, 2002).
Cellular melanin binding of the drugs takes place in the mela-
nosomes and there is a complex interplay of drug permeation
across the cell membrane. Melanin binding may decrease the free
drug concentration that is available for receptor binding, but on the
other hand it can prolong drug retention in the cells and drug re-
sponses. In order to better understand these relationships melanin
binding of drugs was recently studied using pure melanin, RPE cells
and pigmented rats (Rimpel€a et al., 2016). Melanin binding was
modeled at cellular level for timolol and chloroquine (Rimpel€a
et al., 2016). We now extended this analysis to in vivo level to
explore the interplay between plasma membrane permeation and
melanin binding parameters in the RPE cells. Experimental melanin
binding affinities of timolol and chloroquine were used (Rimpel€a
et al., 2016), the dissociation rate constant was set to 0.1 h1 and
plasma membrane permeability was varied. The simulations reveal
interesting relationships (Fig. 23): 1) Melanin binding affects free
drug concentrations in the RPE cells; 2) Prolonged maintenance of
free drug concentrations in the cells is most pronounced when alanin in the RPE cells.
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is an interplay between plasma membrane permeation and
melanin binding; 3) The longest retention and extremely slow
elimination for chloroquine is seen if membrane permeability is
low (107 cm/s). 4) Only a minor fraction (≪1%) of chloroquine in
the RPE cells is in free form. Based on the simulations, the interplay
of melanin binding with other transport processes in the cells de-
termines the concentration profile of free drug within the cells. The
interplay may explain the high impact of melanin binding on
timolol and chloroquine concentrations in the pigmented tissues
in vivo (Larsson and Tj€alve,1979; Rimpel€a et al., 2016; Salminen and
Urtti, 1984). It is known that chloroquine is retained in the pig-
mented ocular tissues for months.
Impact of melanin binding on drug safety is controversial.
Melanin bindingmay protect the tissues from toxic effects (Larsson,
1993). Some melanin binders cause oculotoxicity, for example
chloroquine, but others do not, suggesting that melanin binding as
such is not causing toxicity (Dayhaw-Barker, 2002; Leblanc et al.,
1998). Chronic exposure with toxic compounds that bind to
melanin may cause adverse effects (Dayhaw-Barker, 2002; Larsson,
1993).
Overall, melanin binding is a significant factor that should be
taken into account in the pharmacokinetics and design of drug
delivery strategies. Melanin binding can lead to drug accumulation
to the RPE and choroid, and to prolongation of drug effects when
the drug is released gradually from themelanin depot (Robbie et al.,
2013).
9.3. Transporters
9.3.1. Transporters in the blood-retinal barrier
The transporter proteins facilitate transfer of their substrates
across the cell membranes. The transporters can be classified based
on their gene family or on their functionality. There are 1555 genes
in the human genome that are believed to express membrane
transporters (Ye et al., 2014). About 287 transporters in the human
genome are related to drug transport (Yan and Sadee, 2000). The
largest gene families among these transporters are ABC trans-
porters and SLC solute transporters. Furthermore, the transporters
are usually localized to either the apical or basolateral side of
epithelia and endothelia, and they transfer their substrates either
into the cells (influx transport) or out from the cells (efflux trans-
port). Active transport is a specific process, and therefore, the
protein structure and its expression levels affect the rate of mo-
lecular transport. Obviously, this may give rise to the differences in
the transport among different species, disease states, genetic im-
prints and ethnic origins. There are useful databases that collect
information about the transporters, such as Human Transporter
Database (Ye et al., 2014), UCSF-FDA TransPortal (Morrissey et al.,
2012) and Transporter Classification Database (TCDB, 2016).
Transporters may have influence on the retinal drug delivery in
many ways depending on the route of drug administration.
Expression of the transporters in the BRB is the most important
factor, because the BRB regulates transfer of small molecules from
the eye outwards (intravitreal injection) and inwards into the eye
(systemic, topical (trans-scleral route), sub-conjunctival, and
suprachoroidal administration). Also, the cells of the BRB (RPE,
retinal endothelia) host important drug target sites, for example
the RPE cells are key players in the pathogenesis of age-related
macular degeneration (Ambati and Fowler, 2012).
The transporter expression in the BRB was reviewed in 2006
(Mannermaa et al., 2006). The conclusion was that there are plenty
of ocular drugs that are substrates to the transporters found in
humans, but the expression or functionality of those transporters in
the BRB was mostly unknown. Thereafter, newer reviews on thisspecific topic have been published (Hosoya et al., 2011; Jordan and
Ruíz-Moreno, 2013). Table 4 shows the key data on the BRB
transporters. We have selected to this table those transporters that
have significant drug substrates or inhibitors and are known to be
expressed at a protein level in vivo or in the cultured BRB cells. Note
that the expression of some transporters in certain cells is only
postulated, without in vivo confirmation. Also, it is important to
realize that the mRNA and protein level data on expression are not
truly quantitative, since no targeted quantitative proteomics have
been used. Furthermore, exact localization of the transporters in
the BRB is not known. Transporter proteins can be localized either
on the blood side or on the retinal side. Expression and localization
have a profound impact on the transporter functions. These fea-
tures are important to study, because many BRB transporters are
interacting with important and commonly used drugs (Table 4).
9.3.2. Functionality of transporters
The functionality of the transporters has been investigated in
some cell culture studies to prove that the transporters are active.
These transporters include MRP1 (Juuti-Uusitalo et al., 2012;
Mannermaa et al., 2009; Nevala et al., 2008; Sreekumar et al.,
2012), MRP2 (Ryh€anen et al., 2008; Vadlapatla et al., 2013), MRP5
(Mannermaa et al., 2009), P-gp (Nevala et al., 2008; Zhang et al.,
2012a, 2012b), and BCRP (Vadlapatla et al., 2013). Understanding
of the active drug transport in the BRB is still far from complete, but
there is evidence for the role of some transporters in drug delivery.
For example, ofloxacin efflux in rabbit eyes (Senthilkumari et al.,
2009) and the smaller than expected retinal uptake of digoxin
and vincristine were explained by P-gp activity (Hosoya et al.,
2010). Likewise, higher than expected retinal uptake of L-dopa in
rats was explained by the active transport (Hosoya et al., 2010).
Furthermore the inner blood-retinal barrier organic anion trans-
porter 3 was shown to transport p-aminohippuric acid, benzylpe-
nicillin, and 6-mercaptopurine from the vitreous/retina to the
blood circulation (Hosoya et al., 2009). Intravitreal methotrexate
resistance has been explained in one patient case (intraocular
lymphoma) to be caused by increased MRP expression (Sen et al.,
2008).
Transporters are subject to significant genetic polymorphisms
that might cause inter-individual differences in pharmacokinetics
and drug responses (Wolking et al., 2015), but this aspect has not
been investigated in the context of drug delivery to the posterior
eye segment. Likewise, the possible species differences in terms of
transporter functions in the BRB are still unclear. Transporter
expression should first be reliably quantitated and localized before
these aspects can be studied in detail. They can be significant only
in those cases (drug e transporter pairs) in which the active
transport has a major role in pharmacokinetics, clearly surpassing
the role of passive diffusion.
As discussed earlier (section 3) QSPRmodeling of drug clearance
has been performed from the rabbit vitreous (del Amo et al., 2015).
The model was based on data from 40 compounds and it did not
show clear outliers when a physico-chemical descriptor equation
(including H-bonding and LogD7.4) was plotted against the vitreal
drug clearance. This indicates that among those 40 compounds,
transporter activity did not significantly alter the drug clearance
from the vitreous to the blood circulation as good correlation was
achieved with purely physico-chemical descriptors, which are
important determinants of passive drug diffusion across cellular
membranes. The QSPR model for clearance across blood-ocular
barriers was used as a component in the pharmacokinetic simu-
lation model for prediction of drug transfer from the blood circu-
lation to the vitreous in rabbits (Vellonen et al., 2016, section 4).
Again, good correlation without striking outliers was obtained be-
tween the model and real data. However, in this case some over-
Fig. 23. Simulation of drug concentrations in the RPE cells in vivo at different melanin binding conditions (unpublished simulations). Binding affinities of timolol and chloroquine
from Rimpel€a et al. (2016) were used. The values of melanin binding affinity, rate constants for drug dissociation from melanin (koff ¼ 0.1 h1) and cell membrane permeability
(Papp ¼ 107e105 cm/s) were modified in the simulations. A) Free concentration of timolol in the RPE cells at different plasma membrane permeabilities with and without (NB ¼ no
binding) melanin. B) Free concentration of chloroquine in the RPE cells at different plasma membrane permeabilities with and without (NB ¼ no binding) melanin. C) Free
concentration of chloroquine in the RPE cells. The drug is binding to melanin. Effects of plasma membrane permeability on drug concentration profiles over long time period (6
months) are shown. D) Free and total concentrations of chloroquine in the RPE cells at different plasma membrane permeabilities.
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explained based on the transporter activity in the BRB (ciproflox-
acin, fleroxacin, ofloxacin, mercaptopurine) (Vellonen et al., 2016).
It seems that the transporter activity is capable of modulating the
drug transport in the BRB, but passive diffusion seems to be the
major factor in vitreous to blood clearance. Similarly, passive
diffusion seems to be a key player, together with plasma protein
binding, as a determinant of drug distribution from the plasma to
the vitreous. The BRB data is quite different from the situation in
the blood-brain barrier, where simple physico-chemical models do
not performwell, and there are significant outliers from the trends,
particularly due to the efflux role of P-gp (Dolghih and Jacobson,
2013; Kikuchi et al., 2013).
Another aspect of active transport is its role in the intracellular
drug concentrations of the individual cell types in the retina.
Expression of influx or efflux transporters on the cell surface may
have a big impact on the free drug concentrations in the cells (Chu
et al., 2013), possibly also in the context of melanin binding
(Fig. 22), even though the transporter activity would not causepharmacokinetic changes at the level of vitreal drug concentra-
tions. Unfortunately, the transporter expression of different cell
types in the retina has not been determined, and therefore, there is
no rational basis to design drugs that would be targeted to specific
retinal cells via transporter activity.
10. Special issues
10.1. Disease state effects
Diseases may cause pathophysiological alterations in the ocular
environment that can lead to changes in pharmacokinetics and
drug delivery. This is quite a complicated issue, because the phar-
macokinetic outcomes depend on the disease (nature and extent of
the changes) and drug properties. For example, it is known that
highly permeable lipophilic drugs are relatively insensitive to the
changes in the membrane integrity, whereas transport of poorly
permeable compounds, such as proteins, may be affected much
more.
Table 4
Transporter expression in the blood-retinal barrier. Example substrates and inhibitors are shown in the table. This is not a comprehensive collection, but rather it presents the
transporters that have been found in the cells of blood-retinal barrier at protein level.
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Protein: ARPE-19, D407, HRPEpiC bRPE,





Chapy et al. (2016);
Chen et al. (2013);
Dahlin et al. (2013);
Haritova et al. (2013);
Juuti-Uusitalo et al.
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et al. (2009); Nevala
et al. (2008); Ryh€anen
et al. (2008);
Sreekumar et al.






mRNA: ARPE-19, hESC-RPE hRC, D407,
hRC
Protein: D407, hRC, hRetina
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Haritova et al. (2013);
Mannermaa et al.
(2009); Sreekumar
et al. (2012); Tachikawa
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hESC-RPE, hRetina, dRetinab, mRPE
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Chen et al. (2013);
Dahlin et al. (2013);





(2012); Tachikawa et al.






mRNA: ARPE-19, D407, HRPEpiC, bRPE,
hESC-RPE, hRetina, hRC
Protein: ARPE-19, D407, HRPEpiC, hESC-
RPE, hRC, hRetina, hESC-RPE
Apical membrane
(hESC-RPE)
Chen et al. (2013);




Sreekumar et al. (2012)







mRNA: hESC-RPE, hRC, D407, ARPE-19,
dRetina










Chapy et al. (2016);
Chen et al. (2013);
Dahlin et al. (2013);
Hosoya and Tomi
(2005); Juuti-Uusitalo
et al. (2012); Kennedy
and Mangini (2002);
Mannermaa et al.
(2009); Nevala et al.
(2008); Tagami et al.
(2009); Vadlapatla et al.
(2013); Zhang et al.








mRNA: D407, ARPE-19, hRetina, hRC,
dRetina, mRetina, mRPE
Protein: hRC, ARPE-19, D407, hRetina,








Asashima et al. (2006);
Chapy et al. (2016);
Dahlin et al. (2013);
Gnana-Prakasam et al.




(2009); Nevala et al.
(2008); Tagami et al.
(2009); Vadlapatla et al.
(2013); Zhang et al.
(2008)
Protein: hRPE cell layer, ARPE19 mRNA: TR-iBRB cells
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Table 4 (continued )



















Protein: hRPE cell layer
Dahlin et al. (2013);





mRNA: hRetina Dahlin et al. (2013)
OATP2B1
(SLCO2B1)
unoprostone, cyclosporine mRNA: hChoroid-RPE, hRC
Protein: hRPE
Kraft et al. (2010);
Zhang et al. (2008)
Expression in RPE: Western blot or immunochemistry.
Abbreviations: b bovine, c calf, d dog, h human, hf human fetal, m mouse; hESC-RPE human embryonic stem cell derived RPE cells, RC retina-choroid.
a From Mannermaa et al. (2006), Dahlin et al. (2013), Zhang et al. (2012a, 2012b), UCSF database (Morrissey et al., 2012).
b Found only in 2 dogs out of 6, all different breeds.
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data in the healthy rabbits and human patients was calculated (del
Amo et al., 2015; del Amo and Urtti, 2015). The correlation of
clearances between these two groups was excellent (0.91),
maximum deviation was only 3-fold, and the mean clearance in
humans was 1.4 times higher than in the rabbits (Fig. 24; Human
apparent CLivt ¼ 1.41  Rabbit CLivt þ 0.04, units are ml/h;
R2¼ 0.82; note that there was an erroneous equation in the original
reference (del Amo and Urtti, 2015)). This difference is explained
based on the size difference as the membranes in the human eye
have a higher surface area (membrane controlled
clearance¼ permeability x surface area). In these data, the diseases
of the patients included choroidal neovascularization, diabetic
retinopathy, cytomegalovirus retinitis, and post-operative
endophthalmitis with and without core vitrectomy (del Amo and
Urtti, 2015). The eight compounds in the data set were relatively
hydrophilic as they had been given as intravitreal injections as
solutions. Thus, the correlation does not include lipophilic drugs,
but on the other hand, the BRB permeability of lipophilic com-
pounds is expected to be less sensitive to the changes in the
membrane integrity than the hydrophilic compounds.
We explored the impact of pathological conditions on the
pharmacokinetics and compiled the newanalysis to this review.We
collected the published data where posterior segment pharmaco-
kinetics in animal disease state models and healthy animals has
been compared. We determined the essential pharmacokinetic
parameters from the published data. The outcome of these analyses
is shown in Table 5.
It has been postulated that the vitreal elimination of those
compounds that are eliminated via the anterior route (e.g. vanco-
mycin, aminoglycosides, macrolides, rifampicin), and which poorly
cross the blood-retinal barrier, should increase in the disease state
upon breakdown of the blood-retinal barrier (Coco et al., 1998;
Maurice and Mishima, 1984; Radhika et al., 2014). In the case of
posteriorly eliminated compounds, drug elimination should be
decreased for those drugs that use active transport mechanisms
(e.g. penicillin) due to the inactivation of the transporter in the
blood-retinal barrier (Maurice and Mishima, 1984). As seen in
Table 5 we did not find experimental evidence to support the
impact of disease state effects on posterior segment
pharmacokinetics.
Breakdown of BRB is considered to be part of clinical diabetic
retinopathy. In humans, insulin levels were determined in the post-
mortem serum and vitreous (Palmiere et al., 2015). There is a cav-
eolae mediated transport of insulin in the retinal capillaries and,
therefore, insulin transport to the eye might involve active trans-
port process in diabetic patients (Klaassen et al., 2013). Based on thedata of Klaassen et al. (2013) it is impossible to know if the differ-
ence between healthy and diabetic subjects is negligible or sub-
stantial. It has been proposed that fluorescein could be used as an
early marker for diabetic retinopathy that would report about the
leaky BRB, but the results have not been reproducible (Krogsaa
et al., 1981; T€ornquist et al., 1990). Likewise, fluorometric studies
with streptozotocin induced diabetes rats have also given con-
flicting results on BRB permeability (Klein et al., 1980; Waltman
et al., 1978), and no change in the BRB permeability was seen
with radioactive tracers after 1e2 weeks of streptozotocin induced
diabetes rats (M€aepea et al., 1984).
Overall, there is no strong evidence that would support the
notion that diseased BRB would cause major changes in the ocular
pharmacokinetics or drug delivery. The data so far suggests that the
changes in the pharmacokinetics either do not exist or are only
modest. The disease-induced changes shown in Table 5 (less than
1.5-fold) are negligible in relation to the range of clearance values
(about 50-fold) that are seen with different molecular structures
(Fig. 6A). We have not found quantitative evidence for any major
changes that the disease state would cause in the posterior eye
segment. Therefore, pharmacokinetic studies in healthy animals
should be valid, because the disease effects on pharmacokinetics do
not cause major changes in the drug dosing levels.10.2. Immunological aspects
The eye is considered to be an immunologically privileged or-
gan, but this old paradigm is not quite right, because immunolog-
ical reactions can be seen in the eye. This is relevant in drug
delivery, because human proteins are first tested in laboratory an-
imals where immunological issues may complicate the data inter-
pretation. Also, formulations may cause activation of the immune
system.10.2.1. Protein interactions of biologicals and drug delivery systems
Proteins are the key players in immunology, and knowledge of
the ocular proteome is expanding with the Human Eye Proteome
Project (open initiative launched in 2012). So far 4842 proteins have
been identified from ocular tissues and fluids (Semba et al., 2013).
In total, 1317 proteins were found in both the eye and plasma,
whereas 3525were unique to the ocular environment and 611were
only found in plasma. More information can be found in the data-
bases (Peptide Atlas, 2016; The Ocular Tissue Database, 2016). The
number of proteins identified in the vitreous humor, retina and
choroid are 545, 672 and 897, respectively.
After ocular application, for instance in the vitreous, drugs or
formulations may associate with proteins. This is particularly
Fig. 24. Intravitreal clearance in the healthy rabbits and human patients. The dotted and dashed lines represent 2 and 3-fold deviation from perfect match (solid line). Human CLivt,
apparent ¼ 1.41  Rabbit CLivt þ 0.04, units are ml/h. For more details of the data, see del Amo and Urtti (2015). Note that in the original article and in later publication of Vellonen
et al. (2016) the prediction equation was formulated incorrectly.
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protein corona may form on the particle surface and this will
change and define its biological properties (Docter et al., 2015;
Tenzer et al., 2013; Walczyk et al., 2010). This protein corona (or
opsonisation) may change the pharmacokinetics, and this is well
known in the systemic nanoparticle field (Owens and Peppas,
2006; Vonarbourg et al., 2006). Albumin is one of the major pro-
teins in the vitreous and it is prone to bind to nanoparticles (Docter
et al., 2015; Yan et al., 2013). The protein corona can have various
effects: 1) A non-specific increase in the particle size can change the
distribution and elimination kinetics (Choi et al., 2010); 2) Protein
corona, e.g. albumin, may lead to specific cell uptake by macro-
phages or microglial cells (Ibrahim et al., 2011); 3) Material toxicity
may be altered, e.g. masking of positive chargesmay reduce toxicity
(Oh et al., 2010); 4) Protein binding may change the protein
conformation and render it immunogenic (Deng et al., 2011; Nel
et al., 2009); 5) An active targeting ligand or epitope may be
masked, leading to a loss in activity (Lehtinen et al., 2012a;
Mirshafiee et al., 2013). It is evident from the systemic drug de-
livery studies that protein interactions can have profound effects on
the behaviour of nanoformulations and biologicals, but how these
aspects contribute in the eye is not known.
Most biotechnological products elicit an immune response that
leads to formation of neutralizing antibodies in the systemic blood
circulation. The neutralizing antibodies interfere at site of action,
increase drug clearance, andmay lead to adverse effects (Sauerborn
et al., 2010). This is also relevant in ocular therapeutics that are
administered suprachoroidally, transsclerally or in the sub-
conjunctival space. Although an antibody response does not
necessarily affect therapeutic efficacy, immunological assessment
of biologicals is required in early development (U.S. Food and Drug
Administration, 2013). Impurities, aggregation, modification of
proteins by glycosylation or PEGylation, as well as patient and
disease-related factors may influence the immunogenicity of pro-
tein therapeutics (Sauerborn et al., 2010). Monomeric forms of a
proteins are less likely to elicit an immune response than aggre-
gates (Rosenberg, 2006; Sauerborn et al., 2010).
Polyethylene glycol (PEG) that is commonly used to modify
therapeutic proteins, drug delivery systems and biomedical de-
vices, reduces the protein adherence and thereby slows down the
particle and protein elimination. PEG is not biodegradable and is
mostly eliminated via renal filtration. PEG is not completely inert,
since it activates the complement system and the production ofanti-PEG antibodies (Knop et al., 2010; Schellekens et al., 2013).
Interactions of drug delivery devices with the cells and proteins of
the immune system may lead to stimulation or suppression of
immune function (Elsabahy and Wooley, 2013; Farrera and Fadeel,
2015). In the blood stream, drug delivery systems are taken up in
the mononuclear phagocyte system, which is facilitated by opso-
nisation or plasma proteins adsorption onto their surfaces, result-
ing in altered biodistribution and accelerated blood clearance
(Owens and Peppas, 2006; Vonarbourg et al., 2006). Drug delivery
devices are able to activate the complement system but require a
co-stimulus to activate immune cells (Farrera and Fadeel, 2015).
Immune activation may result in clinical manifestations such as the
mild-to-severe pseudoallergic reactions observed with PEGylated
liposomal therapeutics (Szebeni, 2005a; Szebeni et al., 2011a).
However, safety assessment of drug delivery devices has yet to be
standardized and harmonized to the same extent as with protein
therapeutics (Nystr€om and Fadeel, 2012).10.2.2. Ocular immune defence
Depending on the route of administration, ocular therapeutics
may also encounter the immune cells and other components on the
ocular surface (conjunctiva, cornea, tear fluid). The cornea, anterior
chamber, lens, vitreous cavity and sub-retinal space are immune
privileged sites (Bora et al., 1993; Luke et al., 1993). However, a
number of immune system effector molecules and cells are present
in the inner eye and they can interact with intravitreal therapeutics
(Anderson et al., 2010; Rutar et al., 2014). Ocular tissues produce
complement system components and rat eyes contain a functional
complement system with membrane attack complex (Sohn et al.,
2000). This complex could influence also the integrity of lipo-
somes (Sohn et al., 2000). The effect of age-related changes in
ocular proteins on the function of the ocular immune system have
yet to be established (Perez and Caspi, 2015). Particulate-associated
antigens can also bypass the immune privilege and induce a normal
immune response in the eye (D'Orazio and Niederkorn, 1998). As a
result of immune deviation, the eye is less able to deal with an
exaggerated immune response (Forrester et al., 2016). Sterile
endophthalmitis that resolves without treatment has been re-
ported with the anti-VEGF therapeutics bevacizumab, ranibizumab,
pegaptanib, and aflibercept (Agawa et al., 2014; Agrawal et al.,
2013). In most cases, ocular inflammation is transient and consid-
ered as an acceptable safety risk in the treatment of posterior eye
diseases (Short, 2008). However, animals display significant and
Table 5
Comparison of pharmacokinetics in normal and disease state animal models (unpublished pharmacokinetic parameter analyses). Barza et al., 1982; Barza et al., 1993; Bienert
et al., 2012; Ficker et al., 1990; Ozcimen et al., 2015; Coco et al.,1998; Mandell et al., 1993; Meredith, 1993; Park et al., 1999; Shen et al., 2014.
Disease model 
and species
Drug, administration route, drug 
properties1 and primary route of 
elimination
Pharmacokinetic parameters 




ml of 109 heat-
killed Staph. 
epidermis injected 








t1/2,ivt (h) AUCivt (h
μg/ml)
Healthy 0.039 29.0 7,729













Not possible to curve fit the data. 
The concentration curves are similar. 

















t1/2,ivt (h) AUCivt 
(h.μg/ml)
Healthy 0.161 17.3 205.34





ml of 500 cfu/ml 
S.aureus injected 








t1/2,ivt (h) AUCivt 
(h.μg/ml)
Healthy 0.166 6.4 6,030





ml of 109 heat-
killed S. epidermis








t1/2,ivt (h) AUCivt 
(h.μg/ml)
Healthy 0.165 7.2 15,182





ml of 500 cfu/ml 
S.aureus injected 




Cefepime -2.29 481.57 4
Ceftazidime -2.95 547.58 5
Ceftizoxime -4.35 383.4 4
Ceftriaxone -5.32 554.58 5
Posterior route
No concentrations available.
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Infection and 
inflammation: 0.1 
ml of 109 heat-
killed 
S. epidermis
injected into the 
vitreous of rabbits 
Ceftazidime intravitreal
Posterior route CLivt(ml/h)
t1/2,ivt (h) AUCivt 
(h.μg/ml)
Healthy 0.077 13.3 29,236
















t1/2,ivt (h) AUCivt 
(h.μg/ml)
Healthy 0.041 24.6 4,850







alloxan 90 mg/kg 
in rabbits
Paracetamol intravenous Drug concentrations in plasma and aqueous humour 
but not in vitreous. 








Healthy 24.61 5.68 4.3
Diseased 13.13 2.71 4.8






ml of 2,000 cfu/ml 
S.aureus injected 








t1/2,ivt (h) AUCivt 
(h.μg/ml)
Healthy 0.041 26.9 23,796







injected into the 
Vancomycin intravitreal
Anterior route
Not possible to curve fit the data. 
The concentration curves are similar.
Time (h) Vitreous conc. (μg/mL)2
Healthy Diseased
Park et al. 
(1999)
rabbit vitreous 24 280.8 197.5
48 204.3 129.7
72 110.4 67.0
1: calculated using ACDlabs® software (version 12, Advanced Chemistry Development, Inc., 
Toronto, Canada)
2: obtained from the pharmacokinetic graphs using GetData Graph Digitizer® (version 2.24. Digital 
River, Inc., Cologne, Germany).
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vitreal therapeutics and are poor predictors of ocular inflammation
in humans (Short, 2008). It is likely that this conclusion also applies
to drug delivery devices.
In the posterior segment of the eye, microglial cells distributed
around blood vessels represent the mononuclear phagocytic sys-
tem in the retina (Zeng et al., 2008). The macroglial Müller cells of
the retina are able to phagocytose foreign material and produceproinflammatory cytokines upon activation (Bringmann et al.,
2006). Müller cell gliosis, or the activation of microglial and mac-
roglial cells is central in the retinal response to damage or a path-
ogen, including extravasation of plasma immune system
components (for review see, Bringmann et al. (2006)). The entry of
plasma proteins into the eye as a result of inflammation overcomes
the immune privilege of the vitreous (Streilein et al., 2002).
Exudative diseases may modulate the immune responses towards
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sponses, like phagocytic antigen-presenting cells (Kumar et al.,
2004). RPE cells express several Toll-like receptors and co-
stimulatory molecules capable of recognizing pathogen-
associated molecular motifs leading to inflammasome activation
and production of proinflammatory cytokines, demonstrating their
role in both innate and adaptive immune responses (Kumar et al.,
2004; Percopo et al., 1990). Photoreceptors (Singh and Kumar,
2015), microglia (Kochan et al., 2012) and Müller cells (Kumar
and Shamsuddin, 2012) have been shown to express Toll-like re-
ceptors with the ability to initiate an innate immune response. Toll
like receptor 4 that is present on photoreceptors, RPE, ciliary body,
cornea, conjunctiva and choroid recognizes endotoxins that should
be avoided in the intraocular pharmaceutical products (Agrawal
et al., 2013; Crist et al., 2013; Kumar et al., 2004; Tu et al., 2011;
U.S. Food and Drug Administration, 2015). In preclinical studies,
endotoxin contamination may alter clearance and biodistribution
and lead to inflammation. Toll like receptors also recognize viral
DNA and RNA motifs, lipoproteins and heat shock proteins, and
could interact with therapeutic proteins, nanoparticles or viral
vectors (Micera et al., 2005).
10.2.3. Interactions of drug delivery systems with ocular immune
defence
Immune responses to intravitreal biologics (e.g. bevacizumab,
aflibercept) have been shown in many studies (Forooghian et al.,
2011, 2009; Ho et al., 2013; Rosenfeld et al., 2006), but a lack of
antibody formation has also been reported (Gaudreault et al.,
2005). The clinical significance of these phenomena is still un-
clear, but the possible role of antibody formation in the tachyphy-
laxis to aflibercept and bevacizumab has been proposed
(Forooghian et al., 2009; Ho et al., 2013). Although immune re-
sponses in the eye are geared towards an anti-inflammatory
response and systemic tolerance, the need for repeated adminis-
tration of intravitreal biologics in chronic therapies may exacerbate
this issue. To our best knowledge, studies on the interactions be-
tween drug delivery systems and intraocular complement system
components have not been reported. Since the ocular environment
contains a functional complement system (Sohn et al., 2000), the
possibility of complement-mediated immune responses especially
in exudative disease states cannot be ruled out. Drug delivery de-
vices have induced clinically significant complement-mediated
hypersensitivity reactions in the blood circulation of susceptible
individuals (Szebeni et al., 2011b). However, complement-
mediated hypersensitivity reactions typically arise at first expo-
sure, but become milder or absent in repeated administration
(Szebeni, 2005b).
There are several studies that report interactions or lack of in-
teractions of drug delivery systems with the ocular immune
defence. The individual studies demonstrate different aspects of
interactions between the immune system and drug delivery sys-
tems. Activation increases the phagocytic capacity of microglial
cells and macrophage-related cells in general (Hanisch and
Kettenmann, 2007). For example, choroidal neovascularization in
age-related macular degeneration is associated with the infiltration
of blood-derived macrophages to the retina underlying the choroid
(Caicedo et al., 2005). Most were found in close proximity to Müller
cells of the retina. Resident microglial cell densities were not
increased or decreased as a result of infiltration.
Cationic materials, such as chitosan, are often harmful and may
cause inflammatory cell infiltrations in the eye after intravitreal and
sub-retinal delivery (Prow et al., 2008). In general, positively
charged nanoparticles are phagocytosed efficiently into the
mononuclear phagocytic system (Xiao et al., 2011). No immune cell
infiltration was observed with negatively charged polylactic acidnanoparticles (140 ± 20 nm) in the ciliary body or retina in the first
hour, but after 6 and 24 h, some infiltrating cells were found in the
vitreous and retina, but signs of inflammation decreased by 48 h
(Bourges et al., 2003). Poly-lactic acid particles were present in the
RPE cells four months after single intravitreal injection (Bourges
et al., 2003). Some of the infiltrating cells were shown to phago-
cytose the rhodamine-modified nanoparticles (Bourges et al.,
2003). On the other hand, negatively charged ganciclovir-loaded
bovine serum albumin nanoparticles (size range 257e351 nm)
remained in the rat vitreous for two weeks after a single injection,
with no inflammatory changes (Merodio et al., 2002).
Barza et al. (1987) used a model of bacterial inflammation to
assess the effect of inflammation on the rate of clearance of small
and large unilamellar liposomes from the rabbit eye. The authors
speculated that the liposomes could be cleared by diffusion
through the anterior route, by phagocytic cells (e.g. RPE) or by
degradation in the vitreous. The relative contribution of these
different routes could not be estimated based on the data. Since
only 1e2% of the 125I label was found in the choroid and retina, the
contribution of phagocytic cells is likely to be low.
10.3. Non-invasive analytical methods for ocular pharmacokinetics
and drug delivery
Ocular pharmacokinetics and drug delivery studies in vivo are
challenging, because the studies are invasive. It is not possible to
withdraw repeated samples from the aqueous humor and vitreous
of humans or animals, because the sampling would cause changes
in the fluid volumes and other reactions in the eye that might
hamper the reliability of the pharmacokinetic results. Furthermore,
ocular pharmacokinetics are usually studied in rabbits or monkeys,
because the sampling is even more difficult from small animals and
pharmacokinetics in the small rodents do not translate well to the
human situation. An invasive pharmacokinetic rabbit study in-
volves use of many rabbits. For example, a simple pharmacokinetic
comparison of three drugs or formulations requires 36 rabbits (i.e. 3
formulations x 6 time points x 4 eyes/time point).
Non-invasive imaging is an attractive option for pharmacoki-
netics and drug delivery studies, since it would replace, reduce and
refine the animal experiments. Imaging allows observations from
the same animal at many time points thereby decreasing the
number of animals in the test (in the aforementioned experiment 6
rabbits would be enough). This approach also reduces the data
variability that is due to the variation among the animals. The
imaging modalities include optical, radiochemical and magnetic
resonance methods.
10.3.1. Optical imaging
Optical fluorescence based imaging has been used in ophthal-
mology since the 1980's. Originally, in vivo fluorometers were
developed as clinical instruments to determine blood-retinal bar-
riers (in diabetes), early cataract formation, tear flow rates and
aqueous turnover (Knudsen, 2002). In vivo fluorophotometry has
been used to monitor the fluorescence levels mainly in humans and
rabbits. The fluorometer is detecting the emission signals after
excitation through the transparent ocular tissues (cornea, aqueous
humor different depths of visual axis over time).
The drawbacks of in vivo fluorophotometry are obvious. Firstly,
exact quantitation is very difficult, because the fluorescence signal
depends on the geometrical factors, and the properties of the
fluorescent probe. Most widely used probes of ocular in vivo fluo-
rophotometry (e.g. fluorescein) show fluorescence emission, which
is dependent on the environment (e.g. pH), concentration (i.e. non-
linear relationship between the signal and fluorophore concen-
tration), and light exposure (i.e. photo-quenching) (Song et al.,
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spectra that would allow their non-invasive fluorometric imaging.
In general, fluorometric imaging cannot be used for pharmacoki-
netic monitoring of small molecular drugs. Thirdly, the stability of
the fluorophore in the studied object (e.g. drug or delivery system)
is a crucial issue. If the label is detached from the study object, the
imaging will thereafter follow only the kinetics of the label. The
stability of the label should be checked in vitro in relevant media to
avoid such artefacts in the imaging study.
Despite its limitations, optical imaging can give useful infor-
mation about the pharmacokinetics of macromolecules and drug
delivery systems in the eye. Recently, intravitreal kinetics of rani-
bizumab was studied using in vivo fluorophotometry (AlexaFluor
488 label) and ELISA (Dickmann et al., 2015). Similar pharmacoki-
netic parameters were obtained with both approaches. This study
demonstrated that it is crucially important to use a minimal
number of fluorophores for labelling and select fluorophores that
have maximal brightness, photostability and minimal pH sensi-
tivity. Currently, there are various fluorophores (such as Alexa dyes)
available that are compatible with the wavelengths of in vivo flu-
orophotometers. They have improved brightness, stability in the
presence of light excitation andmore robust fluorescence spectra in
changing environments (Wysocki and Lavis, 2011). These features
provided broader dynamic range of linearity (fluorescence emis-
sion vs drug concentration) that enabled intravitreal pharmacoki-
netic monitoring of ranibizumab over a 20-fold concentration
range (Dickmann et al., 2015).
Potential uses of this technique include monitoring the reten-
tion of drug delivery systems on the ocular surface or in the vit-
reous. Also, the effects of drugs and delivery systems on the blood-
ocular barrier can be detected by following the entrance of intra-
venous FITC-dextran to the eye. Several groups have also demon-
strated the use of this method to study transscleral drug delivery
(Berezovsky et al., 2011; Ghate et al., 2007; Lee et al., 2008).
Currently, there are also new in vivo fluorometers that are more
robust than the classic ocular in vivo fluorometer potentially
expanding the use of this metholodology.
10.3.2. Radiochemical imaging
Radiochemical imaging is based on the detection of the radio-
isotopes that are emitting gamma irradiation. The isotopes can be
used in single photon emission computed tomography (SPECT) or
positron emission tomography (PET). The isotopes in SPECT/CT
imaging include technetium (99mTc), indium (111In) and iodine (131I,
123I), whereas PET isotopes include, e.g. 18F. Radio imaging has a
quantitation advantage over optical imaging: the sensitivity is high
(about 1 nM), the radioactive signal is insensitive to changes in the
environment thereby giving excellent depth and dynamic linear
range of the measurements. However, these are expensive tech-
niques, since special labelling techniques and isotopes are needed
and the imaging equipment is very expensive. Another challenge is
the spatial resolution: typically, the resolution with mouse, rat and
rabbit collimators range from 0.5 to 2 mm, respectively. This res-
olution allows only coarse imaging of the eyes, but not to the levels
of individual tissues (e.g. retina). Computed tomography and MRI
are used for the anatomical localization of the tissues (spatial res-
olution MRI: 25e100 mm, CT: 50e200 mm).
The investigator should be aware that the labelling might
change the properties of the compound, potentially leading to the
alterations in the biodistribution. Labelling is challenging, partic-
ularly in the case of small molecules. Pharmacokinetics of proteins,
other large molecules and drug delivery systems may not be as
sensitive to the labelling changes. Typical labelling strategies
include the use of peptide linkers in labelling of proteins (Liu,
2008), encapsulation of hydrophilic or lipophilic compounds toliposomes or nanoparticles (Lehtinen et al., 2012b; Psimadas et al.,
2012), radiometal complexation radiotracers with DOTA (Liu,
2008). In the case of ocular studies BRB is an important consider-
ation, because changes in the molecular size and lipophilicity may
change the permeability in the BRB and cause changes in the vitreal
clearance (Fig. 6). Different labelling techniques have been
reviewed in detail in specialized review articles (Hom and
Katzenellenbogen, 1997; Liu, 2008).
SPECT/CT has been used to study ocular distribution of intra-
venously injected radio labelled 3-123I-iodochloroquine in rats
(Rimpel€a et al., 2016). This study showed that the SPECT/CT is a
suitable technique for drug distribution studies, since it allowed
non-invasive quantitation of the drug in the eyes over time.
Another application of SPECT/CT approach was imaging the vitreal
kinetics of HSP-70 protein in ex vivo bovine eyes (Subrizi et al.,
2015).
Micro-PET has not been used for ocular drug delivery studies.
10.3.3. Magnetic resonance imaging (MRI)
Magnetic resonance imaging has been used to study ocular
structures (Fanea and Fagan, 2012; Shih et al., 2011) and ocular drug
delivery (Li et al., 2008). This method relies on nuclear magnetic
resonance signals emitted by magnetically labelled nuclei (e.g. Gd)
(Fanea and Fagan, 2012). A nice feature of MRI is its excellent spatial
resolution, but its usefulness is limited in ocular pharmacokinetic
studies, because the linear range of quantitation and sensitivity
(about 0.1 mM) are quite limited compared to the radioimaging and
optical imaging techniques. These are serious shortcomings and
currently MRI imaging is not an attractive option for ocular phar-
macokinetic studies. However, MRI may be a useful technique to
improve the localization in association with SPECT and PET imag-
ing. Also, it is useful in monitoring the fate of the delivery systems
in the eye (Li et al., 2008).
10.3.4. Summary
Imaging techniques, especially optical imaging, have been used
in ocular pharmacokinetics. At the moment their utility is still
limited, but the situation may improve significantly in the future.
Imaging methods are continuously developing, optical coherence
tomography being a nice example in ophthalmology. It is likely that
various imaging methods will be developed, alone and as combi-
nations, towards better quantification, resolution and label free
approaches. Such a progress will also facilitate the studies in ocular
drug delivery, hopefully allowing non-invasive quantification both
in animals and humans.
10.4. Species differences
Ocular research on mechanisms of diseases and pharmacology
of drug candidates are usually carried out using in vitro methods
and mouse models, but ocular drug delivery and pharmacokinetics
are studied in larger animals with bigger eyes (e.g. rabbits, mon-
keys). Obviously, translation tools between animal species and from
preclinical models toman are essential in ocular drug development.
Currently, there are some tools for translation, but much more
progress is still needed. Ocular pharmacokinetic data in rabbits and
monkeys exist, but it is sparse in humans, and even less in rodents.
Therefore, inter-species translation cannot be done at the current
stage. We shall discuss some aspects of the species differences for
each route of drug application.
Physiologically based pharmacokineticmodels and inter-species
scaling is based on anatomical and physiological values. We have
collected some key values from rabbit, mouse, cynomolgus mon-
keys and humans in Table 6.
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After topical drug delivery, the eye drop is subject to the factors
that are removing the applied solutions from the ocular surface
(Mishima, 1981). In humans, the blinking frequency is much higher
than in the rabbits and this leads to faster clearance of applied
solutions (Mishima, 1981), but this factor has not been investigated
in mice and rats. It is known that the mouse and rat studies are
giving over-optimistic results on the posterior segment drug de-
livery after topical administration (Joussen et al., 2016). This is
probably due to the geometric factors, because the distance to the
posterior segment tissues is much shorter in mice and rats as
compared to rabbits and humans. Also, mouse and rat sclera are
much thinner and thus more permeable than the sclera in rabbits
and man. The same factors are relevant in the case of sub-
conjunctival injections, probably leading to over-optimistic results
in retinal drug delivery. Furthermore, drug distribution to the
contralateral eye via systemic circulation is more pronounced in the
mice, rats and rabbits than in man. One should be particularly
cautious when making conclusions based on the rodent studies in
terms of posterior segment drug delivery after topical
administration.10.4.2. Intravitreal delivery
The species differences of intravitreal pharmacokinetics have
been mostly discussed in the case of rabbits and humans. It is
known that there are differences between the human and rabbit
eye (Laude et al., 2010; Rowe-Rendleman et al., 2014): 1) Vitreal
viscosity in the rabbit eyes may be higher than in elderly human
patients; 2) Retinal capillaries are different and sparser in rabbits
than in humans; 3) The relative size of the lens is bigger in the
rabbit than in the human eye; 4) Overall, the human eyes are bigger
than the rabbit eyes. The significance of these differences on the
intravitreal drug clearance was analysed after collecting all avail-
able literature on drug concentrations in the human patients and
rabbits (del Amo and Urtti, 2015). The clearance values were
determined and good correlation of the rabbit and human clear-
ance values was obtained (Fig. 24) indicating that the intravitreal
drug clearance can be scaled up reliably from rabbit to patients. As
discussed earlier, disposition of the delivery systems in the vitreous
may differ between man and rabbit (section 3.4), but pharmaco-
kinetic significance of these differences have not been either
proven or quantitated in the scientific literature.
Translation of intravitreal pharmacokinetics from rodents (mice,
rats) to rabbits or man has not been shown in the literature.
Intravitreal injections are given often in mouse and rat studies for
pharmacological drug responses, but intravitreal pharmacokinetics
in mice and rats has not been investigated and there are noTable 6
Physiological values that are relevant in ocular pharmacokinetics.




1.15 ml (del Amo
et al., 2015)
















(Aihara et al., 2003)





et al., 2006)pharmacokinetic data for human translation. We have recently
carried out SPECT/CT imaging after intravitreal drug injections to
mice. As an example, Fig. 25 illustrates elimination of 111In-pente-
treotide (molecular weight of 1394 Da) from the mouse vitreous.
The images show that the injected compound is first seen only in
the posterior segment, presumably mostly in the vitreous, but the
label is later localized in the anterior chamber and during the final
time points the compound seems to be primarily localized in the
anterior chamber suggesting significant elimination via anterior
route. Interestingly, it seems that major part of 111In-pentetreotide
was eliminated from themouse vitreous during 230min and hardly
any tracer is seen in the vitreous at 270min. These observations can
be compared to the intravitreal pharmacokinetics in rabbits and
humans.
The intravitreal elimination rate constant and half-life of a
compound depend on its clearance (CL) and volume of distribution
(Vd): t1/2 ¼ ln2 Vd/CL (del Amo et al., 2015). These values in the
mouse eye can be compared to the rabbit and human data (Figs. 6A
and 24). As we discussed in section 3, the volume of intravitreal
drug distribution almost equals the anatomical volume of the vit-
reous (Fig. 6B). These values are 1.15 ml and 5 ml in the rabbit and
mouse, respectively (del Amo et al., 2015; Remtulla and Hallett,
1985). Posterior drug clearance can be roughly related to the sur-
face area of the RPE (assuming similar permeability in two species):
the surface area in a rabbit is 520 mm2 (Reichenbach et al., 1994)
and in mouse 16.5 mm2 (Jeon et al., 1998). Then, the volume/area
ratio is related to the vitreal half-life from the elimination via BRB.
This calculated half-life for posterior drug elimination is about
seven times shorter in the mouse than in the rabbit.
Drug elimination via the anterior route is a complex function
that depends on the diffusivity in the vitreous, geometrical factors
(distance in the vitreous, open space between the lens and iris,
viscosity of the vitreous humor), and aqueous humor outflow. Most
of these factors are difficult to estimate, but aqueous humor
outflow values are known; rabbit: 0.18 ml/h (Barany and Kinsey,
1949); mouse: 0.0108 ml/h (Aihara et al., 2003). Half-lives (t1/
2 ¼ ln2 Vd/CL) based on the values of outflow clearance and ocular
volumes are 0.3 h in mouse and 4.4 h in rabbit (14 times longer in
the rabbit). These rough calculations hint that the intravitreal half-
life in the mouse is approximately one order of magnitude shorter
in mouse than in the rabbit.
The volume of the mouse vitreous is 230 times smaller than in
the rabbit eye, but the clearance is about 20e30 times smaller in
the mouse, partly cancelling out the volume factor. We cannot
obtain exact experimental value for the half-life from Fig. 25, but
based on the intensity of SPECT images the half-life is in the range
























(Feke et al., 1989)
43 ml/h (Sebag
et al., 1994)
Fig. 25. SPECT/CT imaging of mouse eyes after intravitreal injection of 111In-pentetreotide (unpublished data). The numbers indicate the time after injection (minutes). The anterior
eye segment is seen as the lateral part of the images.
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(MW ¼ 1394 Da) is expected to be in the range of 0.02e0.04 ml/h
(Fig. 6A) meaning half-lives around 20e40 h, values that are one
order magnitude higher than in the mouse (Fig. 24). These calcu-
lations suggest that following scaling factors (rabbit/mouse) can be
used in the interspecies scaling betweenmouse and rabbit: half-life
z10, volume z230 and clearance z 20e30. The scaling factors
man/rabbit are half-life 1.5e3, volume 2e4 and clearance 1.4 (del
Amo and Urtti, 2015). Drug exposure after intravitreal injection is
best described with AUC values that are dependent on the clear-
ance. Therefore, intravitreal doses in the rabbit should be about
20e30 times larger than in the mouse. In man, the doses should be
about 1.4 times higher than in the rabbit.
10.4.3. Systemic delivery
There are only limited experimental data to support rabbit-to-
man translation for ocular distribution of systemic drugs, but the
good correlation of intravitreal clearance between rabbit and man
(Fig. 24) suggests that the modeling approach of Vellonen et al.
(2016) that was used in rabbits (chapter 4) may be useful for hu-
man predictions. No systemic-to-vitreous drug distribution data
exists for rats or mice. It is obvious that the systemic contribution to
the ocular drug concentrations is higher in small animals due to the
smaller systemic volume and clearance. This may be one factor that
leads to the over-optimistic results for posterior drug delivery after
topical administration (Joussen et al., 2016).
10.4.4. Prospects for inter-species translation
PBPKmodeling is a tool that is used for inter-species scaling. The
models are based on the physiology, anatomy and compound
properties. PBPK modeling can serve as an approach to integrate
the information from the scientific community to the models that
can be used to predict in vivo pharmacokinetics in animals and
humans, thereby helping in the design of preclinical and clinical
studies. With increasing data, the models will be more and more
reliable in the future, finally enabling inter-species scaling.
11. Future perspectives
Intravitreal delivery is currently the method of choice for retinal
drug delivery. New delivery systems are needed to prolong the
injection intervals in the new retinal drug treatments, but the
development of intravitreal drug delivery systems is difficult
particularly due to the tolerability issues. More basic research is
needed to improve understanding of the injected material behav-
iour in the vitreal cavity, including the immunological aspects,biodegradation, release control and toxicity. Obviously the delivery
systems must fulfil also the important technological requirements
(e.g. sterility, lack of endotoxins, reproducible manufacturing and
clinical performance).
Systematic understanding of ocular pharmacokinetics and
model building helps to integrate the pharmacological drug prop-
erties, delivery system related factors, anatomy and physiology and
inter-species scaling in the same package. Integration of pharma-
codynamics is an important future challenge, because some drugs
may have prolonged response after biochemical switch is turned
on, while other drugs require continuous presence of drug mole-
cules. The drug features should be taken into account in the de-
livery system design. Applicability of different routes of ocular drug
delivery depend on the drug properties, for example the drug po-
tency. It is important to integrate drug information in the design of
the delivery system, dosing rate and route of drug administration.
Basic research is needed in the field of intracellularly acting
biologicals, since theymust be delivered within certain cell types in
the retina. Unfortunately, knowledge about drug targeting to the
key cell types in the retina and choroid is still sparse. This field may
benefit from the advances in the fields of cellular and retinal im-
aging and nanomedicine. These advances are important for the
development of treatments to the unmet needs in retinal
ophthalmology.
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Moore, S., Tobbia, D., Armstrong, D., Horvath, E., Gupta, N., 2009. Identification
of lymphatics in the ciliary body of the human eye: a novel “uveolymphatic”
outflow pathway. Exp. Eye Res. 89, 810e819.
Zehetner, C., Kralinger, M.T., Modi, Y.S., Waltl, I., Ulmer, H., Kirchmair, R.,
Bechrakis, N.E., Kieselbach, G.F., 2015. Systemic levels of vascular endothelial
growth factor before and after intravitreal injection of aflibercept or ranibizu-
mab in patients with age-related macular degeneration: a randomised, pro-
spective trial. Acta Ophthalmol. 93, e154ee159.
Zelphati, O., Szoka, F.C., 1996. Intracellular distribution and mechanism of delivery
of oligonucleotides mediated by cationic lipids. Pharm. Res. 13, 1367e1372.
Zeng, H., Green, W.R., Tso, M.O.M., 2008. Microglial activation in human diabetic
retinopathy. Arch. Ophthalmol. 126, 227e232.
Zhang, K., Zhang, L., Weinreb, R.N., 2012. Ophthalmic drug discovery: novel targets
and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 11,
541e559.
Zhang, T., Xiang, C.D., Gale, D., Carreiro, S., Wu, E.Y., Zhang, E.Y., 2008. Drug trans-
porter and cytochrome P450 mRNA expression in human ocular barriers: im-
plications for ocular drug disposition. Drug Metab. Dispos. 36, 1300e1307.
Zhang, Y., Li, C., Sun, X., Kuang, X., Ruan, X., 2012a. High glucose decreases
expression and activity of p-glycoprotein in cultured human retinal pigment
epithelium possibly through iNOS induction. PLoS One 7, e31631.
Zhang, Y., Lu, M., Sun, X., Li, C., Kuang, X., Ruan, X., 2012b. Expression and activity of
p-glycoprotein elevated by dexamethasone in cultured retinal pigment
epithelium involve glucocorticoid receptor and pregnane X receptor. Investig.
Ophthalmol. Vis. Sci. 53, 3508e3515.
Zhang, Y., Schlachetzki, F., Li, J.Y., Boado, R.J., Pardridge, W.M., 2003. Organ-specific
gene expression in the rhesus monkey eye following intravenous non-viral
gene transfer. Mol. Vis. 9, 465e472.
Zhu, C., Zhang, Y., Pardridge, W.M., 2002. Widespread expression of an exogenous
gene in the eye after intravenous administration. Investig. Ophthalmol. Vis. Sci.
43, 3075e3080.
